var title_f2_20_2368="Laryngomalacia surgery";
var content_f2_20_2368=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56479&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Laryngomalacia surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 223px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A: Rigid laryngoscopy of laryngomalacia with redundant supraglottic tissue hiding the vocal cords. Panel B: Rigid laryngoscopy of laryngomalacia following resection of redundant tissue from epiglottis and arytenoids.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_20_2368=[""].join("\n");
var outline_f2_20_2368=null;
var title_f2_20_2369="Diphtheritic membrane";
var content_f2_20_2369=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diphtheritic membrane",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 330px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFKAU0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDqfLONpxj/AA71dhRfkbjheDnviqqueCAcHj6dquYAAXjH0rzEfVSbJN5DBlIxnpj0qxGwjj3SYI6DjnP+cVDFjIXtg1ZKBlGMbc9/WtEZyt1JoWLAbB/+r6VZKjcCh59fSoYSCVx1HHpViPvkdefpWqMWPyAMcYGO/SqGoSsoyCSAKuSHeNqnJ55ArP1FtgVF64zz7UprQcFqrmXeOyx443EZP1rFuJABx97mr17I5XJPzYIrMnLFcDBCD5jjHeuabOyESrO7P945JqpMWAwCM/lxirbh2B4ySOMHHaoJVIAIUt3O3nNc8ka7aGefMDgAnd+tTx7mXaF/Lv70siswUruVuo4/wqQIwC7mOB2B75rN+7oWo81iOACBgygcDIb3weDTmmkdQwUN/dxkZ5p3l+YSGIwe2faknlFvAojVcjI79fWs3NtHRCGtktR8zbIiW257knOKpC8LA4AIxwc0ETSw5kx8x9D1xWfPvhkIOMAf0zxUuTbOqFJLRmvFcnAy4BJweKvfaUbarHJOBwQMcVzK3BZsL94Hr+tP8yWTkDcF4Jx6VcakkTLDpnSm4bGw8p2//XVVnzu7ADjnr+I5zVOCYNHtbCnHbio42EcjDt7nkD/CtY1rtJnLUoWuKAuWLyHGcD9KkjJjI7AjI7A/1zVdVxKzMWcdsDoR7flUskiSKADj0wRxVXVjlkmmbNpMhjOc7iOV+lWIpMLySACMfWsS1nxGOcuDx1547n0rVGWhIzzwetaxfMjPrqdFp10AyjIOTxjjmtu2lBLLnqM9f0rh7WYqwOec89eBmuksbguFb+JT+YrWlK+hjUhbU6OJyFAOMDr2496hmwZBsyBgng8HFRxyhl68EUqOT6ge/t6V0JmKVhkgMgBYYz29cc1WmVu4P4dvrVosqkE5wc856Gq8r/w5GM4PvSZcblNZAZAoz8pzznAxx1qKboRxjp+Gf51K4VT8pG3ofaqVyAWI3HOM9f6Vm72OiCTZXlbyxtQBgME5PtTVYtlT3GCPfPWnugWMKOWGKrXQkTc0LKGIA55qDrik9CGYgzchsDgjHT3HbFVbmNVUDcck4FT3sjRRbyOQpJPt7etUVmW4jR42yGHHOaynbY3ina62KdxBtByzsc5HzZwcdPpSSLtQA5J47dOKsyDadw+bI5zxVa4wY2xjdyM+hrmlFLoU5MyblciTbn5s8+lY7wXMzk20LSqOCTW1GnnbISyKWPJJ/Pr1NdRbW0NlaxxqgbPJIq6VPn1ehy1qnKbwX5ht9e/NWMHfg49v8agRwwHJHOKkVs8tjgf4dK67HFe5ajbPQjg4PFTq3ADHoeKgUjoCQalj6gnHHI/KrSM2X4GGCwIH1qaNldeeveqUbKWKk4HSpgcNkYxWiZm0WiBswMZxxWRdkCRzzgcflV4yFQSecCse+mIBHH596JvQcE7mZdMWc4wV5yf8KqXMuNoVAVBy36CrU7KQu726imxKpbbgEE46Zx0Nc0tdDrVlqVZI/MGeASPyqqEcqFUZYnkVpTbnYHpgAAADimBCZ0JxheeR3qGtQUtNSlMgSLATn88c/wD1qhgiEhZmYZ6Dnqff0FX70KoyccnjI681FA0JBwwVBwS3elKN5am0FpoMt7MM65wFJxnpjirN1ZQtIY8k8HOAcZHbP05qGa9XfJbLnyjn5hnt2/UVYkmDKyw5bKhhjIPII6VpTpQtY2fMrNjBawGD93jA6Z7DGPxqhe6LNNuSExOygHcTjr2+tMMrwWSs7EkoNw7hhxx7fSrVvesXCguN5OCT14FHsac2lJGsZThrF3OdfSpImZLiMr68Y696dGgtY/lGFBwc8n/PStjXNQZo1jcBlRRyRyf69q5j7TIykM+UMgUZPrXNVoqMrI7acnVjeZsParIFEZCv169v6U5NPZ4mlDNtBIOMnPvVNbgZnkJI58vOep5p0t80ExjVmMUagtjPJ4oVOK1aMZxlLRMWdfIRt2SCB3xyP/rVUaMqCN3PU/T6Vprc292AHKrJjpnqcf8A1qpzqFfGMnp+HWpnG2qOScGtGS6cw+zKGCg5OBkGtTeET92FyOBmsa1+RgCSQf061cgd9uchiAcc5ojOyscc4Wdy9u+bkgls/nW9o1wScsB1wR7GudaPzFUgHaKns7pkkTByT069q3hLlkRK0lY721x5YGeRx9KsAhl7YFZOmzmSLJAyeD9elaeOMDHpXYjmfmNfaV5zwe/eqkxCneQO7ew/+tVicDa2TwfXqDVGYgKcYPWmzSCuV5pAGIDY/iP5VVLIXyTlj1PSop0Lykq5HPcDp6VFDMhcBWG8EjBPNZt23O6MLK6LcyrGrPk9cDmqkpG8McdOmOlWriMuoIO4Ywe3aoSuAcAEdDnrkVLCEupSvQskflliDtxg1mGJbdAY1IAHQdsVpyurMcHDcAcelVbiMPHgcZBOTWdRXV1udMZW06GXcwzT3MTK22NASy+vFLKPLBAycjj6+1WwwAOQMKOucdsYFUrqZI8ZYZPHORmueUVuKdRvQo2yxw38MjD5vugn35/pSeLNea2uYILd8FVJfr1P+f1rN1K4JfyoMGUEEkc7cf1ot9MadPMl/eO3VjnmpU3BWRzTkpKx6nao0aANk89Se9WxjOQvbv8AlVfazAL9T+lWY2JQBgMjj613I4276kqnjHpTw21UAO49+MUDaACvrzTDL8wUAn3xV7ELUnU56gYPP/1sVYgfe2MDA4x0OP8ACqDSc445NXLRs4IzzTihyWlye6by4iSR82BXP3rfMcYwRjnIxWxqcn7lCCM89fUVzt45bIOfm6+3tSqMKS6kNxIFCsFJA647Utsdylht9uf51UJO8bF6ZGOeasQFo0K4UkgYH+Nc+rZvPRWJiCDyeByarS3Sk7UPzId2CODTvOJOxRkEd/p61QuSsDOxOcdffFKWiui6ULstSzIyb3dQ6rxx15/SufuLwSTNtf5T0x3I9aq6hfGTI+73H1rn9Q1aKBOWww+vWovzpHpwpKmjoItSABEhKlTge5x/hVc+IAsyK8xXAwCPr0+leZ6z4s8tisTs2a5i68QXszZEhXNdFOjOSODE5hh6LcZO78j2a78SI25BOoG4kLnt1/pVR/E0ZXbFLjIIPPTvXij31y7ZaZ8/XFM+0zg586TP+9Wv1WT3ZxLPKUdFB2PbpNcWWLa8u5u2TjoKpNfJtyJR1Bx0/GvIxqN2OPOY/hU0Wr3SkbmBx61Dwku50wz+jtZo9qXUf3MJLrljvAx3JpILppGm3gjPBJPf0ry228SOcByykevQV0Ol6+PKKu3zsfvVlKk4/EdtLG06qvTdzsyU84uDtxjHOeR/kVqLqKk7JeWAGTjpx0rkIr5ZMsr5jXGTnqeKlnvTI26NjubHHT8axlDQ6eZVFaR2MLBgpIBHT68VJBIGk2hiCvbB9P51jaZe/KI5GG8DoMYx0rUlJ4Kkg4BJ9TWDVjgr07OxoLLJjacE4OD0xT7VwsxXb1HHFVI51aPcfvKOenNNhm23gUEbTjtyOKpSsziSbdjudFlBByRtPH1Nb24ELjGPyrktJkG4jjgemK6eBvMiA7444r04u6MZqzCRgGABOQee9QyIrblJHHPXk1PIvGVHeoJRlSTzjtVNFRZmNbqHYEjDEkfnUMtuoYEAE+tWZAWO4fKBnHtxUYkBBAUcVDR1qUiOMBIyDkEdCB2olxnAHB4yO1KZcttIOeg46iopSFhKjgH+eKWxSu2UmQNK5I+UAjnuelVbmRGm2KV3Bcj2q8jgRk8d8jHvWVIitMJNvJGB+FZTvbQ2T11I+BGd3y4Gf/r1y+s6gt5KLayw7qeX64Pt71c1q+mu5fsViQAOJHHbtirmi6EluqkDJI5yO+Otc0nfSJLld6FHRdIYKhZTuA5J7k11lvpgEQGOnarthZqF5xzj2rcjtUKDpVRpMzclEgwGYYOcdMVOpXIwCeKrRKc4GMkH/wDVUrDaVGR/9fpXUji3LGcduhpykMM4Hf8ACnRgEHI69famuACNtWiFqVZIy5PJ4/Crlo4RcZ/WoByxDdSMfQVKsa+UACfahbmrd1ZjdRYOoAJ+Xn6H/IrCuSWU5wCOlauoDbkg44HHrWQyhmwOGPLf59amY6eiuMGQ5GfujqRU4VSRgncO9VmZgxBXIHcgc5xVgHcMKwzj2qFqDEuI1Qhx16gAda5fXLtImxvBGMdelbOq3KwwOD1UdQOnFeV+JdaFv5p38nOR3GaymlJqKO7DLlXOyPXtcFvuUMCe/wDntXnmsa7LdyEKfxqnqmpPeSNgnaf1rOzz1rupYdLWR4+YZtKb9nRencGJY5JJNJRTlUtwoJrqPC1Y2nxxPIcIM1oWemPKRvBx6V0+maVGkbh17YB9KwqV1HY9TC5VUraz0X4nIpp879FqT+yp8Z/pXeQ2SKnGP8adJagICq/MD+lYPFM9ZZHSS1ueeSWMynkUiLcQHKA/hXZXsEYYFxz0/GqEtoMVSxDa1MZZOoO8G0ylp2rPGwV+PY9K6ax1HzGDADcPyrmJ7UH7w4pkUjWzAnOwVEoxl8J0UatWh7tXVdz0u1uVRV+QFjyenGK6GyuDcTqNxKkAEmvONO1JHJO4A4yM11Om6qiEAkDOOmfWuOpBo9RyjVidnHGhk2scnp9ffH408xo868DOOD7jis21cSOkqEtt9+/atSFchSrbiOcemazSPIqLlkbGmXKq+0cEL0Prz/SursJg4ILdcY57iuQtBl8EKMjknqO//wBauisplRxjnnj2rupPQiorm07fKc5qpKSRlcD69/arZdSCBjntVWZBu9fb04rczgU5lJRsYwMZ9sd6pjoGA4P+f61Zu0CocY3Z6ZxVONicEg8DFSdcNiUorKDk9ee2OKqzMAVjAOeoqyGJA5AI/limogAyT8w/DI5qJeQ1K25VZNqknqwOOa5jW7x0cW0JzM4P/AR+Hfiun1GcW1s8jAjYM8/5+lcjpsL3d288i5dye3QVhWlZJLcqEmy1oemLEm5vvHBz6multUwAoA4H50+3swsS+uAKvJb7FBwc9vypQhyoE0LCuNoAHH61biOFxk9ait4ty853dMVpwWDPECcD65rRRb2JnNLcxEO3GOcnA46+9WnTLA44zTVQ4UZGD/hUkX3COMZI6dKpI4+YmQDbyRkZqMqCd3OAf1x6UoYBsL1Apzj5OAN3X61a1DYQsrDoOBmnRkCNcnnoDUUZBJyQQPU4qXGFycHn8qaB6aFPUQPMOO4557CsiIfv3HOFHAx7VsX8i7zkc4wOM1SABHPU5HTv61MlqXFtRsV1iBLdT36dc1KkW2NnboOeBScoFyV6evt/PFVr6chcKRg+nTpQ/dWo1FylZHHeLNRMavtYbFycHvXhnifUDc3LKGOM16Z8R76OJJAdpbGQRxgV4xLIZJGc9TzTw1O8nJizXE+yoqlHdkVFLSgEniu4+ZFjRpGCqMmug0zTwoBYEmodMtNq5YcmugtlCqoAGcelcdarfRH02V5copVai1/IsW0Cog4PrVqFuSo6Y7VAhwMDr0p5cLzx6ZrlZ9FGKRYyc56DPNPL5TAz7+9QCXKA5GR29aiLA5JJ4447moaNU1YZcqGk5UED6+tV3HHPQVNne2BnoeelI8ZRecHJNNOxEoJ6lC6j3HI5qlNEpGCOvatZxw2OhIqvLECcDPGM1pGRy1aKaMcR/ZCNp+T+VdJpV0hQAEMf5VnzWXn27pjDgce9ZVpO1vceVNlXU9K0a9ovM4L/AFWoo7Re3k+x674fvFZxGcKSeT/SuuhXOOAcivK9EviFBjPzdOf89K9L0e5862jJHzEDkfSuRRSlYrF0/to3bOMsqKcYYHd3OB6Vq7gAmB6Yx6//AKqo2cQb/V45GeeO9accYZgDwQAR7YrrUbI4nI1YBuhRjgkDk1HP/reTjjOPpUlpxGykk88dsVFK2QeRkA8Z71p0M09SperuTccEY5qnEisQMnaKvTAyRngdOlUYmBO0Ebx2HfFDZvCVo2J5ECpg8j+tNKqpOQCQOac2GXBB3YH+fzrI13UFs4AM5kOAox1PrUSCN5aGZ4mufNuI7JSN7fM3sM9D/Or2hW4iAXaOn5Vh6LbS3moyTzhix5/px7V29jbpjgHjgHpkVjGPM+Zm90o2J7eNghJz0yKsxqSrAnt+dS7AqDBHrSMwVRggd61sZ3uSQRiPDDP/ANcVae+RMKcVnTXICYB5HSs25lywIb9KblyrQFT59ZFhnKxjByQfT2wamVg2MdO1VoSVJAPA7kfrVpGAwMDnp70I4xxBZue1NmDHCgnp1qRWDOOmOc4psi5OAcehplJkcZw5PGMY/EVMW2qCMYI/KqrZ38kd/elbGQuOSB2ppjtdkWoMRICuCQB/Kq6KWJGRkjOD64qeUlZHwBtx149OnNV4vld2OQxHHt7UPU0S00K9zuUliwDdBxWdcsrROVIyF7jqfWr+phSFxuDAY/8Ar1h+JrgWOjyurrnZnGe+KTV73NYO1rbnh/xGvt1/JGpzk1w/ar2r3TXd/LIzEjccZqj9K6qUOWKR4GPr+3rNrZaITrWhpluZH3noKoqCzAd66K0RURABjjmprT5YmuWYdVqt5bI0LaLChgMn0q1uPTjp6VSSQrjBwKVrjAGDXC9T7BOMUW1m+cevvU5Yupxj1+lY6T/PwfarYlCp8pPvQ4ijVT2Lch2AYPbpUCz7mIJH+PtUMru4XblmYkBRnNdFYeCdTvIopMwwiRNwEjYx7GhQb2FPEQhuzIWQNg81MhLqRxn3qpc2V5YyulxE42HBOOPzHakSfHAI54NQ432N6dZPqW3UkHOM4/GopEwe348U+O5DEA44Azz1NSeYGzwe34cULQtpNDreNWIPUfSq+uaH9rtDPAuLiMcY4zVuBgW46jp9K7fSbXTm0FJJJP8AiYLMVaMjIeMgYPoD1+tXCTTujmxFONSnyzV0zyvRbqSCRUuVMbZxhhXqfhi73mNVdduOWf8AQcdKwvFXh2GeEzWA/eryAO9Z/hDVApEM3Drx1x/k1M0pe8jlScYezlrpoe32LBUGMEr3B7VtW43sCT9MexrjtBuyYgTKrZ7c8V19hIXkIUDABz+n6Yrpg1JXPNqQcWX7cYZ09gelR3Kbs4Kjj0x/npSs7R3ka7SVboQfxqS5Hy5IAzweO9XZNGbVtTIiJEmwsMEY7iqY2rOAMZ3ZOfTNTM6rcDHILYOT05qvessU6BQeRjj61PQ1UtS1eTJa27St1zjHqfTFcy1rJdyvcTcsTwOuPariyHUbwoWPlxHGO2fWtBdhkWJFJweTjpioTj8T/pji7aF3Q9LWNCVHUcEjtWgIvKTAwCPbFTWj+VGoAHI9OlQzS9QMGnokgpttiSM2/qMY6ZqvLPnqR0ps24DIJGeKgKsxHXGP6VFzpVkhsjk5ORgDFZF7d7JcbgKv3dxHBCdzAHr1ryzxV4qigv8Ay433YznHbpWNST2iEZX2PYo2ViMEgkYP+NW1+oxWYrFdjLyOvHNaCMCc4GP61tE856EhAEgwCD+XNJLhiBnB5zTm59M/TtUbAFjkc44+taDKd1IUUhAfxpjyMzqwJBPX26UkzDzDkHjBGecVXMh8z5QSAemetJm8EWCwDspHy4+X/P1pI0+85X72evYdOlMfBbLEAhs8denSpWYIpAI5GccHFBe2xTuleVWMbEgchQeSBzxXmHxZ1drXRhGGbdIcAE9O1ekvL5j5GehyfWvKPjJbG4sEeJSfLYFifSmmna5dRSVOTjuk7Hi5OaKSlFdp8kXNOjDyEnoK2osKuBWfYpsj571eTJwAMk9MVx1ndn02X01TpruSs+3vVK7uPLGcZFdnovhSa7BlvMogAwo6ms3WdHt0+1QhT5iOAmejL7jtwfzrNWjrI2xFZzTjB6nJw3bSSBQOK9A8EaDNq8pmZM2qZVm9GPfH41yviLSbbSINOuLZnYXKEsHIJVl4P869g+D0LP4YaVADvlbcD6Zx/SrnaSUo7HBh8ROEZRm9S9pHhDSrGQS4IKuAZ3O4rxnhB2x+dQNeFZREXXIBP1/+vXaaztFuryuWkChBz0A6D6Y4rya9tvP8R30Uky+dEiyRrGfvg5yMeuKyq3taJpTlztubJNX1Fp0KQle+Qy53D3zWRdaZDqB3rCttKQAGT5UzjqR/WqzajGNTy4KKvG0jkkH/AArqrONbjSWulKgbiNvcD19AOorFOZ0ybpWsebyCS3naKX5XU4Iq3aSZbk80eIYtl4JMkiTkE1Qhcg8Vruj0qNa+5tKxjIbByD7/AMq6TTL0SW8YAXI45rkVlLJggVf0a5CEAk5BzgdqzkjsUkzuYsrclUR/LbjD+mOvWvPvEsP9meIDPEAIZjuA7AjqPz/nXo+n68r2ElqyxFCQxYr83GR1649q47xvDHdae8kTfPEwfn07/wBPyqoWT06nHXcnFyas0dH4e1YT28LxNhhnIJ9/SvUNFukeJGVjkjHfA75+lfM+i6j9nYKzHb/KvZPB2uB7RDIyLEpBLM2OBjr7U4fu5NM5a0IzgpxPUgQVQkAkDj8fSi4yQRk8DIyc4Fef6v8AFjw3oysjzG8mXgR23zDPTGen615h4o+NmuamHh0m3h06BuA4PmSgf73QfgK7EnLY8mrXhT0bPYvEOqWelukl7dwW0e4HMjhfy9/YV514v+K+lxT7dGjkvXXjzCCsec9Rnk/55rxi+u77U5zNfXE08hPLSuWNJFaD+M5ocIr4jBVqtR2pxt6n0N8L9bi1/TWu5lWOcysHRDwD+fpivRI406oF7jA4/GvmbwJ4hTw7fP5jP9nccqgz835/WvcdC8S2OowLLb3CMCMld3I9iDyPxrlk1F2todcYyS13OskkMYyKptfgMFJG7+tVZ9SheI7ZFyc4+tc/dapHG252XHJPPeolUS6nTSs1qdDcakAxzncOn5VnXmuQ28bPJKBgZweOgrz7XPGUFqjuLiNyp+6Dzn+v+eleZ+IPF11qUzmMmNG7A8CiCqVfhVh1q1KkvfdjtfHHjpWDxWrbiTjg15XdXs9zM0kjncT61Wd2diXJJPc02u+lQjTXmeHicbOs7R0ifZ0LMqhQRgd/XNXYVGMEg4yKoW5DRDI6Ej369auIDtJBG7sPeuSJ6LJySBy2SMggUi/MSUPIoRBncfvHJxnvTwvJCsST+laIL6FO75+UDg88nvWSxCTc9R6nqeta86hurHBGM+lc5HbXFvqN28s6yWsrq6J1aPC4I+nHA9amTNqbNSPBQ9ScZz71DLIWJHUEc49qfvIA6D8OoqCeNlkjSFlJPJ7+vrUy0Nk+4o2shZgAD79Md/51zHiazi1GBowMrjuBn25/z1rfllDTRRqMEE7s9xiql1CJp2dsFRkZ+nt3/Gk5XR1Ut7s+b/Eejtpt3J5YzFuOPasYHpmvdvF3h1Z4JCkQLEZyBn0rx7V9Ils7l0CHAJGDXTRrX92W542Y5c4P2tFaPp2FhkUxqVPFaekyol0sjDdt5AI79q5pTJEeQR9a17BxjJxn3pTjy6o0weI9q+SWh3tn4gLQ+WWCn1qnLNHMbm4lJwB1J5BrnImRpMPIFXPJqTWrmGS1jhtHYogJIxyW6enpXJyXkdVaEYL3SxrLWuoaJCZ7lftisVhgU8gFu+K9z+GXhq503TkhnVv3UYkaDBwx6kZHfBPcV4L8NLewXxdZ3OvTJb2Vu3mnzFLbmH3RwD3wea+kNS8b+GFWKGHXYHAwzBA23PPTjGeR1+ldXJGCte9jyY+0qa8tr+QeIbaFrR8DEhXAA/hz65rxTVPDerWl2mqQxyywQvmaRSB5fzY574JNev2/iPw/PKGGr2JA5AeQLj8DXPeOJtA1qOCO41y2toI2LF4ZBISQpx8inJyRjNRZSOiHPF2see3VkdSuDfKqxO0zKqg9cNg9O3vxXVPdm00poWh2kg7QrcHArk9IvLe3tY40lTyyx25cb1GcjPPBrpbh4JbcSmRZiBnhgQOP5VhzSjex0Tje1zj9dkW4jyOHHOD2rBRtprR16RTeSeWy7R6DFYbSY71cI3R186ppGvDOS2D9Kekpjl3rwKyPtSxHLMAfSoJ9VB/1aZPqelUqUpbI1lmNKnH35anoVtKXG2PGep+lZut6pYwwOk1wjyEEbIzuIPuK4p76+uhs81lQ9QpwDSwWKEgyPuPoKqNFQ1mzCea1K/u4eHzZX+1yHARcH6ZNXorbVL5FjcyiLPAc4UfhWlYwwRgbIlz6kc10VnD5ihu/GPSnOuo/Cjlp5fOS/ezduyMGx8J5QvO5OBnAqxLoEUKHykbI9a7vSo4ZG8uRwueORxWhPpqsNttGZmJONiFs5+nFc8q1SWtzdYWjS0itTxa5haFyrKQfemxjOM16D4m8J6rIvmm1WONBwWIBI+gzXPS+ErxLaKWSRSZeiKM4zz1/CuhSutTnkuV3Rgt5afxDPtzTorqaB91szI3rnFd7pPgKGby2lmkIKglQAMHvn9K6KDwRptuUzDvz/fJ/lTe21wT87eh5cuu60BtjvJgPTNZ1/qOpzf8AHxcyv+Jr25/DtlEB5VvGEz2XGSBXHeIPDUbKXhAVySzD29KyVSMJaxQpU3UVlJo8sdmY/MSTTa2NR0qSCQhlKt6Gsx4ZE6rXdCpGS0PHr4apSfvIhopTRVnMfYVs4JGMg4Axnr7/AKVooxU5AyOOlYsBYHYSMg8e9akTl1IYgDtXl0ZXR9E0aKMCRyOhp6ngE84yPwqtDuLFWPqBx/WpuAuRjpxz6V0RIZWvXYYKAnBOeenB5FZcyCQNtJyp7itG+JEBAP8AD3rOjmwSGPBFJq+5rC/QkZSIsKOQBnNUnl3PvT3A47CrbMdpUrncAAR2xVSYiFnTAO4EDvg81EjVMYxCzKVCn5snJ5H/ANarL4dAVUA9Vx9OtUrXMwG4AEA89ucVoxRgfd5JyOvSiGuptexkXMQd2BU4PQ9+OMVw3ijQkkkZwB8xJGB19/8A9deg3ALNxyQc9+apzwJLGd4OSD155rGafQ7ISPF59C/0gqylR2HQ1BDopY8rgZx9K9YfQGk5KqM4Pfn/AOtVSfw+4ZViUYOWwo6A8/8A16l1JRWppGnTk72R55LoZVhxgHt1NTx6FIuMDk84I9q7q30VxdKHQbeC2ee2MflWium5MG5TgfeJ549qj2jZ0KnBdDzY6RMp2vAFI/2TVmHRRKQu0k98DrXocWkSTFikRcMTnPQDJqY6DJHGHKADpwOearmm1dIq1NaXPNLnw4yjIUbR3HOKry+Hi0W9VIx+tenTaUY1IKk8HgY/Ws+bT5BBhUO3J6Dof8M1PtZLcaowmjzZ9LwOE7ZHvVaSxli+dSUHXINeoW+ivNgpGc7ec8YNR6h4faSEAj5gOhH4VUakrXInQg9DySS3eaQqJAeCfmPJrIvIpf4B8v616XJ4eXzDiI7s4GPrWZqGiNAWWSIjuDjGa3p10jzMVlvtE1ex50yOOqsPqKQZHauym08LGrYHJx+tQjTd3ITIPH0rp+sLqjyJZLJP3ZHKZkJz8xqeGaeP7qsfwNdTFpGZNrYH9a6fRvDjb1fyxtHf0rOeKilsa0sonF39pY43SLbVb59trZSuQMk8LgfjXc6B4N169x5s0dtEfvHlmHtj1/Gu10bTApUlCu1cDHcfzrqLZZEVcMAvAB557VlGSqatWPRjSdNcrncy9A8Eadauv215bx+/nMCo4HAUcdR6V30UNjDEqRxoiKMAAYxj6VjWb7Wym3J59OemanuZNi7mzknHpjtitI2WqRFSmurF1+G2nsm8wqO/PpXnmp6UpsbQRA8IpUZzx/jzmuk8V3hSxZVI+YYAGDzjA61y9vdyJfxoCSsQVACOo9cetVKSfuyPPnG2xvaXp21BhPugDv8A57VJdwnzPmH3cZ4Ax0rT02/QQM0iD52468YGKgZ4mDBm3MxJH/1v1pO3QcL9TGlixsViBxk+/WsPUYx9qPA24wMjt/k12E8UYVsqNxwBn8q5zWkEILKRgD69u+a5qsbK5vBnnXiKNHVlABbPYcj6muPuYwPp2rq9anYRuqsPmOcelcpdOCf0p0Lm8klDUyLtVU8VVNT3bZkqCvTjsfLYhp1HY+soXJyecjkY5zzWpbNldzEYI596wbOQOiA4Kntz0z1rVgby0Kk8Dofb0rxqM+p70uyNeCU716c57fQU+VsAfQkn3qG2b5VBIBU4/wA+1LcP/cxkDnuCT/Ku6L0I3ZXunLxlSTgBhkVnbRvyc9M/p0qeUs2V5yCevbFEChI2+YEnpgD07frTZolbYeVCqrEncBn6YIrN1CQNdMc4+XofQ9/yzWnAWaJgMdCORyM5rLuk8y4cEgqFAOfUVnO7Whcd9SG1uAxdAQCMfhmti1AMAC/eHf14xXOwJ8zMq8ArnnGe/wCXU1u6Y7tEATyeBj0qKcn1OiSVtB6w+ZKxzzjP8qiW12tnhv6+9anl4yVxk8HjPUjinRwbt25jgDn6darlQ1UKUkasFUAArjr+X+H50Qwq4wNocAZ+mcVYkhLSEjnA/UGpLeMqSUUkjIPFG7LUlYY1mrhtqKGKjtVi1sbdbceZGGZiT0P86tQKcfP3P+f5VPGBtXA7fpVqCvciVR2tcIbWBIiEiADDOR6EUl3FE6FAF+THP0/z1p8twsKLuVuTgEc4pSRs4wSeTxWt1axkm78xni0hYqWiAVT+fWnJY2kaPmMOTyeM4461bKs6noB9KqXDqGIBPHBA/lU2XY0U5S0TIbSBS6lYQqBmY8Yz2/L2pt3pysivJsy38IHrT1unQkBSewFSFnuFJOFwecnPYUcqtYpuSlzHOXOnpFNmNF6nrjg5rk9XsJmkdnAdCcc9vpXoV1GBlTnOP1+lZF3bhlzgf41z1ad1aJ1U673Z5rdaKsUgBA2nB6df8ioLrSDDHvQEgnIGP0zXd3NlGE/eEAHOMjNU3sw0TAgFSMDP8xXPdoHURzuk2aTMoaMKw/i+vY/yrsdNsEUbc+1VrKwI5XDE556d66exs1VVyCffnn/CiK5mY1J36ha2qq23ByRzx1q+q84BIxwMn8KkKhRjcOwqOdlTah4Y5zxnHauxKyM07jGh8hvMQcDGRkdf5VHPP58yqzAIvJH09PxqC+uvLjILA4JP4f5NIqi1s0eUFJJCGJ5OPb8qd1sZ1Juyuc74yuQpt0G1sOCQD2Azx+lc7pZ36mGywlA3Ac9senuKva/MtxeyS4BVMoCf72en/wBf1pPDlsFmaRSpIzlicn/9VZaymcUmdTCwW1QEYx2Pf1qFNryEsRsjyxAzz7f57UrN8h3sScfL9T3/AEGKrSMY7dlbnLfTn14q6jRUCS4ujIzbSPk+ZiePUD8a5rXr4yR7EAJbOB6ntzWhf3BghKKRubl/8K43WbskbmAyV4wR8o69R0461yzm5Ox0Qhc5nWZ8yOrHPP5Vzlw3WtLUZmlldm61i3bfIcmuujEjF1OSBQc5am0lFd58w3d3PpywuApVTjGcD1rat5FkjOF4U5PuOlczajzlRh2HP1/yK2tLkPmsGwVPAHXjHevnaLadmfRM6GNtyrjnn8euamYAMT2I6e/PWs5dx+QSEFefwq9HJ+6PQkcn/wDV9K9ODuZtspzOd54AGTxz1p6RBEQKp2nHJ44H60SKDICQCc559qkGXGRk849MVo0VGVxHKxMSc5YYwazNQUSlpYyFwMHHfIxWtIheQKduCTj8qo3MPAQD5STx68DrUtX0NkzLhg2xsD0JGB175q9pjSBvmzgnP4DNV41LSBTngk9/XFakMW4YAKj8M4HNYqDvdG3NpqaEB3ZBBJ55NW7TmEkn52ztGM/jVWDKlQMleR26ehq7arsXAAyQfw9q01IewskZBQAcnJzjpT0j6jA49ODzVhXGMEDHf606ILuwcHPcU0iOZkKxiULt4Cng+9SiPaoGRgcYxViFVB6g9fyqWRVKgAgEDj2q0iXN3sUZYsrmQgqDnn61IYSY8qD07DtVgxny8H73r0qOVyisC3A/CqsO7exSuWZUOV46DjAB96z5Y8vvGSxODyOT9BVu+k3hfLlGBx07/wBarGQZwA+ATnnHpSbOiCaRNsBiwcA5JPH4d6VYsRcfLzxz1Hr+lKuN7YH3V/Ig9qlkwY85B7gnsfagltoyrlSTtQY/yazrmI4OMcHtx6VqtIBI27Bx0yO9Ry4Kk4PPJ4qJamyk1YwZrMuxyRlc/r6VDFbBSqKARnvW80SeVkDdnr9arRxBWG9evA46Vzygtx810V7e32bQQRjjbj1/yK2IkEaZQcd/ao3iOFwfmHfrUkeQnBAZevv7/pVxjYzcrigEgnAzgcYqnc7iyFsZU9PXmrFzKFTJIyOvpVC7mMmRGScngfXjj37VbWguZojjtxf36Iyny1+d+OD1wPzxUmuTxmCVSSVA+Xqcdh/KrtoiW9q4J+c4Jbue+M1zevXG2NIzgZ+Zs8YH+cUnojCbb1OX1JxO0aMpYqSdozgn+WP8K2NJiSGzgRSAxwSOw6ZrHhLS3O9TuGdpI54xng9jW9FGEWIMQDggfQ/15qY6anOXJJMQbhjGdq5x1/p0qmsmYixCs+PlXcPpk+2akvpN4SNMAbiFGRkc9f0J6VQnk2MyADC8cdsf1waipJ8xtBaGTrdwIky7g5+Y+g+neuE1S6815GYlQTxntj27V0XiK5UpJ3Y4BH9P/rVw17MXJ3de9Y043dzspqyuU7qQMSeKx7psvgfjV66fCkispjk5r1KMbHiZjWu+UbRRRW55J9B6NcAsgXOQMHPGCP51u2w8li4PysD+fWuH0K6MihyzBgcdT09f1rsrd/Nj24G0gYx2P+RXzqVnY+in7rNpJCXB3EYBBFWY5EjhITOck9/pWZbS+W3GARjOf8+lTxyrvCjGew9fw/Gu2lK25nJmmriQZQnsOf8APtU8bAAjP0qirEErzkjn6561K07YCjsPU9D/AJFdb2uVTTasTqwZt+TxnHfJqtOuVVuTjoOn40w7/KCodpBz9eR2qW4/c2+DyeSKm+h08pXdSjEIP8/5zUtpMCxUY+XA/DFIzrhOuACOe9S26qwLEZO7oO+QKUt7jj2ZoRkhsIAR2OK0opFjwx6+9ZUCblBOeeM+mD0qznEoTJYeuOlSU4p6GggUtyevapVIL8KAOlUlbYVXJOTn6D3q4hJxgj7vp0prYiSsTPLtwAMqfw5oDHB5JYEdO1V5W3Hqfl6AcUKTt3EADGf0qkxKOhd+Uodxy2eM8VTnIx8gBY8YHJ6dTUhkGzODknoe9C+WATvALcYzyD/kVT1CK5SjMGkJwMkcEAf5zWdO0ikhVI6jkZ5+lbRU4zhsE9T3rPvV/eEk/e9Kzlc6qctbFMzkOc4wAASOPSkN5IjoFBaPJwD6Yx9aiAOCGAyTgY7UqKWDAjkj/wCtUJu5s4xW6LQmSQLlTsJBbH+fpUjwloiVxg/0qpGMAAcds1YtmdX3HJXvz+uKu5zzVthkaFcg4yP1p7BSpyCMep7+lSNGFUuScZyPaoLiYfLknBHOB+tK1iL8z0IppUjYjOVH6UpdV5jYEMMkevf8KgvY12ZUkjPGcc96ijJQowYFh1/+v+dK7TsW0nHQjuZSr8lVXowo0dDLcZJOxGz+PT8OhqO4xKM7SRj8qtadE0EJ2g7zk89807NsUvhJ710S2cM2CWyB659P5Vw2u3JkeTcScsqKc9hyf0rpNZuNqNzzjj1yeMVw2rSAyKAeAdn4njP5VFR9Ec0i9pCL5a7lAVz1zyB1x/8AWrTedUJLgYCnbnsenb3NUNPQ/KqgALx7cA81LCGkuV80nYPmOCOc9P8A9VJt2SMoko5YFiQ3tzgcfkfWsa/ldTIkZDEkjPTjnk/nVy7uVjHzkjB3MPp3rltWvCyllJG7naOCF6Yz/n0rnnq7I3pxbMrxBcru+VgcjJ/LH9O/tXJ3D5JJ61papceYwxt49P61i3DjHvXRRjobVZKELFO6bIqkamuW3NUNejBWR8xiJ80wFWrS3MysT2qK3iaaQKtb0NsqRgLWdWooaHXl+Ddd8zWiOl0G72xkEksche/t+Fdxpd0HgDA89vbg8V5fEJrG9kt5gVmiYqR6EH1rsdBvQiIr9W6kfX+deTXp8ruerUipLmR3MU3mIGwScDP+fSrkEuY0YLwp2jnv/hWFaS/MFGWBx1461s2LAFlIzznkY49aVKWhyM1Vk/fAt1AIx1HrVi4IaFG4z0POff8AKqSH5wRzj17Yz+HSrEeMsGJK+nXANehF3RUHZk0BL+XnkgnP40+bEoIxgE989enH6VGW/eqUXAAHPHOe2KmlcKADjqOevcin5HSn1RTeP7meqnPHHb/9VXIDvBUIeMYzxUU4zKAuThc/Q1JFhGKhiM9MnHWoRqtS7CVUfLjr39elWiEQKQp3YJP4DpWdaAlj5mdgBwfXvirZcuAcDp+n+TQPl1JUkPl7j94nHSrEc21RgAt3FUpWYHAAz7e9PLZKgjBC8AHGTzQtDTkvuWXMgQNjnOc+g9KkDtInykFV68d/XjtTArNEfn5xnnn9KRlaNSSCxPGM44qri5SyVwAoI3YzhT1zVpIQQNoPmYxtPPI9j0plsE4DEAhc8DJ69KtKwhLAKQx756+9apGEpPZFfylRWX5s9yecH27Cs+7H97kc4+vrWlcMVco5PzHKhT/P9KpSAMSGA3c4qZLoVBvcy3AzuQE9z7UjIPKZyCM/yqVk2SnaDgj68+1Rudytvz2GKyaOp+RCoJUE8KeOKVX2YAOT/KmSPsAAyR7+tRq+dpIGMdfWpuLluW1kaaPZ3X9ajdRvy2cHjr0pitufjggcdRmpG+aMKxwff05qlqZSViL5AoDdxnjP0qpNGASMjNWtkZdduWzx16HH/wBaoZlYE8jOMY/rTsLm1GIiZXcWAb2OPpinPIF3rnDDp9MU5H/cHgbk6556dqzr98LlsbiCeOOPWhuyE9TJ1uXIhO47i2Scdhnp7VyQl+036qwVlG6QDGdpBArU1q93WiushwCFGM8Dr9axtJy7NNwfMYKMgjgc5Hvk8/SsG09Tnm9Gb8e6Lcu4ggcduvP1PFSM6w25dlG6Q9m7f48VFbRPNI3mElVJYkdh/jzjHaodXnDoFBRFUcnPUDv9aHomzOOuhn6heb42B4Ucke+Dx/U1xmrXQ3Nyc5/T/PNaerXflRsgcjfkdyMHBz65xiuVu5SzEE55zms4Qu7s7qS5Vcrzvliazrls9atTOMGs+Ri7EKeld9KJwY2r0K8nWmU5zk02ulHgy1ZtaFb7g7mtx4cYxkVBpkXl2ybMcjvWkIJJOcgcelebVnzSbPu8BhVTw8YW1Nz4zacdO8YvKECrcpv49QSD/KsDRr3Y3OCRyM9q9Q/aI0/fp2n6iqktDIYmPs3P8xXidrNscFT+ddGKpXkzwsHU5qaiz1PSroTxFuAQeOevSuit7ndGrDhlODj/APX615roN7g4JGAQByOPwz612mk3AxyVw/oeleS04SsFSHKzo4GxIMH7xPPsRir0D/vgCRtYZHr/AJxisWzdVcbmHDcmtG2fLcEYA+Xn1/8A1V10paIyT1NFXzOU5wnoelWH2sBuYbTweMc1TyUdWBHzdc9/85qdpC2c44Hr6D06V0JnVGWlySFdw3kkYyOQR3/P/PpTY0ZSFkLuMkk57E+vpUluwuE+Vhg4zx159KsyLlcBQpAH4+/60n5GkXZ6gUC2y5BYZIGOxPSiJnwF59z68U5jshA4+mfeo4idw3tkg54/Oh7nRDYuMFDgrjGBn3pHJ37tx2nBAotkEi4wevf3qUoAQoByBxgdadm0aJpaF63AYh2Ue1TxrvOSpwcD3qvFIqooOemD9avxICnXtjr1q0rnPN2J4o/KG8sB26dRVh4Rt3yx5ZiSOpJ+ntUEBJI3DjjtWsH3KVHBPcd+K2grnHUk0Ys0JwN+Rg4Ax0qtOiHI6kd8VuSwq8QKgO2fWsuaDa7DoATjFKUbGkKlzLaA7jkAgdKo3CkFsk4HP8q1pAd5xnjIHHWs+5QOee3+FYyidcJXepnlQ645YH9BSlNsZGCeOOOBVlFDAKufl44FOnQJEAQeeB7ZqLWLlK2hTiB35Hb8KkkwDvGeR/8AX/OnBMEAMevAPpTRGSTuIxjGOfWnaxnJq9yojgKeDnJwBxzTd4kZgxbhc5x0OTjH5Ut7GNq7Dg54wMD/AD0ogXaigk5AOSc9KV3ewna1yNnCIxGA7Nz29BWFqs4YlTkZ+UEDoeK17hi5ZwCRtOee5/8ArVzuqSCKMEHnkc+uO1KpotDOUrHEeIrhYCkMYbYq/Kfc9/xxzVrS3aC1BBO1QFHfp/Xmuf1G9a81Qhiu0ZZsDHbAGfSui8OM7TkkF4YkxleeeKwSd0kZ1V7upvqfIt1Riu5xlse2e/auZ1S+jLOpIUhcdD09B+NXNc1ERRShsliD+QPt9K4rUr5pRkH5ccDPQ9+KJe+7IdCnfVlbULhJGBUYx655/wDrVlStUs0pZcN1HeqUrc5JreETarU5EQ3MhzsFQ7dq8+lSAeZIR6VHO3yMcV0x7Hj1Xe82VHOWOKkgiaaUIvU1EOOa3PDlt50jMeO1aVJckbnLg8P9Zrqn3LloJ7WMBhvjrYttQiaP5sAj1qSWFVGwDoOorOuLb58gYrzHJSep91CnPDpKDuj3D4oavpmseFL61WdWkKF48YzuXkfn0r5tjmKcHNdlc3ryAjBAwR9e1cXdIRdSJjvXcqrrP3kfO4zCrBqLpO9za0u62TK3BBPPFdvouoxyeWjfINvr/MV5jbS7Wwa6HS71kdAGxxj/AOsa48RR6ocJKvDzPVorgKm0gbh07549PStCGbCqSSDxx/SuO0y9W4QHLB1wvI6Ae/TtW5YT7gQSoPTB4xj9fauWLa0OdxcXY61GLRK3HH9R/wDqqUDcScnGcY9azbG6DLhsfLxgVajYiVyHBQkFRjp7V3RkmroqMuhoabE0DDoUPvk1oqxfk55AGPXFU7NvkG7oOPxzV3h34ORjj/61WopKyN1LmHSxgoDkEjken41EZE2jAHGM/wD1/epUBZSp5GOOOh/wpwiWSM5OMn/IptXN4TtuSWDZUjgls5744qyqmNucEDOCT15NQwxKgVYMDB9fxrQYx7B8o3D2qraFSmr6CRRqY+xP51aACheTnHFVrdd3zLjpx9M9aeHOQpIyM47VWhEtWXElyMcFh09hU6yjYQfl/H6VShfAI4OAO1Tb9wBOMjgCmjKUdTURsrlTtTvz/LNVbsKWJGCB096hS66oV+vtUc04zxnA4x0xVuV0ZxptMqXjbCdoIwfzzVQx5TLZz1I5q9I2+MA55BJHvUEgKIy8nGQcdqz0Z0xlZWKbgbwygjPXjGKikLEsBk4OPyqZpBJwp5B5GPSq7ltw3McEfnU2uaeopwhOOTTNp2vyOcHP596GZih8vg4p7KdoVn6kE44470OJlJ2KU4I27sEswxn047Us67Y+GAPTPX/P0qRo185QwJwDjv0/ziorqQJCduN2eP8APrxSSIlIyL92RDliMjnjpj1rznxlq0cUZRGBYAgYOME/5Fddr2o/Z4ZN5U4BHJ6n6V4tr9817fyNu3DPWsZ2k7Dh72rJ9HZjIc7S8h4J579fz5rrEuDZ2AhRm+c7mJP3scYHocf4VzOgRlMXkqbkj+6Dx68/0qHUdRe6lcuxIznB6Dr+tZtXehco87sT61eGZtqsTg9ATzn1z25rEkfIGST/AEpjSEAgHrVaWTB61pCBcpqnGwssmcjPWqcjMzBc0sr9B606NMDNdCXKrnm1Juq7IUDAqpdnJAFXWHyk1mTNlzV09Wc+MfLC3cRQWYBRkmuh0oPp+GHzA/eFZejpuuwSMqOtdPDYyO7qrAIoypPes8RO3undk2Ecl7Zb9DVSVJI9yHJPH/66e0OeorIeyubfJjPA6gGr1rffugsnDLxjFefKPY+shUu+WorM0ZIIGDDaoz6Yri/ElusV1G0eMYwa6iTZJkRyEEcEZxXOeIIsR7i3INdFF2kefm0VUw7021MVlJAweamtLnawQthh3qOPG3BqGRdrZXrXZZPRnyvNKm1OJ2GianJFOOj56hsnjkcfnXbaZeefEAAgkBz2HH1H0ryiyu/nHJGPSuh0rUnSRVGSvpmuCtRaZ3+7WjzRPTrC7MjYUrwefY+34VtWlwWODk4Oce/tXEafOs8Syo4Eg67e5Hb6+v51t2t9GQrK3zng546dqypT5dznkrbHbW0uEJOMY6+ma0oCGAx1xzXJ6dqQkUruGB2res7pZDkMCa7oyUtjSEjUDFcngAfqcdaax3HAAGByKSMh1yeQD0HenYyw246jn2qjVSLUGFGTnBHBp7OJAFJOAOxxn8KYrZiIxk4I9KaQU+YDnAx/9ehmkZF2BgsQKNweP8gU84Djk5waqJJxy3J9B39KcSWbDAkD2ppFouq42sBgEe3OKQthcA5IOfz7VGcfeyDkDrQZgSB/F6U2BOCEBOM54oVd6HPQ9PwqFH44bn6U1d4yQRg00IfI3zZweuDg9qSSTYmePXHtUJnVWIbt14zUErKxLKQTj0x+GKLDt3HTSRqAV6t1AyKqys0vCj5B69cCmscAA4Gf51G5YcBgPX8O1J7FXSRKjlsgH5fX3pw+ZScAEYGffmolbOAAfTriiWZUTBIB/p60tznlIV22KCcEk4+n4Vga1flN4DgYUkcYq1fXgRGJYDt+B/yK8w8a+IhBIYkYtIRwR6VlUnyqy3JinJmX4417fK0MDncOD/s1x+mW4ublQ7BU7k8Uwbr24eSViFzuYip55UWPbHtjAHA6k596z1WnU6Elsi1qeoBgI7U4jxg8Y/AfyrIZgOe9NJFQSOKuMbaClNQQsr4qvI9Ryv35pqK0pAreMbanm1a7m7IkgQty1WtvYUsceMUriolK7OmlS5I6kM5wrH0rLPrV29kwNlUea3pqyPLxs+adl0Nfw84FyY2/irpjGUV4wSSnIPtXIaf+7mRgeTXXxS+YI5ACSnXjqDXJifiufSZJK9Dke6f4ELGVTuRzu9c1NFcwFALtCXHQqOoqzDAvzJ/EpJFR3NizuCACMdsVzXTPb5JxXNExbjUC/KqARWZfXEk0JBNEh+Wq07YjNd0IJM+TxeKnOLTegsHKipWjzzUFmcmr2DVTdmYYeKnAoujI24HmrlrdE9aGjBXOKquPJbfijSasxWlh5cy2Or0rUjavkAOCfunt78V0thepOmQQNo4xn24zXnNtcggYPIrYsLt1wjMQp5A6Vx1aXU7Fy1VzRPQ7W6eBfMYkqxwMe3OPbmui0fVUL8MAfqefp/jXE6dqSMwV9r7QDnpz/X8K1FVJG82BgpHX3PPJB6Vzxm4MxlBxZ6ZZ36uQuQM++cVoRzI5ypH/AOqvL4L+6t1VVG9QcEjoM/rXQadriMAsrFHHHTqfX+VdsK8ZaMm9jt1lTIGScCiSTcSCeOnXkVz8WqKV5dSCCBz1xVgX0ZBw45AAAFbKz2KU7Gukg3D7vH155qysucnPP+ea51r1FVixGAffmmjVFDcsFA4HXiqSsae0Oq80InOC2fWoCqNMZRkMRjHp+NYI1hU+UNuGcZxin/2p8gYHAJwKLJlRqaG+zYbIxxSNc4cAAVzzasgjJZgPU+lJ/a8BZQpDE9DnHIoKUrm3cScblIJ7j8KzZLlt2W+UdcZ68f4VUuNSQ5CuBxmqUl6hAbeNw5NDaLjUVtTaFwJG5J4Bx9OKas+XA5K/ToKxGvwCFVl55IPpUF3q8VuoMkgyew+lRKasRKSZ0cl2oBI4XGPTpWTf6nGkTPIcADr64rhta8cwwFkh+dsYxnpXE3uu6rqs/lxBl/2V68+/41m6l9ifZt6s6nxV4uRI2jt3DyHcCR0B5x6e3rXnrLPqEzTSnjPJxUsdl5jkzyfNnJxycdc09rpY18uNcRj+E9+KyWm25uqdtCJnaOHywu1V/DJ9aoSSY/CnzzF+SfoPSs+aUk4Fawhcyr1lTQ+SXNV5ZiTjFK53LRDEWINdCSS1PMnOdSVoiRo0h+YVegi2jpToYQoFT7axnUvoehhsLy6y3G4FRScVORiqtw20VMdWb1vdjcz5/wB5OQO1RxLvb2FTshSPnmRqmgh2Ic5966nKyPDVB1KmvqxMFYlI6g102lO32cAY+YGsBEylbeiksiDp2zXJW1R9BlacKnqjXWQpNESBhkH51oLtZQeKz7lR5VvnqAR/KiOaREADCuVrqfSxnyOzOGlfFU5X3U+U5qMrXqxVj83r1HJ2JrP71aSdKyrVtsn1rVTk5rOqtTuwDThYdjNMkiDjpUyLkH1p7KOuD/hWPNY9BxTVmZTRbHBFTQTkPj0qzJGDn2qrJEN3t7VopKS1ON0pUXeBs2d4UZSpxgf54rqNP1QKQSRznkEjH+P4157FKYzzWna3zrHtU8H17fSuerRvqjeFRVbJnptpfRzONzlU7HaKvebCzEbSw7Hnqf5V5zp+qGIjbgEHIyK27bV2K8uWGMY6kdq5XGUQlQ10O3ggDAeW7YI47jH+fSrsSPG/LhjjPyqfz9K5ay1NPJAUnaDxg9B/n3rWj1JUCkuV7Yzn8acanKzCUGaxMrJk5UZ7EHv1p628mMlWYevXJqnDqEJjG4qT1H9envVv+0YjwCAMHqccelbqt3YuRln7GGQBi2ew78f0pklhCE580sevzcD8KVLyBVUAksDjr1pst2sjkB/UdP8AJq3WikHIyFrCI5BZ1Awc89v1rPvInVlWPd5ZBG0Agk/U/hV+a7XbgykkZJ49O31rNnukcDe7Z28AjHP4cVEqy6FxiyC9uZo1EMIYOFwTsJ//AFmsQ3moKjBrtsDoHjH/AOsVeubpV3FS/wAvPT/IrFlvAxIVCQ/QEjBPH589vWs/auTNYwZXvtW1BcpE7fNwAvJPbp1rGlF/O2JZnL5xgvkjPt2/GrFzMxdgX+U/KQpx/L88VXluI4xktlweRnPTuaaudMI2QjWcVurO775txG1ew9c/5/CleVVtNkakBjzhuv1/PpmqNzdbzkHGO3pVSS4Jzk5J9a0UW9xtxitSzPcAjC8DHPvVC4nyck81FJN/+uqsj7mFbwpnJXxaStEkkmyOKr5yec0JGztwOKv2toXYALlj0rVtQOCMaldkEMBcjcDk9q0re1x2xjqTWnZafggNgjPLAfyNWJoFiLeWucZAA7GuWda7sj1KGHjD1M4xhUPBAHrgc1AQO9aE8Z2heCF6DpnvzVGQHHTp7VKdztSsiBzxVSX5mHoKsSnAwKrSZY7E+8fWtoI4MTK+hHCnnzlsfKvSrbDaMEcmpYYBGgGO2aaVy1DndhToOnHXdiAYQ1s6AoKglc4BrHbhK6Pw6ii2YkEMehrOb0PRwMb1lbsWrlWKwqFHCZ/+tVJlZj1GRxWq4DSEEjKqB+dUp48EcD8axPZqRODMYphQCrm0immPHNegpHwkqF9ikBtkGK1bf5lAqjImGFXbUkBSCRj0pVHdF4OPJNosr7k57YqwqZAIwQDjj+dLFGPMB4w3TPY1ct4wSd3KjjpjP/1645SseoVnh3Rl8DH161WmgyW2g1rheo2j5TgZ7dvyphhPm5CkrnPPf8KSqWE4nPPDimKhB4robyyAVdpHr9KoPaEdiDn061rGqmjJ0U3dFJHK1YhuSvHJBpr25PUHJqPyyp6Gq0kUueJrw6nJG6lWOBxjpjitGDWJnPL84wB64rmMlacsrLnn25rOVJMq6e6OzXWiygKoVh3XjP4f/Wq2msb0GWHXIBz19c1wonbpuIHp2p63TAfeOPrWbo9ikonfwaq+75WGcnG0DPr3+lObW1VixZt3QjfjqK4Bbxgep9aU3pyOT6/jil7EHGHU7ttZwqgnc3Ax269CO9UbjWsF1VnAHBIwCOf8iuQ+3SDIVzjpzUD3RI7+4qlhyfcW50E+ru75LbixOT0z2qlPqDOgJcKQOMA5/OsdpiTUbOTWkaSRMqsVsXZblnJ3OTntVdpsmq5bNIVY1qoIylXk9h0k57VCSzdTUywknofyq1DZNIQFUk+mDzVXUTHkqVHqZ4V5Dgce9TQ2Z/i5966K00SWQrwCScbF5aum03wqFiWS4QbiMgGsp4hLY0jh4Rd56s5DTtHluU3hdsQPLH/Cuht9FjiKkF9/p0//AFdeldWLWOIYjQAYx93HTtxx0qk+0Snbj5egxyfY+g6VxyrOZ0xXYxGgVGAwcYIz0/Id/pVfy33EHgDOOnTnrWzMqlgxC5PbHf19MVl3DbmJ3AE5OPTFJO50RMi6bGPQf0rOlye+a1LiF9m6Tnjgce5rLuGA6V0Q8i5PQqzHA9qn0y0Lt5kmeeBTbC2kvrsKg3IOa61LQW6fKFG0HjvnFVVqci5epzUoqc+d9DCu4fLU5B3E8ZH8qqNHtIHfvWrLmebJyUQ8VXkiBc/mc1EZaHU1dmcy5YIfWup0yMx2SKhGW5rBtomluwAAcHpXUqoig44Kj+dKo+h35dS1c2MhIklkPfIH4D/9VNmiDEewqKAgSgIwPOOv9atsMelZuVj0YxU46nCJGeD0oZOc9varkcB6HJJ4HaidFU7U5A5rscj5GMFsZNxGQRUlsCMU+5XPSmwDFXe8TBQ5apsRQmaEEE5QbgAe9aNhEZOCTnj+dV9IUO67h8v3SR2z61qxWwtGyzrhSWBHcf4/nXDUl0Op6aCrbfviowT7jrnPAP5CnxWm1xwRgY5x0z/9b/8AVWlFbK6BwBkjIJHNT+T5gGQeeRx931H0rm5yb3MqexjG3IYHHIHbPpUUmnmQEmMbwfTGff2NbjRh413AlwPvevsfyqa2QMhiIGT04Axwf06fnRztCbdjjpbB0GHRsgmqVzYkFsKcYBHvxXohtFeIcBGzgdDVF9N8tiGUDAPzDkf/AFq1jXGp9zgGszkgAk9MY71G9qccemcV30mkRtG5CDABwcf4VTudBDrvtwSoPA/Dr61qsQiuaLOINuc9DmozHj6V2b6TN5alowR2bHUe9QvouVB2Y9Opx6/hVqug06nI+W3YYoMLYyRXTSaK64bkg8bf6006O6sAVI4PX271SrJi5YnNGNu9N8knHWunGk4Zy+0gHHQ/nUa6R5i5jfJyei4x/OmqyE4Re5zgixSGMV1P9gSZIB3f1q1H4cG0uynPBHPX60nXSE4QOPSEscKMmrUVi7EZA5z1NdjaeHnkkBEfHY4wPTr3/Ktqy8MxR4aU72Hbnb9aiWI7FpRRxum6K84yyNtGecdceldZZaKWiQCJl2jH3fm98+v6V01rp8aoFSJVYHAbGTwe1a9rZrGA20k8AZPr/KsXOUzOWphaToi2oLlR5h9RznHHPar4tgQ6nGU55PC+2a1GUKrBsEEnGO/1/wAKozmRsLGQMnBP41m9wUbmXcAZO05OMcdvp7Vky2+HdnDO27PQda2b2LytpDKCRngYx7mse7lEYYsSpP8AF7Y7VKubQj2M7UGZWIIK9vY+/wBaypIgGY7Q79QCc49z/StQwPJF5rfMc/KG5xWLdQfZ7qWUyMzOD6jHStYm0TO1B9pwWPvz+dYsoaeQRJyxNW9QmDSbUznoBW54Y0Yl/PuEycZ57V08ypx5mTU9/wBxFnQdO+xCMYIY88in6kGmkEMRPy/ebpittwY12LguSceoxUCwbTIoU+pPuc8+tcTqNu7NYR5djCNoY4jhTntxjGapXaGBTlTlhzkdM10N0rOwK/dQ9On/AOsVj3ysJGZhz/XPatKc77lW5mRaPBiTew+7nHB61qT/ADYQn3P+FQ2sfkwLk9f1qVgQjEjJNW3zM9ylD2dJRKn3JlAHQjt68VoKu4ZzVJx8w7ZYEdOP84q6Dx1pSNcOrXOfRT5eI1xgk/rVOZCDzlgPrxW5tAEmABzWbN1b6GteZ3PkIMxrheKihGGFWrv734morf8A1g+tdC2Jkveub2jfJIgbBBPX09/1rsBareQI5xwMEf59ua5jRlG3oPuiu5sQPJIwMccfgK82vvcmrKzKMO6CMxuFyOFI79cHH09KvJBmIEA4IwwP+f8AOagu/vRfUfzrUtObFs+h/nWLFf3blEQ/eUKCehPOMimrAQ/JOcg5x+H9a0AODT41BfkDqKlMtEEasqBSc46FhUqxDZ820lj3/wA47UqczAHpVwqPLxgYz0/KqSFKyKS2pjTjOCcgjofqKDFGP9WvzDAxjof6Vpj/AFf+fSh1HnNwOn9KuxNzOkhBwRnJGCOo/L8qim08OSRGvXPp+PFayAbTwO9XGAMa8DpRYe2xzElt90DAyRzjIxxTWtC5wQvHHzAHNbTKPMAwMc8Y9xSW6ru+6Oh7e1CRXKrXMb+yU6kBieeO+fXtTE0hnK/IoB6++PaujUDy+g60+BRuBwM4FXbUlMw49JZCVwSM5OalSxVDkIXwe+cZNba8kZpLj7x+pqlFMtIz44TvA9B0xjAH6Cr1pbu4zhT14PP4+9Sr9z8F/nWpadB9KuMS3ZK5SiiWEEYKk55xz/8AqqYpyMAEYHJ4/SrYA3HgdKjwCTkCm42RDZTaPPBPQ/T/ACKoTLtO0H5Rkk4/lV49/qaqXPQ/h/KsWO9jD1KTDFYvmZ+3sfWqH2VYiGlJlck/Kemf8K1IQN8pwM4HP41DcgYHFS3Y1T0MHU5BGqxjG04yPr6/nXH61dEPtDAlTgewrp9b/wCPk/SuEuebkZ/vH+ddFGNy72Rr+G9MaeX7VOuQOVHqfWu3igSGIIucAZ6d8VLoaJ9ji+Ve3anXw/dL9Kwqzc3qFPQpiEu/mMGGMge1OkjIUgk568D9auEDA4HWiMDe3Hc/zFZo2bMho2J2gZOc/wD6/wAKyrtftN5kgBF69uldDd/6iU98H+Vc8P8AjzP1FbU9rnTg4KdRyfQcBuk3HG0fd+lJKcIcY4H+TTlHyCkn/wBVVnrt6FNgfMUZ9DyPwq4i5Ubjkj2qtGP3q/hVxOlDFRP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diphtheritic membrane extending from uvula to pharyngeal wall and neck edema in 47-year-old female patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kadirova, R, Kartoglu, HU, Strebel, PM. Clinical characteristics and management of 676 hospitalized diphtheria cases, Kyrgyz Republic, 1995. J Infect Dis 2000; 181:S110. Copyright &copy; 2000 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_20_2369=[""].join("\n");
var outline_f2_20_2369=null;
var title_f2_20_2370="Patient information: Mild cognitive impairment (The Basics)";
var content_f2_20_2370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16423\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/19/43312\">",
"         Dementia caused by changes in the brain",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/14/31970\">",
"         Patient information: Dementia (including Alzheimer disease) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/3/31793\">",
"         Patient information: Evaluating memory and thinking problems (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/37/14934\">",
"         Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Mild cognitive impairment (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/mild-cognitive-impairment-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13608217\">",
"      <span class=\"h1\">",
"       What is mild cognitive impairment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Mild cognitive impairment (MCI) is a brain disorder that causes trouble with memory or thinking. The word &ldquo;cognitive&rdquo; has to do with memory and thinking. The word &ldquo;impairment&rdquo; means having trouble doing something.",
"     </p>",
"     <p>",
"      It is normal for adults to have slight memory problems as they get older. But the problems in MCI are more significant than those of normal aging.",
"     </p>",
"     <p>",
"      Many people with MCI later develop a condition called &ldquo;dementia.&rdquo; Dementia is the general term for a group of brain disorders that cause problems with memory and thinking (",
"      <a class=\"graphic graphic_figure graphicRef51927 \" href=\"UTD.htm?42/19/43312\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Dementia is a more serious problem than MCI. People with MCI usually don&rsquo;t have many problems doing their daily tasks and activities. But people with dementia may not be able to do their daily tasks or activities correctly or at all.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13608232\">",
"      <span class=\"h1\">",
"       What are the symptoms of MCI?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Memory problems are the most common symptom of MCI. Some people have other types of thinking problems. They might have trouble concentrating, reasoning, or remembering the correct word to use.",
"     </p>",
"     <p>",
"      People with MCI might also:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feel sad, worried, or angry",
"       </li>",
"       <li>",
"        Act in a threatening way",
"       </li>",
"       <li>",
"        Believe things that aren&rsquo;t true",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13608247\">",
"      <span class=\"h1\">",
"       How can my doctor or nurse tell if I have MCI?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To tell if you have MCI, your doctor or nurse will:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Talk with you and your family &ndash; He or she will ask about your symptoms, behavior, and daily activities, and how these have changed over time. He or she will also ask about your medical conditions and medicines. That&rsquo;s because some medical conditions and medicines can also cause memory problems.",
"       </li>",
"       <li>",
"        Do an exam",
"       </li>",
"       <li>",
"        Ask questions to check your memory and thinking",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor will probably do tests to check that another medical condition isn&rsquo;t causing your symptoms. These tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        A CT or MRI scan of your brain &ndash; These are imaging tests that can create pictures of your brain.",
"       </li>",
"       <li>",
"        More detailed tests to check your memory, language, and thinking",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13608262\">",
"      <span class=\"h1\">",
"       How is MCI treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sadly, there really aren&rsquo;t helpful treatments for MCI. As of now, no medicines can prevent MCI from turning into dementia.",
"     </p>",
"     <p>",
"      If you have a lot of memory problems, your doctor might prescribe a medicine used to treat a type of dementia called Alzheimer disease. These medicines can sometimes help improve symptoms.",
"     </p>",
"     <p>",
"      Your doctor will also talk with you about ways to keep your brain as healthy as possible. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Getting regular exercise",
"       </li>",
"       <li>",
"        Having an active social life",
"       </li>",
"       <li>",
"        Keeping your brain busy and active",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13608277\">",
"      <span class=\"h1\">",
"       Do people with MCI always get dementia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. Although many people with MCI get dementia later on, some do not.",
"     </p>",
"     <p>",
"      There is no way to know which people with MCI will get dementia. That&rsquo;s why it&rsquo;s important to have regular follow-ups with your doctor. He or she can follow your symptoms to see if they change or get worse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13608292\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/3/31793?source=see_link\">",
"       Patient information: Evaluating memory and thinking problems (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=see_link\">",
"       Patient information: Dementia (including Alzheimer disease) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=see_link\">",
"       Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?2/20/2370?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16423 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-0970125B04-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_20_2370=[""].join("\n");
var outline_f2_20_2370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13608217\">",
"      What is mild cognitive impairment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13608232\">",
"      What are the symptoms of MCI?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13608247\">",
"      How can my doctor or nurse tell if I have MCI?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13608262\">",
"      How is MCI treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13608277\">",
"      Do people with MCI always get dementia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13608292\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16423\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/19/43312\">",
"      Dementia caused by changes in the brain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/3/31793?source=related_link\">",
"      Patient information: Evaluating memory and thinking problems (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_20_2371="Ovarian cysts";
var content_f2_20_2371=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Ovarian cysts (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/20/2371/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/20/2371/contributors\" id=\"au4880\">",
"       Michael G Muto, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/20/2371/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/20/2371/contributors\" id=\"se7382\">",
"       Barbara Goff, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/20/2371/contributors\" id=\"se5145\">",
"       William J Mann, Jr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/20/2371/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/20/2371/contributors\" id=\"de1930\">",
"       Sandy J Falk, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?2/20/2371?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OVARIAN CYST OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Ovarian cysts are fluid-filled sacs that develop in or on the ovary (",
"     <a class=\"graphic graphic_figure graphicRef77045 \" href=\"UTD.htm?0/49/787\">",
"      figure 1",
"     </a>",
"     ). Ovarian cysts occur commonly in women of all ages. Some women with ovarian cysts have pain or pelvic pressure, while others have no symptoms. Irregular menstrual periods are not usually related to an ovarian cyst.",
"    </p>",
"    <p>",
"     Fortunately, most ovarian cysts do not require surgical removal and are not caused by cancer. Cysts can vary in size from less than one centimeter (one-half inch) to greater than 10 centimeters (4 inches).",
"    </p>",
"    <p>",
"     This topic discusses the various causes of ovarian cysts, how ovarian cysts are diagnosed, and what follow up testing",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     treatment might be recommended.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      OVARIAN CYST CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     The most common causes of ovarian cysts depend upon whether you are still having menstrual periods (premenopausal) or have stopped menstruating for at least one year (postmenopausal). (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=see_link\">",
"      \"Differential diagnosis of the adnexal mass\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Premenopausal women",
"     </span>",
"     &nbsp;&mdash;&nbsp;For premenopausal women, the most common causes of ovarian cysts include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Ovulation &mdash; \"Functional\" ovarian cysts develop when a follicle (sac) grows, but does not rupture to release the egg. These cysts usually resolve without treatment.",
"      </li>",
"      <li>",
"       Dermoid cysts &mdash; Dermoid cysts (teratomas) are one of the most common types of cysts found in women between age 20 and 40 years. A dermoid cyst is made up ovarian germ cells (germ cells are reproductive cells, eg, eggs) and can contain teeth, hair, or fat. Most dermoid cysts are benign, but rarely, they can be cancerous. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link&amp;anchor=H10#H10\">",
"        \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\", section on 'Mature cystic teratoma (dermoid cyst)'",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Polycystic ovary syndrome (PCOS) &mdash; Women with PCOS may have many small cysts. These cysts do not need to be removed or treated with medication, but women with PCOS may need treatment for other PCOS problems, such as irregular menstrual periods. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30437?source=see_link\">",
"        \"Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Endometriosis &mdash; Women with endometriosis can develop a type of ovarian cyst called an endometrioma, or \"chocolate cyst.\" (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?25/63/26611?source=see_link\">",
"        \"Patient information: Endometriosis (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Pregnancy &mdash; An ovarian cyst normally develops in early pregnancy, to help support the pregnancy until the placenta forms. In some cases, the cyst stays on the ovary until later in the pregnancy.",
"      </li>",
"      <li>",
"       Severe pelvic infections &mdash; Severe pelvic infections may spread to involve the ovaries and fallopian tubes. As a result, pus-filled cysts form close to the ovaries",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       fallopian tubes.",
"      </li>",
"      <li>",
"       Non-cancerous growths",
"      </li>",
"      <li>",
"       Cancer &mdash; Cancer is a relatively uncommon cause of ovarian cysts in premenopausal women; less than 1 percent of new growths on or near the ovary are related to ovarian cancer.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Postmenopausal women",
"     </span>",
"     &nbsp;&mdash;&nbsp;In women who have stopped having menstrual periods, the most common causes of ovarian cysts include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Non-cancerous growths",
"      </li>",
"      <li>",
"       Fluid collection in the ovary",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In postmenopausal women, new growths on or around the ovary are somewhat more likely to be caused by cancer than in premenopausal women.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Do I have ovarian cancer?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although ovarian cancer is not the most common cause of ovarian cysts, many women who are diagnosed with a cyst are concerned that they could have cancer. Ovarian cancer is more likely in women who have:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       A genetic predisposition to ovarian cancer (eg, family history of ovarian or related cancers)",
"      </li>",
"      <li>",
"       A previous history of breast or gastrointestinal cancer",
"      </li>",
"      <li>",
"       A cyst that appears complex (a cyst with solid areas, nodule on the surface, or multiple fluid-filled areas)",
"      </li>",
"      <li>",
"       A fluid collection (called ascites) found in the pelvis or abdomen during the imaging test",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     However, women without cancer may also have these characteristics. In most cases, further testing will be recommended to gauge the likelihood of cancer.",
"    </p>",
"    <p>",
"     If your doctor is concerned that you could have ovarian cancer, he or she may recommend that you meet with a physician specialist, called a gynecologic oncologist. These physicians have been trained in the surgical treatment of ovarian cancer, and can improve your chances of survival. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=see_link\">",
"      \"Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H925537\">",
"     <span class=\"h1\">",
"      OVARIAN CYST SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Ovarian cysts may be either symptomatic or asymptomatic. Women with symptoms from ovarian cysts typically experience pain or pressure in the lower abdomen on the side of the cyst. This pain may be dull or sharp; it may be constant or come and go. Crampy lower abdominal pain is not usually related to ovarian cysts. If an ovarian cyst ruptures, a woman may experience a sudden sharp pain, which may be severe. Women with torsion (twisting) of an ovary may feel pain along with nausea and vomiting. Abnormal periods or vaginal bleeding is not usually related to ovarian cysts.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      OVARIAN CYST DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Ovarian cysts can sometimes be detected during a pelvic examination, although an imaging test, usually a pelvic ultrasound, is necessary to confirm the diagnosis. Computed tomography (CT) scan or magnetic resonance imaging (MRI) are also sometimes used, but less commonly. These imaging tests can also provide information about the cyst's size, location, and other important characteristics. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=see_link\">",
"      \"Sonographic differentiation of benign versus malignant adnexal masses\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Blood testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;One or more blood tests may be recommended if you are found to have an ovarian cyst. The blood test(s) can help to determine the nature of the cyst.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Pregnancy testing &mdash; A blood or urine pregnancy test is often performed in premenopausal women with an ovarian cyst. Ovarian cysts are common during pregnancy.",
"      </li>",
"      <li>",
"       CA 125 &mdash; CA 125 is a blood test that is sometimes drawn in women with ovarian cysts. However, ovarian cancer cannot be diagnosed based upon the results of a CA 125 test. Many women with early ovarian cancer will have a normal CA 125 level. CA 125 is abnormally elevated in about 80 percent of women with advanced ovarian cancer.",
"       <br/>",
"       <br/>",
"       Also, non-cancerous conditions can cause CA 125 to be elevated, including endometriosis, uterine fibroids, pelvic infections, heart failure, and liver and kidney disease. As a result, measurement of the CA 125 is not recommended in every case. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?6/15/6386?source=see_link\">",
"        \"Patient information: Ovarian cancer screening (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       CA 125 is often recommended for postmenopausal women with an ovarian cyst.",
"      </li>",
"      <li>",
"       CA 125 may be recommended for premenopausal women whose ovarian cyst appears very large or suspicious for cancer on ultrasound.",
"      </li>",
"      <li>",
"       CA 125 is not usually recommended for premenopausal women with ovarian cysts that are small and do not appear suspicious for cancer.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Other blood tests are also available for testing women with an ovarian cyst for ovarian cancer.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Next steps",
"     </span>",
"     &nbsp;&mdash;&nbsp;Depending upon the results of the imaging test, your age, symptoms, results of blood tests, and your family history, your healthcare provider may recommend watchful waiting or surgery. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"      \"Approach to the patient with an adnexal mass\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      OVARIAN CYST TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Ovarian cysts do not always require treatment. In premenopausal women, ovarian cysts often resolve on their own within one to two months, without treatment. In postmenopausal women, ovarian cysts are less likely to resolve.",
"    </p>",
"    <p>",
"     If a cyst is large, causing pain, or appears suspicious for cancer, treatment usually involves surgery to remove the cyst or the entire ovary.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Watchful waiting",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Premenopausal women",
"     </span>",
"     &nbsp;&mdash;&nbsp;In premenopausal women, watchful waiting usually involves monitoring for symptoms (pelvic pain or pressure) and repeating the pelvic ultrasound after six to eight weeks. If the ovarian cyst does not enlarge or if it resolves during the period of watchful waiting, it does not usually require surgical removal. Some premenopausal women will be advised to take a birth control pill during this time to help prevent new ovarian cysts from developing.",
"    </p>",
"    <p>",
"     If a cyst decreases in size or does not change, the ultrasound is often repeated at regular intervals until your healthcare provider is certain that the cyst is not growing. If the cyst resolves, no further testing or follow-up is required. (See",
"     <a class=\"local\" href=\"#H15\">",
"      'Ovarian cyst follow-up'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Postmenopausal women",
"     </span>",
"     &nbsp;&mdash;&nbsp;In postmenopausal women, the decision to undergo watchful waiting depends upon the initial testing (ultrasound and CA 125). If the cyst does not appear to be cancerous, watchful waiting may be an option, and includes a pelvic ultrasound and measurement of CA 125 every three to six months for one year, or until the cyst resolves. However, ovarian cysts do not always resolve in postmenopausal women.",
"    </p>",
"    <p>",
"     If the CA 125 levels increase or the cyst grows or changes in appearance, then surgery to remove the cyst may be recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgery may be recommended in the following situations:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A cyst is causing persistent pain or pressure, or may rupture or twist.",
"      </li>",
"      <li>",
"       A cyst appears on ultrasound to be caused by endometriosis and is removed for fertility reasons.",
"      </li>",
"      <li>",
"       Large cysts (&gt;5 to 10 cm) are more likely to require surgical removal compared to smaller cysts. However, a large size does not predict whether a cyst is cancerous.",
"      </li>",
"      <li>",
"       If the cyst appears suspicious for cancer. If you have risk factors for ovarian cancer or the cyst looks potentially cancerous on imaging studies, your healthcare provider may recommend surgery.",
"      </li>",
"      <li>",
"       If the suspicion for ovarian cancer is low but the cyst does not resolve after several ultrasounds, you may choose to have it removed after a discussion with your healthcare provider. However, surgical removal is not usually necessary in this case.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Surgery to remove ovarian cyst",
"     </span>",
"     &nbsp;&mdash;&nbsp;If surgery is needed to remove an ovarian cyst, the procedure is usually done in a hospital or surgical center. Whether the surgery involves removing only the cyst or the entire ovary depends upon your age and what is found during the procedure. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=see_link\">",
"      \"Oophorectomy and ovarian cystectomy\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     For example:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If there is suspicion of cancer, the whole ovary must be removed since cutting into a cancerous cyst may lead to cancer spread. In some cases, the whole ovary is removed and the cyst turns out to be benign. Having one ovary removed will not cause you to go through menopause and will not cause you to be infertile.",
"      </li>",
"      <li>",
"       If the cyst appears non-cancerous and is able to be removed through small incisions, it may be removed laparoscopically (through several small incisions) and you may be able to go home the same day.",
"      </li>",
"      <li>",
"       If the cyst is large or appears suspicious for cancer, it may be necessary to have an open incision (called a laparotomy) and the surgeon may need to remove the entire ovary and surrounding tissues. You will need to stay in the hospital for one or more nights after a laparotomy.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      OVARIAN CYST FOLLOW-UP",
"     </span>",
"    </p>",
"    <p>",
"     After an ovarian cyst resolves, you will not need further imaging tests if you do not have symptoms.",
"    </p>",
"    <p>",
"     Some types of ovarian cysts are more likely to recur than others. This includes endometriomas and functional ovarian cysts. If you are premenopausal and are concerned about recurrent cysts, taking a birth control pill or other hormonal form of birth control may help to prevent ovarian cysts from developing. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413328185\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11169416\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/27/39346?source=see_link\">",
"      Patient information: Ovarian cysts (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11169433\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/46/30437?source=see_link\">",
"      Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/63/26611?source=see_link\">",
"      Patient information: Endometriosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=see_link\">",
"      Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/15/6386?source=see_link\">",
"      Patient information: Ovarian cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5863?source=see_link\">",
"      Diagnosis and management of ovarian endometriomas",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19352?source=see_link\">",
"      Differential diagnosis of the adnexal mass",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9863?source=see_link\">",
"      Evaluation and management of ruptured ovarian cyst",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15482?source=see_link\">",
"      Management of pregnant women undergoing nonobstetric surgery",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12393?source=see_link\">",
"      Oophorectomy and ovarian cystectomy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23690?source=see_link\">",
"      Ovarian and fallopian tube torsion",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link\">",
"      Approach to the patient with an adnexal mass",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34440?source=see_link\">",
"      Sonographic differentiation of benign versus malignant adnexal masses",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link\">",
"      Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?2/20/2371/abstract/1-7\">",
"      1-7",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?2/20/2371?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2371/abstract/1\">",
"      Modesitt SC, Pavlik EJ, Ueland FR, et al. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol 2003; 102:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2371/abstract/2\">",
"      Castillo G, Alc&aacute;zar JL, Jurado M. Natural history of sonographically detected simple unilocular adnexal cysts in asymptomatic postmenopausal women. Gynecol Oncol 2004; 92:965.",
"     </a>",
"    </li>",
"    <li>",
"     Myers ER, Bastian LA, Havrilesky LJ, et al. Management of Adnexal Mass. Evidence Report/Technology Assessment No.130 (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-02-0025). AHRQ Publication No. 06-E004, Agency for Healthcare Research and Quality, Rockville, MD February 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2371/abstract/4\">",
"      American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol 2011; 117:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2371/abstract/5\">",
"      Dearking AC, Aletti GD, McGree ME, et al. How relevant are ACOG and SGO guidelines for referral of adnexal mass? Obstet Gynecol 2007; 110:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2371/abstract/6\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Management of adnexal masses. Obstet Gynecol 2007; 110:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2371/abstract/7\">",
"      McDonald JM, Modesitt SC. The incidental postmenopausal adnexal mass. Clin Obstet Gynecol 2006; 49:506.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f2_20_2371=[""].join("\n");
var outline_f2_20_2371=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OVARIAN CYST OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           OVARIAN CYST CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H925537\">",
"           OVARIAN CYST SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           OVARIAN CYST DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           OVARIAN CYST TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           OVARIAN CYST FOLLOW-UP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/49/787\" title=\"figure 1\">",
"           Ovarian anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f2_20_2372="Proparacaine: Patient drug information";
var content_f2_20_2372=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Proparacaine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/57/2963?source=see_link\">",
"     see \"Proparacaine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/19/36146?source=see_link\">",
"     see \"Proparacaine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F214470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alcaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F214471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alcaine&reg;;",
"     </li>",
"     <li>",
"      Diocaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to numb the eye.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705948",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to proparacaine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12300 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-5450C57513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_20_2372=[""].join("\n");
var outline_f2_20_2372=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214470\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214471\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031540\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031539\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031543\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031544\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031546\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031542\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031547\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031548\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/57/2963?source=related_link\">",
"      Proparacaine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/19/36146?source=related_link\">",
"      Proparacaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_20_2373="Ferrous fumarate: Patient drug information";
var content_f2_20_2373=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ferrous fumarate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7798?source=see_link\">",
"     see \"Ferrous fumarate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20709?source=see_link\">",
"     see \"Ferrous fumarate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Femiron&reg; [OTC];",
"     </li>",
"     <li>",
"      Ferretts&reg; [OTC];",
"     </li>",
"     <li>",
"      Ferro-Sequels&reg; [OTC];",
"     </li>",
"     <li>",
"      Ferrocite&trade; [OTC];",
"     </li>",
"     <li>",
"      Hemocyte&reg; [OTC];",
"     </li>",
"     <li>",
"      Ircon&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F170763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Palafer&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Accidental overdose of drugs that have iron in them is a leading cause of deadly poisoning in children younger than 6 years of age. Keep away from children. If this drug is taken by accident, call a doctor or poison control center right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691725",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Iron is most often taken during pregnancy to stop anemia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702115",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ferrous fumarate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703226",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Anemia from a cause other than low iron stores, too much iron in your body, or thalassemia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696857",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take calcium, zinc, copper, or multivitamins that have any of these minerals within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take tetracycline within 4 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take antibiotics like ciprofloxacin and levofloxacin 2 hours before this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black stools.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If a child eats your tablets. Poisonings with iron happen most often in children. First signs of overdose include feeling tired, upset stomach, throwing up, belly pain, dark tarry-black stool, and a weak or fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, period changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695812",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 1 hour before or 2 hours after bran, fiber, tea, coffee, dairy products, or eggs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694866",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11191 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-3384FBAA07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_20_2373=[""].join("\n");
var outline_f2_20_2373=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170762\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170763\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019331\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019333\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019332\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019337\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019338\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019340\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019335\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019336\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019341\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019342\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7798?source=related_link\">",
"      Ferrous fumarate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20709?source=related_link\">",
"      Ferrous fumarate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_20_2374="Ectopic pregnancy 2";
var content_f2_20_2374=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Six week ectopic pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The fallopian tube has been opened to reveal the gestational sac.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Aron Schuftan, MD. Copyright &copy; Aron Schuftan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_20_2374=[""].join("\n");
var outline_f2_20_2374=null;
var title_f2_20_2375="Foot anatomy superior view";
var content_f2_20_2375=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Foot anatomy superior view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 521px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_20_2375=[""].join("\n");
var outline_f2_20_2375=null;
var title_f2_20_2376="Chapter 6C: Aldosterone";
var content_f2_20_2376=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 6C: Aldosterone",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/20/2376/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/20/2376/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/20/2376/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/20/2376/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/20/2376/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/20/2376/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/20/2376/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/20/2376/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2003.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The steps involved in adrenal cortical steroid synthesis are illustrated in this figure (",
"    <a class=\"graphic graphic_figure graphicRef70372 \" href=\"UTD.htm?0/7/123\">",
"     figure 1",
"    </a>",
"    ). The major adrenal hormones are synthesized in different areas of the adrenal cortex: aldosterone in the zona glomerulosa, and glucocorticoids (particularly cortisol), androgens, and estrogens in the zona fasciculata and reticularis. The zona glomerulosa is well adapted for the production of aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It has a low concentration of 17-alpha-hydroxylase, the enzyme necessary for cortisol and androgen synthesis. More importantly, the final steps in the conversion of corticosterone to aldosterone, the addition of an hydroxyl group at the 18-carbon position and its subsequent oxidation to an aldehyde, occur only in the zona glomerulosa [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These two reactions are mediated by a single multifunctional cytochrome P450 enzyme called",
"    <strong>",
"     aldosterone synthase",
"    </strong>",
"    (or corticosterone methyl oxidase) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/2-4\">",
"     2-4",
"    </a>",
"    ], the activity of which is normally suppressed in the zona fasciculata. This suppression is important physiologically because it prevents aldosterone secretion from being inappropriately regulated by ACTH.",
"   </p>",
"   <p>",
"    Aldosterone synthase has over 95 percent homology with 11&szlig;-hydroxylase (which converts deoxycortisol to cortisol in the zona fasciculata) and their genes are located in the same region on chromosome 8 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/5\">",
"     5",
"    </a>",
"    ]. This relationship becomes clinically important in the familial disorder glucocorticoid-remediable aldosteronism. A chimeric gene, containing the regulator portion of 11&szlig;-hydroxylase and the synthetic region of aldosterone synthase, is formed in this condition in which the regulator portion of 11&szlig;-hydroxylase makes aldosterone synthesis ACTH-dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22615?source=see_link\">",
"     \"Familial hyperaldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldosterone acts primarily in the distal nephron to increase the reabsorption of Na+ and Cl- and the secretion of K+ and H+ (",
"    <a class=\"graphic graphic_figure graphicRef55485 \" href=\"UTD.htm?22/30/23022\">",
"     figure 2",
"    </a>",
"    ). As with other steroid hormones, aldosterone acts by diffusing into the tubular cell and then attaching to a specific cytosolic receptor (",
"    <a class=\"graphic graphic_figure graphicRef56745 \" href=\"UTD.htm?4/61/5086\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The hormone-receptor complex then migrates to the nucleus, where it interacts with specific sites on the nuclear chromatin to enhance messenger RNA and ribosomal RNA transcription. This in turn is translated into the synthesis of new proteins called aldosterone-induced proteins (AIPs) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The time required for these processes to occur accounts for the 30 to 90 minute latent period before electrolyte excretion is affected [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    How these proteins act is not well understood. Aldosterone increases the abundance of the alpha subunit and promotes the phosphorylation of the beta and gamma subunits of the luminal membrane Na+ channel through which luminal Na+ enters the cells [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. One early AIP is a serine kinase that appears to regulate Na+ channel activity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Another AIP is K-ras2, which also helps stabilize epithelial Na+ channel activity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/11,16\">",
"     11,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cortisol as a mineralocorticoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cortisol, which circulates in much higher concentrations than aldosterone, binds with equal affinity to the aldosterone receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/17\">",
"     17",
"    </a>",
"    ]. However, cortisol does not act as a major mineralocorticoid because target tissues, such as the aldosterone-sensitive cells in the collecting tubules and salivary glands, possess enzymes, such as 11-beta-hydroxysteroid dehydrogenase, that converts cortisol to cortisone and other inactive metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Thus, only aldosterone physiologically activates the receptor.",
"   </p>",
"   <p>",
"    If, however, 11-beta-hydroxysteroid dehydrogenase is inactivated, then cortisol can act as the primary endogenous mineralocorticoid, leading to manifestations of primary aldosteronism such as hypertension, hypokalemia, and metabolic alkalosis (see Chap. 27). One example is the chronic ingestion of licorice, which contains glycyrrhetinic acid, an inhibitor of 11&szlig;-hydroxysteroid dehydrogenase [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40838?source=see_link\">",
"     \"Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     NaCl and potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary sites of action of aldosterone are in the connecting segment and the collecting tubules [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Its effects vary with the specific cell type that is affected. Perhaps most important, aldosterone promotes the reabsorption of NaCl and the secretion of K+ in the connecting segment and in the principal cells in the cortical collecting tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]; it also appears to enhance Na+ reabsorption but not K+ secretion in the papillary (inner medullary) collecting tubule and NaCl reabsorption in the distal tubule by increasing the number of Na+-Cl- cotransporters in the luminal membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cell model for how these processes occur in the principal cells in the cortical collecting tubule is shown in this figure (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"UTD.htm?12/31/12797\">",
"     figure 4",
"    </a>",
"    ). Aldosterone stimulates ionic transport in these cells by increasing the number of open Na+ and K+ channels in the luminal membrane as well as the activity of the Na+-K+-ATPase pump in the basolateral membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/7,8,12,24\">",
"     7,8,12,24",
"    </a>",
"    ]. As an example, going from a high to a low sodium diet (which is associated with enhanced aldosterone release) can increase the number of open Na+ channels per cell from less than 100 to approximately 3000 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/28\">",
"     28",
"    </a>",
"    ]. Both opening of previously silent channels and insertion of new channels in the luminal membrane appear to contribute to this response [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/12,29\">",
"     12,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The aldosterone-induced elevation in luminal Na+ permeability promotes Na+ diffusion into the tubular cell; this Na+ is then returned to the systemic circulation by the Na+-K+-ATPase pump [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/7\">",
"     7",
"    </a>",
"    ]. The movement of Na+ through its channel is electrogenic in that it creates a lumen-negative potential difference. Electroneutrality is maintained in this setting either by passive Cl- reabsorption via the paracellular pathway or by K+ secretion from the cell into the lumen. Na+ reabsorption also enhances K+ secretion by a second mechanism: the transport of reabsorbed Na+ out of the cell by the Na+-K+-ATPase pump increases K+ entry across the basolateral membrane. The ensuing rise in cell K+ concentration permits continued K+ secretion, which is the primary determinant of urinary K+ excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11657?source=see_link\">",
"     \"Chapter 12B: Renal potassium excretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increase in luminal Na+ permeability represents a primary hormonal action, since blocking these channels with the diuretic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    at least transiently prevents the aldosterone-induced increases in K+ secretion, luminal K+ permeability, and Na+-K+-ATPase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/24,30\">",
"     24,30",
"    </a>",
"    ]. Thus, the latter effects are in part secondary to the rise in Na+ entry; as an example, an elevation in cell Na+ concentration directly and rapidly increases the number of active Na+-K+-ATPase pumps in the basolateral membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/31\">",
"     31",
"    </a>",
"    ]. However, the later increase in Na+-K+-ATPase activity is probably induced in part by aldosterone as some aldosterone-induced proteins may be subunits of the Na+-K+-ATPase pump [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/7,32\">",
"     7,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hydrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stimulatory effect of aldosterone on H+ secretion occurs in different collecting tubular cells from those that transport Na+: in the intercalated cells in the cortex and in the tubular cells in the outer medulla [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. These cells, like the principal cells that reabsorb Na+, are able to respond to aldosterone because they contain mineralocorticoid receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/35\">",
"     35",
"    </a>",
"    ]. Their main function in normal conditions is H+ secretion via H+-ATPase pumps in the apical membrane; they do not contribute to net Na+ reabsorption (",
"    <a class=\"graphic graphic_figure graphicRef51361 \" href=\"UTD.htm?38/43/39613\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Aldosterone also indirectly stimulates H+ secretion in the cortex via its effect on Na+ reabsorption in the principal cells. The associated generation of a lumen-negative potential creates a favorable electrical gradient for H+ accumulation in the lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/36\">",
"     36",
"    </a>",
"    ]. These effects of aldosterone are probably permissive, since there is little evidence that acid-base balance directly influences aldosterone release.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Extrarenal effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldosterone reduces the concentration of Na+ and raises that of K+ in colonic and salivary secretions and in sweat [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/7,37\">",
"     7,37",
"    </a>",
"    ]. These changes are generally of limited physiologic importance, although colonic secretion of K+ can become an important route of K+ elimination in patients with end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CONTROL OF ALDOSTERONE SECRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldosterone plays an important role in the maintenance of volume and K+ balance via its effects on NaCl and K+ excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/39\">",
"     39",
"    </a>",
"    ]. Thus, it is appropriate that angiotensin II (the production of which varies inversely with volume) and an elevation in the plasma K+ concentration are the major stimuli of aldosterone secretion.",
"   </p>",
"   <p>",
"    Angiotensin II and hyperkalemia act on the zona glomerulosa, promoting the conversion of cholesterol to pregnenolone and, more importantly, of corticosterone to aldosterone via stimulation of aldosterone synthase (",
"    <a class=\"graphic graphic_figure graphicRef70372 \" href=\"UTD.htm?0/7/123\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. As an example, chronic sodium restriction leads to a 10-fold increase in messenger RNA for aldosterone synthase and in aldosterone synthase activity (as estimated from enhanced conversion of corticosterone to aldosterone) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aldosterone release can also be affected by other factors, being enhanced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/62/2023?source=see_link\">",
"     adrenocorticotropic hormone",
"    </a>",
"    (ACTH) and hyponatremia, and suppressed by atrial natriuretic peptide (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42422?source=see_link\">",
"     \"Chapter 6D: Natriuretic peptides\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Renin-angiotensin system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The volume stimulus to aldosterone secretion is primarily mediated by the renin-angiotensin system [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13720?source=see_link\">",
"     \"Chapter 2B: Renin-angiotensin system\"",
"    </a>",
"    .) In normal subjects, both the plasma renin activity and aldosterone release vary inversely with dietary Na+ intake (",
"    <a class=\"graphic graphic_figure graphicRef78411 \" href=\"UTD.htm?21/10/21678\">",
"     figure 6",
"    </a>",
"    ). An increase in Na+ intake, for example, initially expands the extracellular volume, resulting in reductions in renin and aldosterone production. These changes allow the excess Na+ to be excreted by reducing Na+ reabsorption in the proximal tubule (the site of action of angiotensin II) and in the cortical and papillary collecting tubules (the sites of action of aldosterone) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/24,26,44\">",
"     24,26,44",
"    </a>",
"    ]. ANP, the secretion of which is increased by volume expansion, can contribute to the suppression of the aldosterone release in this setting (see below).",
"   </p>",
"   <p>",
"    Conversely, a reduction in the effective circulating volume will enhance the secretion of renin and therefore that of aldosterone. The ensuing Na+ retention returns the volume toward normal. The importance of renin in this sequence has been demonstrated by the loss of the hypovolemic stimulus to aldosterone release in nephrectomized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Plasma K+ concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldosterone secretion is stimulated by K+, increasing linearly as the plasma K+ concentration rises above 3.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. This represents a direct effect on the zona glomerulosa [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/48\">",
"     48",
"    </a>",
"    ] and is extremely sensitive, as increments in the plasma K+ concentration of as little as 0.1 to 0.2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    can induce a significant elevation in aldosterone release [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/46\">",
"     46",
"    </a>",
"    ]. The resultant increase in K+ excretion then returns the plasma K+ concentration toward normal (",
"    <a class=\"graphic graphic_figure graphicRef67590 \" href=\"UTD.htm?19/22/19822\">",
"     figure 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/25,39\">",
"     25,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There appears to be a positive interaction between K+ and angiotensin II, in that the presence of one stimulus to aldosterone production increases the response to the other [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/47,49\">",
"     47,49",
"    </a>",
"    ]. This synergism may in part involve activation of a local",
"    <strong>",
"     intraadrenal",
"    </strong>",
"    renin-angiotensin system. In isolated zona glomerulosa cells, for example, a rise in extracellular K+ concentration enhances adrenal renin and angiotensin II release [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Furthermore, the associated increase in aldosterone secretion in this setting is impaired by the presence of an angiotensin converting enzyme inhibitor that reduces the local production of angiotensin II [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Adrenocorticotropic hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACTH, released from the anterior pituitary, enhances adrenal glucocorticoid and androgen synthesis and release by increasing the gene expression for a number of adrenal enzymes, including 17-alpha-hydroxylase, 21-hydroxylase, and 11&szlig;-hydroxylase [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/2\">",
"     2",
"    </a>",
"    ]. It also causes a transient rise in aldosterone secretion, that is mediated both by activation of adenylyl cyclase and by a small increase in Ca2+ entry [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/52\">",
"     52",
"    </a>",
"    ]. The limitation in the ACTH response may be due to two factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overproduction of deoxycorticosterone (",
"      <a class=\"graphic graphic_figure graphicRef70372 \" href=\"UTD.htm?0/7/123\">",
"       figure 1",
"      </a>",
"      ), an ACTH dependent steroid with relatively potent mineralocorticoid activity. The ensuing fluid retention will diminish the secretion of renin and secondarily that of aldosterone.",
"     </li>",
"     <li>",
"      The induction by ACTH of 17-alpha-hydroxylase activity in the",
"      <strong>",
"       zona glomerulosa",
"      </strong>",
"      , thereby converting this segment to cortisol production; this is an appropriate response when ACTH production is chronically stimulated in critically ill patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Plasma sodium concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldosterone secretion may be increased by hyponatremia and reduced by hypernatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. These changes can be seen with as little as a 4 to 5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    change in the plasma Na+ concentration. However, the plasma Na+ concentration does not play an important role in modulating aldosterone release in normal subjects, since it is normally held relatively constant (&plusmn; 1 to 2 percent) by the effects of ADH and thirst (see above). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=see_link\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even when hyponatremia is present, its effect on aldosterone is frequently",
"    <strong>",
"     overridden",
"    </strong>",
"    by concomitant changes in the effective circulating volume. As an example, aldosterone secretion is increased in the hyponatremic patient who is volume-depleted, but may be reduced in a patient who is volume-expanded, as in the syndrome of inappropriate ADH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MAINTENANCE OF SODIUM AND POTASSIUM BALANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since aldosterone affects both Na+ and K+ handling, it might be expected that regulation of the excretion of one ion would interfere with that of the other. This does not occur because of two additional effects: (1) K+ secretion is highly dependent upon the rate of sodium and water delivery to the cortical collecting tubule (see Chap. 12); and (2) K+ balance can influence Na+ reabsorption in the thick ascending limb of the loop of Henle (and perhaps the proximal tubule) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    How these factors interact to allow Na+ and K+ excretion to be regulated independently is summarized in Table 1 (",
"    <a class=\"graphic graphic_table graphicRef79401 \" href=\"UTD.htm?39/45/40667\">",
"     table 1",
"    </a>",
"    ). Effective circulating volume depletion, for example, activates the renin-angiotensin-aldosterone system. This response appropriately reduces Na+ excretion by increasing reabsorption both in the proximal tubule (via angiotensin II) and in the distal nephron (via aldosterone). K+ excretion, on the other hand, is not importantly affected in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/59\">",
"     59",
"    </a>",
"    ]; the increase in proximal reabsorption reduces distal fluid delivery, thereby counteracting the stimulatory effect of aldosterone. This explains why untreated patients with heart failure or cirrhosis (who are effectively volume-depleted due to systemic vasodilatation; (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=see_link\">",
"     \"Pathogenesis of ascites in patients with cirrhosis\"",
"    </a>",
"    )) do not spontaneously develop K+ wasting and hypokalemia, even though aldosterone secretion is frequently elevated.",
"   </p>",
"   <p>",
"    Sodium loading reverses this sequence as Na+ excretion is increased, while K+ balance is maintained due to the offsetting effects of increased distal delivery and reduced aldosterone secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/60\">",
"     60",
"    </a>",
"    ]. If, however, aldosterone release is not diminished because of a nonsuppressible adrenal adenoma, K+ wasting and hypokalemia will ensue [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/60\">",
"     60",
"    </a>",
"    ]. Thus, administration of a high Na+ diet has been used as a screening test to unmask primary aldosteronism.",
"   </p>",
"   <p>",
"    A K+ load, on the other hand, enhances aldosterone secretion and may reduce loop Na+ transport [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/58\">",
"     58",
"    </a>",
"    ]. As a result, the aldosterone-induced increase in cortical collecting tubule Na+ reabsorption is counteracted by the elevation in Na+ delivery from the more proximal segments. The net effect is an appropriate increase in the excretion of K+ with little change in that of Na+.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ALDOSTERONE ESCAPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;If aldosterone is given to a normal subject on an adequate salt intake, NaCl and water retention and K+ loss are seen initially, leading to a rise in blood pressure, weight gain, and potassium depletion. However, after a weight gain of approximately 3 kg, a spontaneous diuresis ensues, returning the plasma volume toward normal (",
"    <a class=\"graphic graphic_figure graphicRef62044 \" href=\"UTD.htm?28/29/29150\">",
"     figure 8",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This phenomenon has been called aldosterone escape [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/63\">",
"     63",
"    </a>",
"    ]. It does not, however, represent aldosterone resistance, since urinary K+ loss continues [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/61\">",
"     61",
"    </a>",
"    ] and the cortical collecting tubule remains responsive to aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/64\">",
"     64",
"    </a>",
"    ]. Rather, the escape phenomenon appears to be due to decreased Na+ reabsorption in some other nephron segment, perhaps the loop of Henle or the papillary collecting tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three factors, at least two of which are induced by the initial volume expansion, are thought to play a major role in this response:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased secretion of atrial natriuretic peptide (ANP), which acts both by increasing the glomerular filtration rate and by diminishing Na+ reabsorption in the inner medullary collecting duct (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42422?source=see_link\">",
"       \"Chapter 6D: Natriuretic peptides\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      An elevation in systemic blood pressure producing a pressure natriuretic (",
"      <a class=\"graphic graphic_figure graphicRef62044 \" href=\"UTD.htm?28/29/29150\">",
"       figure 8",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A selective decrease in abundance of the thiazide-sensitive Na-Cl cotransporter that mediates sodium reabsorption in the distal tubule [",
"      <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both animals and humans demonstrate a close temporal relationship in which the rise in plasma ANP levels precedes the onset of the natriuresis by one to two days [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. The role of ANP, however, remains uncertain. Studies in animals made ANP-deficient by immunization reveal no impairment in the escape phenomenon, indicating that ANP may contribute to but is not essential for the natriuresis to occur [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, escape can be prevented if a clamp is placed around the suprarenal aorta to maintain renal arterial pressure at the baseline level (",
"    <a class=\"graphic graphic_figure graphicRef73932 \" href=\"UTD.htm?6/52/6991\">",
"     figure 9",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/69\">",
"     69",
"    </a>",
"    ]. Furthermore, the continued volume expansion in this setting can lead to pulmonary edema and a much more marked degree of hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This ability of the rise in renal perfusion pressure to limit the degree of Na+ retention is called a",
"    <strong>",
"     pressure natriuresis",
"    </strong>",
"    . The site of action of this hemodynamic effect is unclear, as a variety of nephron segments may be involved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6744?source=see_link&amp;anchor=H6#H6\">",
"     \"Chapter 8C: Regulation of renal Na+ excretion\", section on 'Pressure natriuresis'",
"    </a>",
"    .)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/63,70\">",
"     63,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A role for the distal tubule in the escape phenomenon was suggested in an animal model that was able to distinguish the effects of aldosterone alone from those of aldosterone escape [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/65\">",
"     65",
"    </a>",
"    ]. Escape was associated with a selective and marked reduction in the abundance of the thiazide-sensitive Na-Cl cotransporter that paralleled the increase in sodium excretion.",
"   </p>",
"   <p>",
"    The clinical correlate of aldosterone escape occurs in patients with primary aldosteronism, who have autonomous overproduction of aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2376/abstract/71\">",
"     71",
"    </a>",
"    ]. Hypokalemia and hypertension are typically seen in this setting, but not edema since continued fluid retention is prevented. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This discussion is continued elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42422?source=see_link\">",
"     \"Chapter 6D: Natriuretic peptides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/1\">",
"      White PC, New MI, Dupont B. Congenital adrenal hyperplasia. (1). N Engl J Med 1987; 316:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/2\">",
"      White PC. Disorders of aldosterone biosynthesis and action. N Engl J Med 1994; 331:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/3\">",
"      Ulick S, Wang JZ, Morton DH. The biochemical phenotypes of two inborn errors in the biosynthesis of aldosterone. J Clin Endocrinol Metab 1992; 74:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/4\">",
"      Holland OB, Carr B. Modulation of aldosterone synthase messenger ribonucleic acid levels by dietary sodium and potassium and by adrenocorticotropin. Endocrinology 1993; 132:2666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/5\">",
"      Taymans SE, Pack S, Pak E, et al. Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3. J Clin Endocrinol Metab 1998; 83:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/6\">",
"      Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/7\">",
"      Bastl CP, Hayslett JP. The cellular action of aldosterone in target epithelia. Kidney Int 1992; 42:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/8\">",
"      Horisberger JD, Rossier BC. Aldosterone regulation of gene transcription leading to control of ion transport. Hypertension 1992; 19:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/9\">",
"      Minuth WW, Gilbert P, Gross P. Appearance of specific proteins in the apical plasma membrane of cultured renal collecting duct principal cell epithelium after chronic administration of aldosterone and arginine vasopressin. Differentiation 1988; 38:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/10\">",
"      Verrey F. Early aldosterone action: toward filling the gap between transcription and transport. Am J Physiol 1999; 277:F319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/11\">",
"      Stockand JD. New ideas about aldosterone signaling in epithelia. Am J Physiol Renal Physiol 2002; 282:F559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/12\">",
"      Masilamani S, Kim GH, Mitchell C, et al. Aldosterone-mediated regulation of ENaC alpha, beta, and gamma subunit proteins in rat kidney. J Clin Invest 1999; 104:R19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/13\">",
"      Shimkets RA, Lifton R, Canessa CM. In vivo phosphorylation of the epithelial sodium channel. Proc Natl Acad Sci U S A 1998; 95:3301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/14\">",
"      Chen SY, Bhargava A, Mastroberardino L, et al. Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci U S A 1999; 96:2514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/15\">",
"      N&aacute;ray-Fejes-T&oacute;th A, Canessa C, Cleaveland ES, et al. sgk is an aldosterone-induced kinase in the renal collecting duct. Effects on epithelial na+ channels. J Biol Chem 1999; 274:16973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/16\">",
"      Spindler B, Verrey F. Aldosterone action: induction of p21(ras) and fra-2 and transcription-independent decrease in myc, jun, and fos. Am J Physiol 1999; 276:C1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/17\">",
"      Funder JW. Enzymes and the regulation of sodium balance. Kidney Int Suppl 1992; 37:S114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/18\">",
"      Funder JW. Mineralocorticoids, glucocorticoids, receptors and response elements. Science 1993; 259:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/19\">",
"      Kenouch S, Coutry N, Farman N, Bonvalet JP. Multiple patterns of 11 beta-hydroxysteroid dehydrogenase catalytic activity along the mammalian nephron. Kidney Int 1992; 42:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/20\">",
"      Funder JW. 11 beta-Hydroxysteroid dehydrogenase: new answers, new questions. Eur J Endocrinol 1996; 134:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/21\">",
"      Farese RV Jr, Biglieri EG, Shackleton CH, et al. Licorice-induced hypermineralocorticoidism. N Engl J Med 1991; 325:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/22\">",
"      Stanton B, Pan L, Deetjen H, et al. Independent effects of aldosterone and potassium on induction of potassium adaptation in rat kidney. J Clin Invest 1987; 79:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/23\">",
"      Garg LC, Knepper MA, Burg MB. Mineralocorticoid effects on Na-K-ATPase in individual nephron segments. Am J Physiol 1981; 240:F536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/24\">",
"      Sansom S, Muto S, Giebisch G. Na-dependent effects of DOCA on cellular transport properties of CCDs from ADX rabbits. Am J Physiol 1987; 253:F753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/25\">",
"      Rabinowitz L. Aldosterone and potassium homeostasis. Kidney Int 1996; 49:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/26\">",
"      Husted RF, Laplace JR, Stokes JB. Enhancement of electrogenic Na+ transport across rat inner medullary collecting duct by glucocorticoid and by mineralocorticoid hormones. J Clin Invest 1990; 86:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/27\">",
"      Abdallah JG, Schrier RW, Edelstein C, et al. Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(-)-cotransporter abundance: role of aldosterone. J Am Soc Nephrol 2001; 12:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/28\">",
"      Frindt G, Sackin H, Palmer LG. Whole-cell currents in rat cortical collecting tubule: low-Na diet increases amiloride-sensitive conductance. Am J Physiol 1990; 258:F562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/29\">",
"      Kemendy AE, Kleyman TR, Eaton DC. Aldosterone alters the open probability of amiloride-blockable sodium channels in A6 epithelia. Am J Physiol 1992; 263:C825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/30\">",
"      Hayhurst RA, O'Neil RG. Time-dependent actions of aldosterone and amiloride on Na+-K+-ATPase of cortical collecting duct. Am J Physiol 1988; 254:F689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/31\">",
"      Coutry N, Blot-Chabaud M, Mateo P, et al. Time course of sodium-induced Na(+)-K(+)-ATPase recruitment in rabbit cortical collecting tubule. Am J Physiol 1992; 263:C61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/32\">",
"      Fujii Y, Takemoto F, Katz AI. Early effects of aldosterone on Na-K pump in rat cortical collecting tubules. Am J Physiol 1990; 259:F40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/33\">",
"      Garg LC, Narang N. Effects of aldosterone on NEM-sensitive ATPase in rabbit nephron segments. Kidney Int 1988; 34:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/34\">",
"      Hays SR. Mineralocorticoid modulation of apical and basolateral membrane H+/OH-/HCO3- transport processes in the rabbit inner stripe of outer medullary collecting duct. J Clin Invest 1992; 90:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/35\">",
"      N&aacute;ray-Fejes-T&oacute;th A, Rusvai E, Fejes-T&oacute;th G. Minealocorticoid receptors and 11 beta-steroid dehydrogenase activity in renal principal and intercalated cells. Am J Physiol 1994; 266:F76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/36\">",
"      Batlle DC. Segmental characterization of defects in collecting tubule acidification. Kidney Int 1986; 30:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/37\">",
"      Lauler D, Hickler RB, Thorn G. The salivary sodium-potassium ratio. A useful \"screening\" test for aldosteronism in hypertension. N Engl J Med 1962; 267:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/38\">",
"      Panese S, M&aacute;rtin RS, Virginillo M, et al. Mechanism of enhanced transcellular potassium-secretion in man with chronic renal failure. Kidney Int 1987; 31:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/39\">",
"      Young DB. Quantitative analysis of aldosterone's role in potassium regulation. Am J Physiol 1988; 255:F811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/40\">",
"      Shibata H, Ogishima T, Mitani F, et al. Regulation of aldosterone synthase cytochrome P-450 in rat adrenals by angiotensin II and potassium. Endocrinology 1991; 128:2534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/41\">",
"      Adler GK, Chen R, Menachery AI, et al. Sodium restriction increases aldosterone biosynthesis by increasing late pathway, but not early pathway, messenger ribonucleic acid levels and enzyme activity in normotensive rats. Endocrinology 1993; 133:2235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/42\">",
"      Aguilera G, Catt KJ. Regulation of aldosterone secretion by the renin-angiotensin system during sodium restriction in rats. Proc Natl Acad Sci U S A 1978; 75:4057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/43\">",
"      AMES RP, BORKOWSKI AJ, SICINSKI AM, LARAGH JH. PROLONGED INFUSIONS OF ANGIOTENSIN II AND NOREPINEPHRINE AND BLOOD PRESSURE, ELECTROLYTE BALANCE, AND ALDOSTERONE AND CORTISOL SECRETION IN NORMAL MAN AND IN CIRRHOSIS WITH ASCITES. J Clin Invest 1965; 44:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/44\">",
"      Sansom SC, O'Neil RG. Mineralocorticoid regulation of apical cell membrane Na+ and K+ transport of the cortical collecting duct. Am J Physiol 1985; 248:F858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/45\">",
"      Cooke CR, Gann DS, Whelton PK, et al. Hormonal responses to acute volume changes in anephric subjects. Kidney Int 1983; 23:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/46\">",
"      Himathongkam T, Dluhy RG, Williams GH. Potassim-aldosterone-renin interrelationships. J Clin Endocrinol Metab 1975; 41:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/47\">",
"      Young DB, Smith MJ Jr, Jackson TE, Scott RE. Multiplicative interaction between angiotensin II and K concentration in stimulation of aldosterone. Am J Physiol 1984; 247:E328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/48\">",
"      Williams GH, Braley LM. Effects of dietary sodium and potassium intake and acute stimulation on aldosterone output by isolated human adrenal cells. J Clin Endocrinol Metab 1977; 45:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/49\">",
"      Pratt JH, Rothrock JK, Dominguez JH. Evidence that angiotensin-II and potassium collaborate to increase cytosolic calcium and stimulate the secretion of aldosterone. Endocrinology 1989; 125:2463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/50\">",
"      Shier DN, Kusano E, Stoner GD, et al. Production of renin, angiotensin II, and aldosterone by adrenal explant cultures: response to potassium and converting enzyme inhibition. Endocrinology 1989; 125:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/51\">",
"      Kifor I, Moore TJ, Fallo F, et al. Potassium-stimulated angiotensin release from superfused adrenal capsules and enzymatically dispersed cells of the zona glomerulosa. Endocrinology 1991; 129:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/52\">",
"      Rasmussen H. The calcium messenger system (2). N Engl J Med 1986; 314:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/53\">",
"      Braley LM, Adler GK, Mortensen RM, et al. Dose effect of adrenocorticotropin on aldosterone and cortisol biosynthesis in cultured bovine adrenal glomerulosa cells: in vitro correlate of hyperreninemic hypoaldosteronism. Endocrinology 1992; 131:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/54\">",
"      Taylor RE Jr, Glass JT, Radke KJ, Schneider EG. Specificity of effect of osmolality on aldosterone secretion. Am J Physiol 1987; 252:E118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/55\">",
"      Merrill DC, Ebert TJ, Skelton MM, Cowley AW Jr. Effect of plasma sodium on aldosterone secretion during angiotensin II stimulation in normal humans. Hypertension 1989; 14:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/56\">",
"      BARBER JK, BARTTER FC, DELEA C, et al. The regulation of aldosterone secretion in man: the role of fluid volume. J Clin Invest 1956; 35:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/57\">",
"      Good DW, Wright FS. Luminal influences on potassium secretion: sodium concentration and fluid flow rate. Am J Physiol 1979; 236:F192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/58\">",
"      Jamison RL. Potassium recycling. Kidney Int 1987; 31:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/59\">",
"      Finn A, Welt L. Effect of aldosterone administration on electrolyte excretion and GFR in the rat. Am J Physiol 1963; 204:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/60\">",
"      George JM, Wright L, Bell NH, Bartter FC. The syndrome of primary aldosteronism. Am J Med 1970; 48:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/61\">",
"      AUGUST JT, NELSON DH, THORN GW. Response of normal subjects to large amounts of aldosterone. J Clin Invest 1958; 37:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/62\">",
"      Knox FG, Burnett JC Jr, Kohan DE, et al. Escape from the sodium-retaining effects of mineralocorticoids. Kidney Int 1980; 17:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/63\">",
"      Gonzalez-Campoy JM, Romero JC, Knox FG. Escape from the sodium-retaining effects of mineralocorticoids: role of ANF and intrarenal hormone systems. Kidney Int 1989; 35:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/64\">",
"      Schwartz GJ, Burg MB. Mineralocorticoid effects on cation transport by cortical collecting tubules in vitro. Am J Physiol 1978; 235:F576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/65\">",
"      Wang XY, Masilamani S, Nielsen J, et al. The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest 2001; 108:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/66\">",
"      Ballermann BJ, Bloch KD, Seidman JG, Brenner BM. Atrial natriuretic peptide transcription, secretion, and glomerular receptor activity during mineralocorticoid escape in the rat. J Clin Invest 1986; 78:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/67\">",
"      Cappuccio FP, Markandu ND, Buckley MG, et al. Changes in the plasma levels of atrial natriuretic peptides during mineralocorticoid escape in man. Clin Sci (Lond) 1987; 72:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/68\">",
"      Greenwald JE, Sakata M, Michener ML, et al. Is atriopeptin a physiological or pathophysiological substance? Studies in the autoimmune rat. J Clin Invest 1988; 81:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/69\">",
"      Hall JE, Granger JP, Smith MJ Jr, Premen AJ. Role of renal hemodynamics and arterial pressure in aldosterone \"escape\". Hypertension 1984; 6:I183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/70\">",
"      Cowley AW Jr. Role of the renal medulla in volume and arterial pressure regulation. Am J Physiol 1997; 273:R1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2376/abstract/71\">",
"      Melby JC. Primary aldosteronism. Kidney Int 1984; 26:769.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7290 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-61.234.146.186-71903B288C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_20_2376=[""].join("\n");
var outline_f2_20_2376=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cortisol as a mineralocorticoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NaCl and potassium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hydrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Extrarenal effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CONTROL OF ALDOSTERONE SECRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Renin-angiotensin system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Plasma K+ concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Adrenocorticotropic hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Plasma sodium concentration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MAINTENANCE OF SODIUM AND POTASSIUM BALANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ALDOSTERONE ESCAPE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7290\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7290|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/7/123\" title=\"figure 1\">",
"      Adrenal steroid synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/30/23022\" title=\"figure 2\">",
"      Actions of aldosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/61/5086\" title=\"figure 3\">",
"      Steroid hormone action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/31/12797\" title=\"figure 4\">",
"      Collecting tubule transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/43/39613\" title=\"figure 5\">",
"      Distal acid secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/10/21678\" title=\"figure 6\">",
"      Renin aldosterone and sodium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/22/19822\" title=\"figure 7\">",
"      Aldosterone and potassium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/29/29150\" title=\"figure 8\">",
"      Resumption of the steady state in primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/52/6991\" title=\"figure 9\">",
"      Aldosterone escape II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7290|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/45/40667\" title=\"table 1\">",
"      Aldosterone on Na K excretion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40838?source=related_link\">",
"      Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11657?source=related_link\">",
"      Chapter 12B: Renal potassium excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13720?source=related_link\">",
"      Chapter 2B: Renin-angiotensin system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=related_link\">",
"      Chapter 6B: Antidiuretic hormone and water balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/27/42422?source=related_link\">",
"      Chapter 6D: Natriuretic peptides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6744?source=related_link\">",
"      Chapter 8C: Regulation of renal Na+ excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22615?source=related_link\">",
"      Familial hyperaldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=related_link\">",
"      Pathogenesis of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_20_2377="Bevacizumab: Drug information";
var content_f2_20_2377=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bevacizumab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/29/1494?source=see_link\">",
"    see \"Bevacizumab: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/44/20166?source=see_link\">",
"    see \"Bevacizumab: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F141002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avastin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3422982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Avastin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F141022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Monoclonal Antibody;",
"     </li>",
"     <li>",
"      Vascular Endothelial Growth Factor (VEGF) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F141004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Colorectal cancer, metastatic, in combination with fluorouracil-based chemotherapy:",
"     </b>",
"     I.V.: 5 mg/kg every 2 weeks (in combination with bolus-IFL)",
"     <b>",
"      or",
"     </b>",
"     10 mg/kg every 2 weeks (in combination with FOLFOX4)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     5 mg/kg every 2 weeks (in combination with fluorouracil-based chemotherapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Colorectal cancer, metastatic, following first-line therapy containing bevacizumab:",
"     </b>",
"     I.V.: 5 mg/kg every 2 weeks",
"     <b>",
"      or",
"     </b>",
"     7.5 mg/kg every 3 weeks (in combination with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based regimen)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Glioblastoma:",
"     </b>",
"     10 mg/kg every 2 weeks as monotherapy",
"     <b>",
"      or",
"     </b>",
"     (unlabeled dosing) 10 mg/kg every 2 weeks (in combination with irinotecan) (Vredenburgh, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Nonsmall cell lung cancer (nonsquamous cell histology):",
"     </b>",
"     I.V.: 15 mg/kg every 3 weeks (in combination with carboplatin and paclitaxel) for 4-6 cycles followed by maintenance treatment (unlabeled use) of bevacizumab 15 mg/kg every 3 weeks as monotherapy until disease progression or unacceptable toxicity (Sandler, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Renal cell cancer, metastatic:",
"     </b>",
"     10 mg/kg every 2 weeks (in combination with interferon alfa)",
"     <b>",
"      or",
"     </b>",
"     (unlabeled dosing) 10 mg/kg every 2 weeks as monotherapy (Yang, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Age-related macular degeneration (unlabeled use/route):",
"     </b>",
"     Intravitreal: 1.25 mg (0.05 mL) monthly until improvement/resolution, usually ~1-3 injections (Avery, 2006) or 2.5 mg (0.1 mL) every 4 weeks for 3 doses (Bashshur, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Breast cancer, metastatic (unlabeled use):",
"     </b>",
"     I.V.: 10 mg/kg every 2 weeks (in combination with paclitaxel) (Miller, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Ovarian cancer, advanced recurrent, platinum-sensitive (unlabeled use):",
"     </b>",
"     I.V.: 15 mg/kg every 3 weeks in combination with gemcitabine and carboplatin for 6-10 cycles, followed by 15 mg/kg as monotherapy every 3 weeks until disease progression or unacceptable toxicity (Aghajanian, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Soft tissue sarcoma, angiosarcoma (unlabeled use):",
"     </b>",
"     I.V.: 15 mg/kg every 3 weeks until disease progression or unacceptable toxicity (Agulnik, 2013)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F141005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13301090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in manufacturer's labeling",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13301091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in manufacturer's labeling",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F141023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. administration (systemic): There are no recommended dosage reductions. Temporary suspension is recommended for severe infusion reactions, at least 4 weeks prior to (and after) elective surgery, in moderate-to-severe proteinuria (in most studies, treatment was withheld for &ge;2 g proteinuria/24 hours), or in patients with severe hypertension which is not controlled with medical management. Permanent discontinuation is recommended (by the manufacturer) in patients who develop wound dehiscence and wound healing complications requiring intervention, necrotizing fasciitis, fistula (gastrointestinal and nongastrointestinal), gastrointestinal perforation, intra-abdominal abscess, hypertensive crisis, hypertensive encephalopathy, serious bleeding/hemorrhage, severe arterial thromboembolic event, nephrotic syndrome, or RPLS.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F140982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avastin&reg;: 25 mg/mL (4 mL, 16 mL) [derived from or manufactured using Chinese hamster ovary cells]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F140970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F140985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V. infusion, usually after the other antineoplastic agents. Infuse the initial dose over 90 minutes. The second infusion may be shortened to 60 minutes if the initial infusion is well tolerated. The third and subsequent infusions may be shortened to 30 minutes if the 60-minute infusion is well tolerated. Monitor closely during the infusion for signs/symptoms of an infusion reaction. Some institutions use a 10-minute infusion (0.5 mg/kg/minute) for bevacizumab dosed at 5 mg/kg (after tolerance at the 90-, 60-, and 30-minute infusion rates has been established; Reidy, 2007). Do not administer I.V. push. Do not administer with dextrose solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intravitreal injection (unlabeled use/route): Adequate local anesthesia and a topical broad-spectrum antimicrobial agent should be administered prior to the procedure; administer topical ophthalmic antibiotics for 3 days after procedure (Avery, 2006; Bashshur, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F14266279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS; do not mix or administer with dextrose solutions.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F140984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic colorectal cancer (first-or second-line treatment and second-line after progression on a first-line treatment containing bevacizumab); treatment of unresectable, locally advanced, recurrent or metastatic nonsquamous, nonsmall cell lung cancer; treatment of progressive glioblastoma; treatment of metastatic renal cell cancer (not an approved use in Canada)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Not indicated for the adjuvant treatment of colorectal cancer. For the treatment of glioblastoma, effectiveness is based on improvement in objective response rate.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F141018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic breast cancer, recurrent cervical cancer, recurrent advanced ovarian cancer (platinum-sensitive), soft tissue sarcomas (angiosarcoma or hemangiopericytoma/solitary fibrous tumor), age-related macular degeneration (AMD)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2110715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Avastin&reg; may be confused with Astelin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bevacizumab may be confused with brentuximab, cetuximab, ranibizumab, riTUXimab",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Avastin [U.S., Canada, and  multiple international markets] may be confused with Avaxim, a brand name for hepatitis A vaccine [Canada and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F141020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages reported as monotherapy and as part of combination chemotherapy regimens. Some studies only reported hematologic toxicities grades &ge;4 and nonhematologic toxicities grades &ge;3.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (12% to 34%; grades 3/4: 5% to 18%), thromboembolic event (&le;21%; grades 3/4: 15%; venous thrombus/embolus: 8%; grades 3/4: 5% to 7%; arterial thrombosis 6%; grades 3/4: 3%), hypotension (7% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (8% to 62%), headache (24% to 37%; grades 3/4: 2% to 4%), dizziness (19% to 26%), fatigue (&le;45%; grades 3/4: 4% to 19%), sensory neuropathy (grades 3/4: 1% to 17%; in combination with paclitaxel: 24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (6% to 32%), dry skin (7% to 20%), exfoliative dermatitis (3% to 19%), skin discoloration (2% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (8% to 61%; grades 3/4: 8%), vomiting (47% to 52%; grades 3/4: &le;11%), anorexia (35% to 43%), constipation (4% to 40%), diarrhea (grades 3/4: 1% to 34%), stomatitis (30% to 32%), gastrointestinal hemorrhage (19% to 24%), dyspepsia (17% to 24%), taste disorder (14% to 21%), weight loss (15% to 20%), flatulence (11% to 19%), nausea (grades 3/4: &le;12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemorrhage (&le;40%; grades 3/4: 1% to 5%), leukopenia (grades 3/4: 37%), neutropenia (grade 4: 21% to 27%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (8% to 19%), back pain (&le;12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Proteinuria (4% to 36%; grades 3/4: &le;7%; median onset: 5.6 months; median time to resolution: 6.1 months)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection (40% to 47%), epistaxis (19% to 35%), dyspnea (25% to 26%), rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (&le;55%; serious: 7% to 14%; pneumonia, catheter, or wound infections)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: DVT (6% to 9%; grades 3/4: 9%), HF (grades 3/4: 1% to 4%), syncope (grades 3/4: 3%), intra-abdominal venous thrombosis (grades 3/4: 3%), cardio-/cerebrovascular arterial thrombotic event (2% to 4%), left ventricular dysfunction (grades 3/4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: CNS hemorrhage (1% to 5%; grades 3/4: 1%), dysphonia (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Skin ulcer (&le;6%), wound dehiscence (1% to 6%), acne (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration (grades 3/4: &le;10%), hyponatremia (grades 3/4: 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (4% to 7%), colitis (1% to 6%), ileus (grades 3/4: 4% to 5%), gingival bleeding (2% to 4%), fistula (1%), gastrointestinal perforation (&le;4%), gastroesophageal reflux (&le;2%), gingivitis (&le;2%), mouth ulceration (&le;2%), tooth abscess (&le;2%), intra-abdominal abscess (1%), gastritis (&le;1%), gingival pain (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginal hemorrhage (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenic fever/infection (5%; grades 3 and/or 4: 4% to 5%), thrombocytopenia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (10%), neuropathy (other than sensory: grades 3/4: 1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (&le;2%), deafness (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Voice alteration (5% to 9%), pneumonitis/pulmonary infiltrates (grades 3/4: 5%), hemoptysis (nonsquamous histology 2%), pulmonary embolism (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infusion reactions (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, anastomotic ulceration, angina, antibody formation (anti-bevacizumab and neutralizing), bladder perforation, cerebral infarction; fistula (biliary, bladder, bronchopleural, duodenal, enterocutaneous, esophageal, gastrointestinal, rectal, renal, tracheoesophageal [TE] and vaginal); gastrointestinal ulcer, gall bladder perforation, hemorrhagic stroke,  hypersensitivity, hypertensive crises, hypertensive encephalopathy, intestinal necrosis, intestinal obstruction, mesenteric venous occlusion, microangiopathic hemolytic anemia (when used in combination with sunitinib), MI, nasal septum perforation, nephrotic syndrome, osteonecrosis (jaw), ovarian failure, pancytopenia, polyserositis, pulmonary hemorrhage, pulmonary hypertension, renal failure, renal thrombotic microangiopathy, reversible posterior leukoencephalopathy syndrome (RPLS), sepsis, subarachnoid hemorrhage, toxic anterior segment syndrome (TASS), transient ischemic attack, ureteral stricture, wound healing complications",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Reported from unlabeled use: Eye disorders: Endophthalmitis (infectious and sterile), hemorrhage (conjunctival, retinal or vitreous), intraocular inflammation (iritis, vitritis), intraocular pressure increased, ocular hyperemia, ocular pain/discomfort, permanent vision loss, retinal detachment, visual disturbance, vitreous floaters",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F140988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the FDA-approved manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to bevacizumab, any component of the formulation, Chinese hamster ovary cell products or other recombinant human or humanized antibodies; untreated CNS metastases",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F140973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fistula/abscess formation: Gastrointestinal fistula (including enterocutaneous, esophageal, duodenal, and rectal fistulas), and intra-abdominal abscess have been reported in patients receiving bevacizumab for colorectal cancer and other cancers (not related to treatment duration). Nongastrointestinal fistula formation (including tracheoesophageal, bronchopleural, biliary, vaginal,renal, and bladder fistulas) has been observed, most commonly within the first 6 months of treatment. Permanently discontinue in patients who develop internal organ fistulas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal perforation:",
"     <b>",
"      [U.S. Boxed Warning]: Gastrointestinal (GI) perforation, (sometimes fatal) has occurred in 0.3% to 2.4% of clinical study patients receiving bevacizumab; discontinue if GI perforation occurs.",
"     </b>",
"     Most cases occur within 50 days of treatment initiation; monitor patients for signs/symptoms (eg, fever, abdominal pain with constipation and/or nausea/vomiting).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Among approved and nonapproved uses evaluated thus far, the incidence of heart failure (HF) and/or left ventricular dysfunction (including LVEF decline) is higher in patients receiving bevacizumab plus chemotherapy when compared to chemotherapy alone. Use with caution in patients with cardiovascular disease. The safety of therapy resumption or continuation in patients with cardiac dysfunction has not been studied. In studies of patients with metastatic breast cancer (an unlabeled use), the incidence of grades 3 or 4 HF was increased in patients receiving bevacizumab plus paclitaxel when compared to the control arm. Patients with metastatic breast cancer who received prior anthracycline therapy had a higher rate of HF compared to those receiving paclitaxel alone (3.8% vs 0.6% respectively). A meta-analysis of 5 studies which enrolled patients with metastatic breast cancer who received bevacizumab suggested an association with an increased risk of heart failure; all trials included in the analysis enrolled patients who either received prior or were receiving concurrent anthracycline therapy (Choueiri, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemorrhage:",
"     <b>",
"      [U.S. Boxed Warning]: Severe or fatal hemorrhage, including hemoptysis, gastrointestinal bleeding, central nervous system hemorrhage, epistaxis, and vaginal bleeding have been reported (up to 5 times more frequently if receiving bevacizumab). Avoid use in patients with serious hemorrhage or recent hemoptysis (&ge;2.5 mL blood).",
"     </b>",
"     Serious pulmonary hemorrhage has been reported in patients receiving bevacizumab (primarily in patients with nonsmall cell lung cancer with squamous cell histology [not an FDA-approved indication]). Intracranial hemorrhage, including cases of grade 3 or 4 hemorrhage, has occurred in patients with previously treated glioblastoma. Treatment discontinuation is recommended in all patients with intracranial bleeding or other serious hemorrhage. Use with caution in patients at risk for thrombocytopenia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: May cause and/or worsen hypertension; the incidence of severe hypertension in increased with bevacizumab. Use caution in patients with pre-existing hypertension and monitor BP closely (every 2-3 weeks during treatment; regularly after discontinuation if bevacizumab-induced hypertension occurs or worsens). Permanent discontinuation is recommended in patients who experience a hypertensive crisis or hypertensive encephalopathy. Temporarily discontinue in patients who develop uncontrolled hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infusion reactions and hypersensitivity: Infusion reactions (eg, hypertension, hypertensive crisis, wheezing, oxygen desaturation, hypersensitivity [including anaphylactic/anaphylactoid reactions], chest pain, rigors, headache, diaphoresis) may occur with the first infusion (uncommon). Interrupt therapy in patients experiencing severe infusion reactions; there are no data to address routine premedication use or reinstitution of therapy in patients who experience severe infusion reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mortality: Bevacizumab, in combination with chemotherapy (or biologic therapy), is associated with an increased risk of treatment-related mortality; a higher risk of fatal adverse events was identified in a meta-analysis of 16 trials in which bevacizumab was used for the treatment of various cancers (breast cancer, colorectal cancer, nonsmall cell lung cancer, pancreatic cancer, prostate cancer, and renal cell cancer) and compared to chemotherapy alone (Ranpura, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Necrotizing fasciitis: Cases of necrotizing fasciitis, including fatalities, have been reported (rarely); usually secondary to wound healing complications, GI perforation or fistula formation. Discontinue in patients who develop necrotizing fasciitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular adverse events: Serious eye infections and vision loss due to endophthalmitis have been reported from intravitreal administration (unlabeled use/route).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian failure:  In premenopausal women receiving bevacizumab in combination with mFOLFOX (fluorouracil/oxaliplatin based chemotherapy) the incidence of ovarian failure (amenorrhea &ge;3 months) was higher (34%) compared to women who received mFOLFOX alone (2%). Ovarian function recovered in some patients after treatment was discontinued. Premenopausal women should be informed of the potential risk of ovarian failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Proteinuria/nephrotic syndrome: Proteinuria and/or nephrotic syndrome have been associated with use; risks may be increased in patients with history of hypertension. Thrombotic microangiopathy has been associated with bevacizumab-induced proteinuria. Withhold treatment for &ge;2 g proteinuria/24 hours and resume when proteinuria is &lt;2 g/24 hours; discontinue in patients with nephrotic syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Reversible posterior leukoencephalopathy syndrome: Cases of reversible posterior leukoencephalopathy syndrome (RPLS) have been reported. Symptoms (which include headache, seizure, confusion, lethargy, blindness and/or other vision, or neurologic disturbances) may occur from 16 hours to 1 year after treatment initiation. Resolution of symptoms usually occurs within days after discontinuation; however, neurologic sequelae may remain. RPLS may be associated with hypertension; discontinue therapy and begin management of hypertension, if present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolism: Bevacizumab is associated with an increased risk for arterial thromboembolic events (ATE), including cerebral infarction, stroke, MI, TIA, angina, and other ATEs,  when used in combination with chemotherapy. History of ATE or &ge;65 years of age may present an even greater risk. Although patients with cancer are at risk for venous thromboembolism (VTE), a meta-analysis of 15 controlled trials has demonstrated an increased risk for VTE in patients who received bevacizumab (Nalluri, 2008). Permanently discontinue therapy in patients with severe ATE or life-threatening pulmonary embolism; the safety of treatment reinitiation after ATE has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Wound dehiscence:",
"     <b>",
"      [U.S. Boxed Warning]: The incidence of wound healing and surgical complications is increased in patients who have received bevacizumab; discontinue with wound dehiscence. Although the appropriate interval between withholding bevacizumab and elective surgery has not been defined, bevacizumab should be discontinued at least 28 days prior to surgery and should not be reinitiated for at least 28 days after surgery and until wound is fully healed.",
"     </b>",
"     In a retrospective review of central venous access device placements, a greater risk of wound dehiscence was observed when port placement and bevacizumab administration were separated by &lt;14 days (Erinjeri, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS metastases: Use with caution in patients with CNS metastases; one case of CNS hemorrhage was observed in a study of NSCLC patients with CNS metastases. Use in patients with untreated CNS metastases is contraindicated in the Canadian labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Safety and efficacy have not been established in hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Safety and efficacy have not been established in renal impairment. An increase in diastolic and systolic blood pressures were noted in a retrospective review of patients with renal insufficiency (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;60 mL/minute) who received bevacizumab for renal cell cancer (Gupta, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anthracyclines: May potentiate cardiotoxic effects of anthracyclines. HF is more common with prior anthracycline exposure and/or left chest wall irradiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myelosuppressive chemotherapy: When used in combination with myelosuppressive chemotherapy, increased rates of severe or febrile neutropenia and neutropenic infection were reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sorafenib: The incidence of hand-foot syndrome is increased in patients treated with bevacizumab plus sorafenib in comparison to those treated with sorafenib monotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sunitinib: Microangiopathic hemolytic anemia (MAHA) has been reported when bevacizumab has been used in combination with sunitinib. Concurrent therapy with sunitinib and bevacizumab is also associated with dose-limiting hypertension in patients with metastatic renal cell cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients &ge;65 years of age; greater risk for adverse events, including arterial thrombotic events and proteinuria. Serious adverse events occurring more frequently in the elderly also include deep thrombophlebitis, sepsis, hyper-/hypotension, MI, CHF, leukopenia, anemia, dehydration, hypokalemia, and hyponatremia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F140976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Anthracycline, Systemic): Bevacizumab may enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: Bevacizumab may enhance the adverse/toxic effect of Irinotecan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Bevacizumab may enhance the adverse/toxic effect of SORAfenib. Specifically, the risk for hand-foot skin reaction may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: May enhance the adverse/toxic effect of Bevacizumab. Specifically, the risk for a specific form of anemia, microangiopathic hemolytic anemia (MAHA), may be increased. Bevacizumab may enhance the hypertensive effect of SUNItinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F140978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F140991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal reproduction studies. Angiogenesis is of critical importance to human fetal development, and bevacizumab inhibits angiogenesis. Adequate contraception during therapy is recommended (and for &ge;6 months following last dose of bevacizumab). Patients should also be counseled regarding prolonged exposure following discontinuation of therapy due to the long half-life of bevacizumab.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Based on animal studies, bevacizumab may disrupt normal menstrual cycles and impair fertility by several effects, including reduced endometrial proliferation and follicular developmental arrest. Some parameters do not recover completely, or recover very slowly following discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F141011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F140992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if bevacizumab is excreted in breast milk. Immunoglobulins are excreted in breast milk, and it is assumed that bevacizumab may appear in breast milk. Because of the potential for serious adverse reactions in the nursing infant, the decision to discontinue bevacizumab or to discontinue breast-feeding during therapy should take into account the benefits of treatment to the mother. The half-life of bevacizumab is up to 50 days (average 20 days), and this should be considered when decisions are made concerning breast-feeding resumption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Canadian labeling recommends to discontinue breast-feeding during treatment and to avoid breast-feeding a minimum of 6 months following discontinuation of treatment.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F140990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Avastin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/4 mL (4 mL): $745.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg/16 mL (16 mL): $2980.27",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F140980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor closely during the infusion for signs/symptoms of an infusion reaction. Monitor CBC with differential; signs/symptoms of gastrointestinal perforation, fistula, or abscess (including abdominal pain, constipation, vomiting, and fever); signs/symptoms of bleeding, including hemoptysis, gastrointestinal, and/or CNS bleeding, and/or epistaxis. Monitor blood pressure every 2-3 weeks; more frequently if hypertension develops during therapy. Continue to monitor blood pressure after discontinuing due to bevacizumab-induced hypertension. Monitor for proteinuria/nephrotic syndrome with urine dipstick; collect 24 hour urine in patients with &ge;2+ reading.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     AMD: Monitor intraocular pressure and retinal artery perfusion",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F140993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Avastin (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HN, ID, IE, IL, IT, KP, MT, MX, MY, NL, NO, NZ, PE, PH, PL, PT, RU, SE, SG, SK, TH, TR, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F140972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bevacizumab is a recombinant, humanized monoclonal antibody which binds to, and neutralizes, vascular endothelial growth factor (VEGF), preventing its association with endothelial receptors, Flt-1 and KDR. VEGF binding initiates angiogenesis (endothelial proliferation and the formation of new blood vessels). The inhibition of microvascular growth is believed to retard the growth of all tissues (including metastatic tissue).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F140987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 46 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~20 days (range: 11-50 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Clearance: 2.75-5 mL/kg/day",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aghajanian C, Blank SV, Goff BA, et al, &ldquo;OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol,",
"      </i>",
"      2012, 30(17):2039-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/22529265/pubmed\" id=\"22529265\" target=\"_blank\">",
"        22529265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Agulnik M, Yarber JL, Okuno SH, et al, &ldquo;An Open-Label, Multicenter, Phase II Study of Bevacizumab for the Treatment of Angiosarcoma and Epithelioid Hemangioendotheliomas,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2013, 24(1):257-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/22910841/pubmed\" id=\"22910841\" target=\"_blank\">",
"        22910841",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Allegra CJ, Yothers G, O'Connell MJ, et al, &ldquo;Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(20):3385-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/19414665/pubmed\" id=\"19414665\" target=\"_blank\">",
"        19414665",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Avery RL, Pieramici DJ, Rabena MD, et al, &ldquo;Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration,&rdquo;",
"      <i>",
"       Ophthalmology",
"      </i>",
"      , 2006, 113(3):363-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/16458968/pubmed\" id=\"16458968\" target=\"_blank\">",
"        16458968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Azad NS, Aragon-Ching JB, Dahut WL, et al, &ldquo;Hand-Foot Skin Reaction Increases With Cumulative Sorafenib Dose and With Combination Anti-Vascular Endothelial Growth Factor Therapy,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2009, 15(4):1411-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/19228742/pubmed\" id=\"19228742\" target=\"_blank\">",
"        19228742",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bansal N and Hoffman M, &ldquo;Bladder Perforation in a Patient With Recurrent Epithelial Ovarian Cancer After Treatment With Bevacizumab,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2011, 120(2):313-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/21055796/pubmed\" id=\"21055796\" target=\"_blank\">",
"        21055796",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bashshur AF, Bazarbachi A, Schakal A, et al, &ldquo;Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-Related Macular Degeneration,&rdquo;",
"      <i>",
"       Am J Ophthalmol",
"      </i>",
"      , 2006, 142(1):1-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/16815245/pubmed\" id=\"16815245\" target=\"_blank\">",
"        16815245",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bracarda S, Bellmunt J, Melichar B, et al, \"Overall Survival in Patients With Metastatic Renal Cell Carcinoma Initially Treated With Bevacizumab Plus Interferon-&alpha;2a and Subsequent Therapy With Tyrosine Kinase Inhibitors: A Retrospective Analysis of the Phase III AVOREN Trial,\"",
"      <i>",
"       BJU Int",
"      </i>",
"      , 2011, 107(2):214-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/20942831/pubmed\" id=\"20942831\" target=\"_blank\">",
"        20942831",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burger RA, Brady MF, Bookman MA, et al, &ldquo;Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(26):2473-83.  PMID: 22204724",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/22204724/pubmed\" id=\"22204724\" target=\"_blank\">",
"        22204724",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burger RA, Sill MW, Monk BJ, et al, &ldquo;Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(33):5165-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/18024863/pubmed\" id=\"18024863\" target=\"_blank\">",
"        18024863",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cannistra SA, Matulonis UA, Penson RT, et al, &ldquo;Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(33):5180-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/18024865/pubmed\" id=\"18024865\" target=\"_blank\">",
"        18024865",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Christodoulou C, Pervena A, Klouvas G, et al, \"Combination of Bisphosphonates and Antiangiogenic Factors Induces Osteonecrosis of the Jaw More Frequently Than Bisphosphonates Alone,\"",
"      <i>",
"       Oncology",
"      </i>",
"      , 2009, 76(3):209-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/19212145/pubmed\" id=\"19212145\" target=\"_blank\">",
"        19212145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Choueiri TK, Mayer EL, Je Y, et al, &ldquo;Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(6):632-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/21205755/pubmed\" id=\"21205755\" target=\"_blank\">",
"        21205755",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cloughesy TF, Prados MD, Wen PY, et al, &ldquo;A Phase II, Randomized, Non-Comparative Clinical Trial of the Effect of Bevacizumab (BV) Alone or in Combination With Irinotecan (CPT) on 6-Month Progression Free Survival (PFS6) in Recurrent, Treatment-Refractory Glioblastoma (GBM),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(Supp):2010B [abstract 2010b from 2008 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Erinjeri JP, Fong AJ, Kemeny NE, et al, &ldquo;Timing of Administration of Bevacizumab Chemotherapy Affects Wound Healing After Chest Wall Port Placement,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2011, 117(6):1296-301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/21381016/pubmed\" id=\"21381016\" target=\"_blank\">",
"        21381016",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Escudier B, Pluzanska A, Koralewski P, et al, &ldquo;Bevacizumab Plus Interferon Alfa-2a for Treatment of Metastatic Renal Cell Carcinoma: A Randomised, Double-Blind Phase III Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2007, 370(9605):2103-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/18156031/pubmed\" id=\"18156031\" target=\"_blank\">",
"        18156031",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Estilo CL, Fornier M, Farooki A, et al, \"Osteonecrosis of the Jaw Related to Bevacizumab,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(24):4037-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/18711196/pubmed\" id=\"18711196\" target=\"_blank\">",
"        18711196",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feldman DR, Baum MS, Ginsberg MS, et al, &ldquo;Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(9):1432-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/19224847/pubmed\" id=\"19224847\" target=\"_blank\">",
"        19224847",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feldman DR, Ginsberg MS, Baum M, et al, &ldquo;Phase I Trial of Bevacizumab Plus Sunitinib in Patients With Metastatic Renal Cell Carcinoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(Supp):5100 [abstract 5100 from 2008 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glusker P, Recht L, and Lane B, &ldquo;Reversible Posterior Leukoencephalopathy Syndrome and Bevacizumab,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(9):980-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/16510760/pubmed\" id=\"16510760\" target=\"_blank\">",
"        16510760",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greuter S, Schmid F, Ruhstaller T, et al, \"Bevacizumab-Associated Osteonecrosis of the Jaw,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2008, 19(12):2091-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/18977851/pubmed\" id=\"18977851\" target=\"_blank\">",
"        18977851",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gray R, Bhattacharya S, Bowden C, et al, &ldquo;Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(30):4966-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/19720913/pubmed\" id=\"19720913\" target=\"_blank\">",
"        19720913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta S, Parsa VB, Heilbrun LK, et al, &ldquo;Safety and Efficacy of Molecularly Targeted Agents in Patients With Metastatic Kidney Cancer With Renal Dysfunction,&rdquo;",
"      <i>",
"       Anticancer Drugs",
"      </i>",
"      , 2011, 22(8):794-800.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/21799472/pubmed\" id=\"21799472\" target=\"_blank\">",
"        21799472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson DH, Fehrenbacher L, Novotny WF, et al, &ldquo;Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(11):2184-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/15169807/pubmed\" id=\"15169807\" target=\"_blank\">",
"        15169807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kreisl TN, Kim L, Moore K, et al, &ldquo;Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(5):740-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/19114704/pubmed\" id=\"19114704\" target=\"_blank\">",
"        19114704",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leighl NB, Bennouna J, Yi J, et al, \"Bleeding Events in Bevacizumab-Treated Cancer Patients Who Received Full-Dose Anticoagulation and Remained on Study,\"",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2011, 104(3):413-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/21245868/pubmed\" id=\"21245868\" target=\"_blank\">",
"        21245868",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leighl NB, Zatloukal P, Mezger J, et al, \"Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL),",
"      <i>",
"       J Thorac Oncol",
"      </i>",
"      , 2010, 5(12):1970-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/20978447/pubmed\" id=\"20978447\" target=\"_blank\">",
"        20978447",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lou E, Turner S, Sumrall A, et al, &ldquo;Bevacizumab-Induced Reversible Posterior Leukoencephalopathy Syndrome and Successful Retreatment in a Patient With Glioblastoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(28):e739-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/21900098/pubmed\" id=\"21900098\" target=\"_blank\">",
"        21900098",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miles D, Chan A, Dirix LY, et al, \"Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(20):3239-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/20498403/pubmed\" id=\"20498403\" target=\"_blank\">",
"        20498403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller KD, \"E2100: A Phase III Trial of Paclitaxel Versus Paclitaxel/Bevacizumab for Metastatic Breast Cancer,\"",
"      <i>",
"       Clin Breast Cancer",
"      </i>",
"      , 2003, 3(6):421-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/12636887/pubmed\" id=\"12636887\" target=\"_blank\">",
"        12636887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller KD, Chap LI, Holmes FA, et al, \"Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(4):792-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/15681523/pubmed\" id=\"15681523\" target=\"_blank\">",
"        15681523",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller K, Wang M, Gralow J, et al, &ldquo;Paclitaxel Plus Bevacizumab Versus Paclitaxel Alone for Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(26):2666-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/18160686/pubmed\" id=\"18160686\" target=\"_blank\">",
"        18160686",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monk BJ, Choi DC, Pugmire G, et al, &ldquo;Activity of Bevacizumab (rhuMAB VEGF) in Advanced Refractory Epithelial Ovarian Cancer,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2005, 96(3):902-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/15721449/pubmed\" id=\"15721449\" target=\"_blank\">",
"        15721449",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monk BJ, Sill MW, Burger RA, et al, \"Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(7):1069-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/19139430/pubmed\" id=\"19139430\" target=\"_blank\">",
"        19139430",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nalluri SR, Chu D, Keresztes R, et al, &ldquo;Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients: A Meta-Analysis,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2008, 300(19): 2277-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/19017914/pubmed\" id=\"19017914\" target=\"_blank\">",
"        19017914",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ozcan C, Wong SJ, and Hari P, &ldquo;Reversible Posterior Leukoencephalopathy Syndrome and Bevacizumab,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(9):981-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/16514715/pubmed\" id=\"16514715\" target=\"_blank\">",
"        16514715",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Park MS, Patel SR, Ludwig JA, et al, &ldquo;Activity of Temozolomide and Bevacizumab in the Treatment of Locally Advanced, Recurrent, and Metastatic Hemangiopericytoma and Malignant Solitary Fibrous Tumor,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2011, 117(21):4939-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/21480200/pubmed\" id=\"21480200\" target=\"_blank\">",
"        21480200",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perren TJ, Swart AM, Pfisterer J, et al, &ldquo;A Phase 3 Trial of Bevacizumab in Ovarian Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(26):2484-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/22204725/pubmed\" id=\"22204725\" target=\"_blank\">",
"        22204725",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Polyzos A, Kalbakis K, Kentepozidis N, et al, &ldquo;Salvage Treatment In Metastatic Breast Cancer With Weekly Paclitaxel and Bevacizumab,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2011, 68(1):217-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/20922389/pubmed\" id=\"20922389\" target=\"_blank\">",
"        20922389",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ranpura V, Hapani S, and Wu S, &ldquo;Treatment-Related Mortality With Bevacizumab in Cancer Patients,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2011, 305(5):487-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/21285426/pubmed\" id=\"21285426\" target=\"_blank\">",
"        21285426",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reck M, von Pawel J, Zatloukal P, et al, &ldquo;Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab as First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAil,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(8):1227-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/19188680/pubmed\" id=\"19188680\" target=\"_blank\">",
"        19188680",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reidy DL, Chung KY, Timoney JP, et al, &ldquo;Bevacizumab 5 mg/kg Can be Infused Safely over 10 minutes,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(19):2691-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/17602073/pubmed\" id=\"17602073\" target=\"_blank\">",
"        17602073",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rini BI, Halabi S, Rosenberg JE, et al, &ldquo;Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(33):5422-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/18936475/pubmed\" id=\"18936475\" target=\"_blank\">",
"        18936475",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robert NJ, Dieras V, Glaspy J, et al, &ldquo;RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab (B) for First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(15s):1005 [abstract 1005 from 2009 ASCO Annual Meeting]",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saltz LB, Clarke S, D&iacute;az-Rubio E, et al, &ldquo;Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(12):2013-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/18421054/pubmed\" id=\"18421054\" target=\"_blank\">",
"        18421054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sandler A, Gray R, Perry MC, et al, &ldquo;Paclitaxel-Carboplatin Alone or With Bevacizumab for Non-Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(24):2542-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/17167137/pubmed\" id=\"17167137\" target=\"_blank\">",
"        17167137",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sane DC, Anton L, and Brosnihan KB, &ldquo;Angiogenic Growth Factors and Hypertension,&rdquo;",
"      <i>",
"       Angengenesis",
"      </i>",
"      , 2004, 7(3):193-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scappaticci FA, Skillings JR, Holden SN, et al, &ldquo;Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated With Chemotherapy and Bevacizumab,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2007, 99(16):1232-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/17686822/pubmed\" id=\"17686822\" target=\"_blank\">",
"        17686822",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al, &ldquo;Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(30):4722-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/17947719/pubmed\" id=\"17947719\" target=\"_blank\">",
"        17947719",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner AD, Thomssen C, Haerting J, et al, &ldquo;Vascular-Endothelial-Growth-Factor (VEGF) Targeting Therapies for Endocrine Refractory or Resistant Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2012, 7:CD008941.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/22786517/pubmed\" id=\"22786517\" target=\"_blank\">",
"        22786517",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yang JC, Haworth L, Sherry RM, et al, &ldquo;A Randomized Trial of Bevacizumab, An Antivascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(5):427-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/12890841/pubmed\" id=\"12890841\" target=\"_blank\">",
"        12890841",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhu J, Sharma DB, Gray SW, et al, &ldquo;Carboplatin and Paclitaxel With vs Without Bevacizumab in Older Patients With Advanced Non-Small Cell Lung Cancer,&rdquo;",
"      <i>",
"       JAMA,",
"      </i>",
"      2012, 307(15):1593-601.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/20/2377/abstract-text/22511687/pubmed\" id=\"22511687\" target=\"_blank\">",
"        22511687",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8683 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-2BDF7BB03E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_20_2377=[""].join("\n");
var outline_f2_20_2377=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708647\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141002\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422982\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141022\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141004\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141005\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13301090\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13301091\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141023\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140982\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140970\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140985\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14266279\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140984\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141018\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110715\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141020\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140988\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140973\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298861\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140976\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140978\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140991\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141011\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140992\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140990\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140980\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140993\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140972\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140987\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8683\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8683|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/29/1494?source=related_link\">",
"      Bevacizumab: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/44/20166?source=related_link\">",
"      Bevacizumab: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_20_2378="Clinical manifestations of varicella-zoster virus infection: Herpes zoster";
var content_f2_20_2378=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of varicella-zoster virus infection: Herpes zoster",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/20/2378/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/20/2378/contributors\">",
"     Mary A Albrecht, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/20/2378/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/20/2378/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/20/2378/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/20/2378/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/20/2378/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella-zoster virus (VZV) infection causes two clinically distinct forms of disease. Primary infection with VZV results in varicella (chickenpox), characterized by vesicular lesions in different stages of development on the face, trunk, and extremities. Herpes zoster, also known as shingles, results from reactivation of endogenous latent VZV infection within the sensory ganglia. This clinical form of the disease is characterized by a painful, unilateral vesicular eruption, which usually occurs in a restricted dermatomal distribution.",
"   </p>",
"   <p>",
"    This topic will address the clinical manifestations and complications of herpes zoster in immunocompetent and immunosuppressed hosts. The epidemiology, pathogenesis, diagnosis, and treatment of shingles, and the clinical manifestations of chickenpox, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=see_link\">",
"     \"Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33096?source=see_link\">",
"     \"Treatment of herpes zoster in the immunocompetent host\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/77?source=see_link\">",
"     \"Diagnosis of varicella-zoster virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=see_link\">",
"     \"Clinical features of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presenting clinical manifestations of herpes zoster are usually characterized by rash and acute neuritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rash of herpes zoster starts as erythematous papules, which quickly evolve into grouped vesicles or bullae (",
"    <a class=\"graphic graphic_picture graphicRef58282 \" href=\"UTD.htm?11/25/11669\">",
"     picture 1",
"    </a>",
"    ). Within three to four days, these vesicular lesions can become more pustular or occasionally hemorrhagic (",
"    <a class=\"graphic graphic_picture graphicRef52440 \" href=\"UTD.htm?11/49/12048\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65213 \" href=\"UTD.htm?9/42/9903\">",
"     picture 3",
"    </a>",
"    ). In immunocompetent hosts, the lesions crust by 7 to 10 days and are no longer considered infectious. The development of new lesions more than a week after presentation should raise concerns regarding possible underlying immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/1\">",
"     1",
"    </a>",
"    ]. Scarring and hypo- or hyperpigmentation may persist months to years after herpes zoster infection has resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Zoster is generally limited to one dermatome in previously healthy hosts, but can occasionally affect two or three neighboring dermatomes (",
"    <a class=\"graphic graphic_figure graphicRef64754 \" href=\"UTD.htm?17/63/18420\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef79158 \" href=\"UTD.htm?14/59/15282\">",
"     figure 2",
"    </a>",
"    ). Some patients have a few scattered vesicles located at some distance away from the involved dermatome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The thoracic and lumbar dermatomes are the most commonly involved sites of herpes zoster&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef64754 \" href=\"UTD.htm?17/63/18420\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/4\">",
"     4",
"    </a>",
"    ]. A more serious infection, such as zoster keratitis or zoster ophthalmicus, can result from involvement of the ophthalmic branch of the trigeminal cranial nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. These can be sight-threatening infections. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Complications in immunocompetent patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Fewer than 20 percent of patients have significant systemic symptoms, such as headache, fever, malaise, or fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acute neuritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is the most common symptom of zoster [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/6\">",
"     6",
"    </a>",
"    ]; approximately 75 percent of patients have prodromal pain in the dermatome where the rash subsequently appears [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/1\">",
"     1",
"    </a>",
"    ]. Prodromal pain may be constant or intermittent and can precede the rash by days to weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/7\">",
"     7",
"    </a>",
"    ]. Most patients describe a deep \"burning\", \"throbbing\", or \"stabbing\" sensation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/7\">",
"     7",
"    </a>",
"    ]. Some individuals describe the pain only when the involved area is touched, whereas others complain primarily of pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/8\">",
"     8",
"    </a>",
"    ]. Pain that is induced by simple mild brushing against the skin is referred to as \"allodynia\".",
"   </p>",
"   <p>",
"    In the absence of vesicular rash, certain pain syndromes can be confused with other etiologies, such as angina, cholecystitis, or renal colic, depending on the involved dermatome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/4,9\">",
"     4,9",
"    </a>",
"    ]. In one study of 1669 patients with confirmed herpes zoster, 18 percent had acute neuritis for at least 30 days and the duration of pain increased with age [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Atypical pain without rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept that atypical pain syndromes may be related to herpes zoster without rash, or \"zoster sine herpete\", has been raised. Some clinical data showing serologic and PCR evidence of concurrent VZV reactivation have supported this theory [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RECURRENT ZOSTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence of clinical zoster in the immunocompetent host is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In one retrospective study of 5180 unvaccinated patients &gt;60 years of age with a history of zoster within the previous four years, only 25 well-documented recurrent cases were identified on medical chart review during an average of 4.5 years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/13\">",
"     13",
"    </a>",
"    ]. Three or more episodes recurring in the same individual are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, recurrences are more common in the immunocompromised host [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In one study of HIV-infected patients (mean age 41 years), 282 episodes of herpes zoster were identified in 239 patients. Of these episodes, 158 were new occurrences of zoster and 124 were recurrent zoster events [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, patients who present with recurrent herpes simplex outside of the mouth or genital areas may be misdiagnosed with recurrent zoster. Thus, viral cultures or other detection assays (eg, antigen or DNA) should be performed when a diagnosis of recurrent zoster is being considered. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COMPLICATIONS IN IMMUNOCOMPETENT PATIENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complication of herpes zoster is postherpetic neuralgia. In one study, the percentage of patients with herpes zoster who developed postherpetic neuralgia (defined as at least 90 days of documented pain) increased from 5 percent in those younger than 60 years to 20 percent in those aged 80 years or older [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/16\">",
"     16",
"    </a>",
"    ]. A randomized placebo-controlled trial in more than 38,000 adults demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    in the elderly reduces the incidence of PHN following zoster by 67 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other complications include ocular, neurologic, bacterial superinfection of the skin, which can delay healing of the zoster lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/2,5,18,19\">",
"     2,5,18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21608?source=see_link\">",
"     \"Postherpetic neuralgia\"",
"    </a>",
"    .) Herpes zoster is not always limited to a spinal nerve distribution, but may also extend centrally, which can result in meningeal inflammation and clinical meningitis. Occasionally, VZV reactivation affects motor neurons in the spinal cord and brainstem, resulting in motor neuropathies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/2,3,5\">",
"     2,3,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Incidence of complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a review of 859 patients with herpes zoster, 100 patients (12 percent) developed 123 complications within 60 days [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/5\">",
"     5",
"    </a>",
"    ]. A single complication occurred in 83 percent, two in 12 percent, and three or more in 5 percent. The risks of specific complications at 60 days were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Postherpetic neuralgia &mdash; 7.9 percent",
"     </li>",
"     <li>",
"      Bacterial skin infection &mdash; 2.3 percent",
"     </li>",
"     <li>",
"      Ocular complications including uveitis and keratitis &mdash; 1.6 percent (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=see_link\">",
"       \"Uveitis: Etiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Motor neuropathy &mdash; 0.9 percent",
"     </li>",
"     <li>",
"      Meningitis &mdash; 0.5 percent",
"     </li>",
"     <li>",
"      Herpes zoster oticus &mdash; 0.2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Twenty-seven percent of patients with complications had ophthalmic (trigeminal) zoster compared to the group of patients without complications in whom only 5 percent had this dermatome involved. Advanced age was associated with postherpetic neuralgia, bacterial superinfection of the skin, ocular complications, and motor neuropathy. Patients with one or more complications had more frequent comorbidities (eg, diabetes, cancer, HIV, transplant recipient).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Postherpetic neuralgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 to 15 percent of all patients with herpes zoster will develop postherpetic neuralgia (PHN) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/20\">",
"     20",
"    </a>",
"    ]; individuals older than 60 years account for 50 percent of these cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/21\">",
"     21",
"    </a>",
"    ]. PHN refers to pain persisting beyond four months from the initial onset of the rash. Sensory symptoms can include pain, numbness, dysesthesias, and allodynia (pain precipitated by movement) in the affected dermatome. Immunosuppressed patients have a higher incidence of PHN.",
"   </p>",
"   <p>",
"    This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21608?source=see_link\">",
"     \"Postherpetic neuralgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Herpes zoster ophthalmicus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes zoster ophthalmicus (HZO), a serious sight-threatening condition, has been linked to VZV reactivation within the trigeminal ganglion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Incidence rates of HZO complicating herpes zoster in various population surveys have ranged from 8 to 56 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/22,24\">",
"     22,24",
"    </a>",
"    ]. The frontal branch within the first division of the trigeminal nerve is most frequently involved, and 50 to 72 percent of patients experience direct ocular involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The acute syndrome typically begins with a prodrome of headache, malaise, and fever; unilateral pain or hypesthesia in the affected eye, forehead, and top of the head may precede or follow the prodrome. With the onset of a vesicular eruption along the trigeminal dermatome, hyperemic conjunctivitis, episcleritis, and lid droop can occur (",
"    <a class=\"graphic graphic_picture graphicRef74420 \" href=\"UTD.htm?27/50/28453\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/18,22,23\">",
"     18,22,23",
"    </a>",
"    ]. Almost two-thirds of HZO patients develop corneal involvement (keratitis) that results from a necrotic ganglionitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/22\">",
"     22",
"    </a>",
"    ]; epithelial keratitis may feature punctate or dendriform lesions. Iritis occurs in approximately 40 percent of patients with herpes zoster ophthalmicus and can be associated with chronic vasculitis, atrophy, and poorly reactive pupils [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians should also be aware that vesicular lesions on the nose are associated with a high risk of herpes zoster ophthalmicus (Hutchinson's sign) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/25\">",
"     25",
"    </a>",
"    ]. Lesions in this area of the face signify involvement of the nasociliary branch of the trigeminal nerve, which also innervates the globe [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early diagnosis is critical to prevent progressive corneal involvement and potential loss of vision [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/27\">",
"     27",
"    </a>",
"    ]. The standard approach to herpes zoster ophthalmicus is to initiate antiviral therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    ) to limit VZV replication and to use adjunctive topical steroid drops to reduce the inflammatory response and control immune keratitis and iritis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/22,23,27,28\">",
"     22,23,27,28",
"    </a>",
"    ]. Selected surgical procedures including corneal transplant and lid repair are performed less often.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acute retinal necrosis (ARN)",
"    </span>",
"    &nbsp;&mdash;&nbsp;VZV has been implicated as the leading causative pathogen of acute retinal necrosis (ARN) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/29\">",
"     29",
"    </a>",
"    ]; HSV has occasionally also been identified as an etiologic agent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/30-32\">",
"     30-32",
"    </a>",
"    ] and has been described in patients with a history of herpes encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/33\">",
"     33",
"    </a>",
"    ]. In a study evaluating samples of aqueous humor, VZV DNA was detected in seven of the nine patients with necrotizing retinopathies of suspected viral origin and in four of six patients with ARN [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33561?source=see_link\">",
"     \"Retinal vasculitis associated with systemic disorders and infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     ARN in the immunocompetent host",
"    </span>",
"    &nbsp;&mdash;&nbsp;ARN has been reported in immunocompetent hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The clinical presentation features acute iridocyclitis, vitritis, necrotizing retinitis, occlusive retinal vasculitis with rapid loss of vision, and eventual retinal detachment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/18,30,34,35\">",
"     18,30,34,35",
"    </a>",
"    ]. Patients typically complain of blurred vision and pain in the affected eye due to progressive necrotizing retinitis; the disease can subsequently involve the other eye in 33 to 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/30\">",
"     30",
"    </a>",
"    ]. The mechanism of bilateral involvement is not clear, but one study found a diminished or absent VZV-specific delayed hypersensitivity reaction in patients with ARN compared to patients with herpes zoster involving only the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/36\">",
"     36",
"    </a>",
"    ]. Retinal detachment is a common complication of ARN [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/29,37\">",
"     29,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    therapy for ARN usually affords clinical improvement in 48 to 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/37\">",
"     37",
"    </a>",
"    ] and can decrease the risk of contralateral eye involvement when administered for more than three months [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/34\">",
"     34",
"    </a>",
"    ]. One pharmacokinetic study evaluated intravitreal drug concentrations in 10 patients with ARN after 24 hours of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    and found substantial penetration, even in the uninflamed eye [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/38\">",
"     38",
"    </a>",
"    ]. Some practitioners use oral antiviral agents for maintenance therapy, although there does not appear to be a consensus on the need for long-term treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/32\">",
"     32",
"    </a>",
"    ]. There are few data on the use of oral agents for the initial treatment of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic corticosteroid use may decrease the severity of ocular inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     ARN in HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with advanced AIDS and ARN, the following observations have been reported in the early era of potent ART [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid progression was characteristic; only 4 of 20 involved eyes retained useful vision at two-month follow-up, and 70 percent had no light perception at the conclusion of the study.",
"     </li>",
"     <li>",
"      Eighty-two percent of patients had bilateral eye involvement; 70 percent sustained retinal detachment.",
"     </li>",
"     <li>",
"      Seventy-three percent of patients had accompanying central nervous system (CNS) disease presumably due to VZV virus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are few data in the past decade regarding the management of this syndrome, which may be related to a decreased incidence of ARN in the era of potent HIV therapy. In one 2007 case report, aggressive antiviral therapy with intravitreal injections, initiation of ART, and serial sampling of vitreous for evidence of viral replication led to a good clinical outcome in the setting of immune reconstitution [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Ramsay Hunt syndrome (Herpes zoster oticus)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major otologic complication of VZV reactivation is the Ramsay Hunt syndrome, which typically includes the triad of ipsilateral facial paralysis, ear pain, and vesicles in the auditory canal and auricle [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Taste perception, hearing (tinnitus, hyperacusis), and lacrimation are affected in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/42\">",
"     42",
"    </a>",
"    ]. Ramsay Hunt syndrome is generally considered a polycranial neuropathy with frequent involvement of cranial nerves V, IX, and X [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/41\">",
"     41",
"    </a>",
"    ]. Vestibular disturbances (vertigo) are also frequently reported. Ramsay Hunt syndrome has also been reported in association with herpes simplex type 2 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ramsay Hunt syndrome has been linked to reactivation of latent VZV residing within the geniculate ganglion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/44\">",
"     44",
"    </a>",
"    ] with subsequent spread of the inflammatory process to involve the eighth cranial nerve. This results in auditory and vestibular disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/45\">",
"     45",
"    </a>",
"    ]. VZV DNA has been detected in 11 of 14 trigeminal ganglia (79 percent) and in 9 of 13 geniculate ganglia (69 percent) in adults but was not isolated from any newborn ganglia specimens or from one adult seronegative for VZV [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/45\">",
"     45",
"    </a>",
"    ]. These results indicate that VZV becomes latent in the human geniculate ganglion after primary varicella infection, and reactivation of VZV from the geniculate ganglion most likely precipitates the Ramsay Hunt syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The facial paralysis seen in Ramsay Hunt syndrome is felt generally to be more severe than Bell's palsy attributed to HSV, with increased rates of late neural denervation and a decreased probability of complete recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Antiviral therapy is usually prescribed, although there are few data on this complication and management [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other neurologic complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Aseptic meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies conducted in patients with herpes zoster have demonstrated that subclinical meningeal irritation, evidenced by a reactive cerebrospinal fluid (CSF) pleocytosis, can occur in 40 to 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. A subset of immunocompetent patients with herpes zoster develops clinically evident aseptic meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/51\">",
"     51",
"    </a>",
"    ]; lumbar puncture typically confirms a brisk CSF pleocytosis and an elevated protein concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In a Finnish epidemiologic study of 144 patients with aseptic meningitis, an etiology was established in 66 percent of patients, 8 percent of whom had VZV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Peripheral motor neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Segmental motor paresis develops in approximately 3 percent of patients with zoster [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/49,54\">",
"     49,54",
"    </a>",
"    ]. Peripheral motor weakness is felt to result from spread of VZV from the dorsal root ganglia to the anterior",
"    <span class=\"nowrap\">",
"     root/horn;",
"    </span>",
"    the onset is typically coincident with the development of pain and cutaneous eruption in a dermatomal distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/49,54,55\">",
"     49,54,55",
"    </a>",
"    ]. Muscle atrophy may result in the affected region, but approximately 75 percent of patients experience gradual recovery of motor strength [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Myelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transverse myelitis occasionally complicates herpes zoster (usually involving thoracic dermatomes (",
"    <a class=\"graphic graphic_figure graphicRef64754 \" href=\"UTD.htm?17/63/18420\">",
"     figure 1",
"    </a>",
"    )) within days to weeks following the initial onset of the vesicular rash [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/49,56\">",
"     49,56",
"    </a>",
"    ]. Myelitis is a more frequent complication in HIV-infected patients and involves direct spread of VZV from the dorsal root ganglia centrally into the spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Several reports describing zoster myelitis in HIV-infected patients in the absence of any rash have documented VZV DNA within spinal cord specimens at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Zoster-associated encephalitis typically presents with delirium within days following the vesicular eruption but may occur prior to the onset of rash or follow an episode of zoster by more than six months [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/49,59\">",
"     49,59",
"    </a>",
"    ]. While apparently normal hosts may develop VZV encephalitis, the majority of cases have been reported in immunosuppressed patients, such as HIV-infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/18,49,59-61\">",
"     18,49,59-61",
"    </a>",
"    ]. Major risk factors identified for the development of zoster encephalitis include cranial or cervical dermatomal involvement, two or more prior episodes of zoster, disseminated herpes zoster, and impaired cell-mediated immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/49,60\">",
"     49,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AIDS patients may develop a leukoencephalitis associated with CNS white matter demyelination and cerebral vasculopathy due to ongoing VZV replication within the brain parenchyma [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/49,62\">",
"     49,62",
"    </a>",
"    ]. Response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    therapy in AIDS patients has been variable due to the frequent emergence of acyclovir-resistant VZV strains during long-term exposure to the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. CSF PCR assays, in conjunction with MRI brain imaging studies, have facilitated more rapid diagnosis of VZV-induced encephalitis in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4574869\">",
"    <span class=\"h3\">",
"     Guillain-Barr&eacute; syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from a Taiwan health registry was extracted to determine if there was an increased risk of Guillain-Barr&eacute; Syndrome (GBS) among those with a history of herpes zoster within the prior two months of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/68\">",
"     68",
"    </a>",
"    ]. Of 315,595 patients with a history of herpes zoster, 0.03 percent developed GBS. Although GBS was a relatively rare event, the risk of developing this syndrome was significantly higher among patients with a recent history of zoster compared with controls, who were matched by age and sex. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=see_link\">",
"     \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Stroke syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;VZV infection can produce stroke syndromes secondary to infection of cerebral arteries. In a series of 30 patients with VZV vasculopathy, diagnosed by either VZV-specific antibodies or VZV DNA in the CSF, rash occurred in 19 (63 percent) and CSF pleocytosis in 20 (67 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/69\">",
"     69",
"    </a>",
"    ]. Angiography demonstrated the involvement of both large and small arteries in approximately half of the patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21288?source=see_link\">",
"     \"Stroke caused by varicella zoster virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of stroke following an episode of dermatomal zoster has been linked to direct viral invasion of cerebral arteries with VZV by extension along the intracranial branches of the trigeminal nerves resulting in an inflammatory process within the internal carotid artery or its branches on the side ipsilateral to the rash [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/18,70\">",
"     18,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Granulomatous vasculitis of the large and small arteries, with VZV antigens detectable in the smooth muscle cells of the media, has been confirmed in several autopsy studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/71\">",
"     71",
"    </a>",
"    ]. These pathologic findings have suggested that the syndrome results from direct VZV invasion of the arterial surface via spread along the intracranial branches of the trigeminal nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/49,71\">",
"     49,71",
"    </a>",
"    ]. The mortality rate is at least 20 percent, and survivors have severe neurologic deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HZO has rarely been complicated by contralateral thrombotic stroke syndrome in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/49,71,72\">",
"     49,71,72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21288?source=see_link\">",
"     \"Stroke caused by varicella zoster virus\"",
"    </a>",
"    .) This catastrophic syndrome typically occurs within several weeks to a few months after the zoster eruption [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/49\">",
"     49",
"    </a>",
"    ] and is heralded by the abrupt onset of severe headache and rapid evolution to contralateral motor weakness. Cerebral angiography demonstrates multifocal occlusion of the proximal branches of the anterior and middle cerebral arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1051738\">",
"    <span class=\"h2\">",
"     Bacterial infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunocompetent and immunocompromised adults with localized herpes zoster are at risk for developing soft tissue infection with bacterial pathogens, such as staphylococcus and streptococcus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. In addition to antiviral therapy, antibiotics targeting these bacterial pathogens is indicated when this complication occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     COMPLICATIONS IN IMMUNOCOMPROMISED HOSTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunocompromised hosts, including both HIV-infected patients and transplant recipients, remain at substantial risk for severe VZV-related complications [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/18,49,57,58,76-79\">",
"     18,49,57,58,76-79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunocompromised patients such as transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/80,81\">",
"     80,81",
"    </a>",
"    ] and HIV-infected individuals with advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/80,82\">",
"     80,82",
"    </a>",
"    ] are at increased risk for developing complicated herpes zoster infections including cutaneous dissemination and visceral end organ involvement. Cutaneous dissemination often presents with multiple vesicular skin lesions in a generalized distribution affecting a number of distinct dermatomes that cross the midline. Visceral organ involvement due to herpes zoster may present in a fulminant and rapidly evolving syndrome with pneumonia, hepatitis, or encephalitis and may occasionally develop in the absence of coincident rash [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disseminated VZV has been documented in both solid organ transplant recipients and in patients with hematologic malignancies undergoing chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/77,83,84\">",
"     77,83,84",
"    </a>",
"    ]. Cutaneous dissemination is often accompanied by visceral involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. Visceral dissemination in the immunosuppressed transplant patient is a life-threatening emergency [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/86\">",
"     86",
"    </a>",
"    ]. In transplant patients, reactivation of VZV typically occurs later than CMV or HSV [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/87\">",
"     87",
"    </a>",
"    ]. Cutaneous lesions may be delayed, or atypical with hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VZV pneumonitis in transplant recipients has been associated with a high mortality despite prompt diagnosis and the empiric institution of antiviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Bone marrow transplant recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;VZV dissemination remains the most frequent late infection of allogeneic bone marrow transplant (BMT) recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]; concurrent graft versus host disease (GVHD) has been identified as a major risk factor for dissemination [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .) Infection with reactivated VZV occurs in 35 percent of allogeneic BMT recipients at one year; almost 50 percent of these patients will develop disseminated VZV [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/89\">",
"     89",
"    </a>",
"    ]. Visceral VZV dissemination can be accompanied by pneumonitis, hepatitis, pancreatitis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    meningoencephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Selected BMT recipients have presented with acute, severe abdominal pain as the initial manifestation of visceral reactivated VZV in the absence of antecedent cutaneous rash, hepatitis, or pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/83,90\">",
"     83,90",
"    </a>",
"    ]. The appearance of a zoster rash as long as 10 to 14 days after abdominal pain begins has frequently delayed prompt diagnosis and resulted in a poor outcome despite the institution of appropriate antiviral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients are at increased risk of developing herpes zoster than the general population and are at increased risk of neurologic and ophthalmologic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence and clinical spectrum of herpes zoster was evaluated in an urban clinic of HIV-infected patients; 52 episodes of zoster occurred in 45 patients during 1614 person-years of follow-up (incidence, 3.2 episodes per 100 person-years) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/76\">",
"     76",
"    </a>",
"    ]. In this study conducted in the pre-HAART era, low CD4 count was associated with zoster-related complications, such as retinal necrosis and aseptic meningitis.",
"   </p>",
"   <p>",
"    One retrospective study evaluated VZV infections before and after the introduction of potent ART [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/91\">",
"     91",
"    </a>",
"    ]. The incidence of HZ in the pre-HAART era (17 per 100 person years) was significantly higher than that in the post-HAART era (5 per 100 person-years). Furthermore, in both eras, the incidence of HZ was higher in the first six months after initiating ART than between 6 and 12 months. Another retrospective study with a case-control design determined that 18 percent of patients who had herpes zoster developed PHN [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reactivation of herpes zoster has also been reported as part of the immune reconstitution inflammatory syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/20/2378/abstract/92-94\">",
"     92-94",
"    </a>",
"    ]. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shingles is typically characterized in immunocompetent individuals by a unilateral vesicular eruption with a well-defined dermatomal distribution. The diagnosis is usually established based solely on the clinical presentation.",
"   </p>",
"   <p>",
"    Shingles, however, may occasionally present with atypical skin lesions, especially in immunosuppressed individuals. Patients with recurrent HSV reactivation may develop vesicular lesions in an unusual distribution that are difficult to distinguish from a VZV eruption. In circumstances where the clinical presentation is uncertain, laboratory confirmation is indicated.",
"   </p>",
"   <p>",
"    Diagnostic techniques include viral culture, direct immunofluorescence testing, and the polymerase chain reaction assay, which is the most sensitive test. These diagnostic assays are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/77?source=see_link\">",
"     \"Diagnosis of varicella-zoster virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the rash of herpes zoster has appeared, the diagnosis is usually readily apparent. The other main agent to consider in the differential diagnosis is herpes simplex. Herpes zoster is mainly characterized by a painful sensory prodrome, dermatomal distribution, and lack of prior history of a similar rash. If the patient has had a similar vesicular rash in the same location, then recurrent zosteriform herpes simplex should be considered. A non-infectious etiology to consider is contact dermatitis.",
"   </p>",
"   <p>",
"    The immunocompromised host may present with atypical findings, such as nodular lesions or chronic crusting of the skin. Diagnostic laboratory testing should be utilized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/0/14338?source=see_link\">",
"       \"Patient information: Shingles (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/12/13507?source=see_link\">",
"       \"Patient information: Shingles (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presenting clinical manifestations of herpes zoster are usually characterized by rash and acute neuritis. The thoracic and lumbar dermatomes are the most commonly involved sites of herpes zoster (",
"      <a class=\"graphic graphic_figure graphicRef64754 \" href=\"UTD.htm?17/63/18420\">",
"       figure 1",
"      </a>",
"      ). Immunocompromised hosts may develop disseminated lesions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrence of clinical zoster in the immunocompetent host is rare, but does occur in the immunosuppressed host. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Recurrent zoster'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common complication of herpes zoster is postherpetic neuralgia. Other complications include herpes zoster ophthalmicus or oticus, acute retinal necrosis, aseptic meningitis, and encephalitis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Complications in immunocompetent patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunocompromised hosts are at risk for cutaneous and visceral dissemination. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Complications in immunocompromised hosts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is usually made clinically; available diagnostic techniques include viral culture, direct fluorescent antibody testing, and the polymerase chain reaction assay. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/4/77?source=see_link\">",
"       \"Diagnosis of varicella-zoster virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The principle other main infectious agent to consider in the differential diagnosis of vesicular lesions is herpes simplex. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Educational materials on this topic are available for patients. (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/12/13507?source=see_link\">",
"       \"Patient information: Shingles (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/1\">",
"      Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/2\">",
"      Straus SE, Ostrove JM, Inchausp&eacute; G, et al. NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med 1988; 108:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/3\">",
"      Oxman MN. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 1995; 45:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/4\">",
"      Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/5\">",
"      Galil K, Choo PW, Donahue JG, Platt R. The sequelae of herpes zoster. Arch Intern Med 1997; 157:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/6\">",
"      Jumaan AO, Yu O, Jackson LA, et al. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005; 191:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/7\">",
"      Kost RG, Straus SE. Postherpetic neuralgia--pathogenesis, treatment, and prevention. N Engl J Med 1996; 335:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/8\">",
"      Liddell K. Letter: Post-herpetic pruritus. Br Med J 1974; 4:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/9\">",
"      Wareham DW, Breuer J. Herpes zoster. BMJ 2007; 334:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/10\">",
"      Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, et al. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 2000; 342:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/11\">",
"      HOPE-SIMPSON RE. THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS. Proc R Soc Med 1965; 58:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/12\">",
"      Head H, Campbell AW. The pathology of herpes zoster and its bearing on sensory localization. Brain 1900; 23:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/13\">",
"      Tseng HF, Chi M, Smith N, et al. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. J Infect Dis 2012; 206:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/14\">",
"      Gebo KA, Kalyani R, Moore RD, Polydefkis MJ. The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 2005; 40:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/15\">",
"      Yawn BP, Wollan PC, Kurland MJ, et al. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc 2011; 86:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/16\">",
"      Bowsher D. Postherpetic neuralgia and its treatment: a retrospective survey of 191 patients. J Pain Symptom Manage 1996; 12:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/17\">",
"      Oxman MN, Levin MJ, Shingles Prevention Study Group. Vaccination against Herpes Zoster and Postherpetic Neuralgia. J Infect Dis 2008; 197 Suppl 2:S228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/18\">",
"      Gnann JW Jr. Varicella-zoster virus: atypical presentations and unusual complications. J Infect Dis 2002; 186 Suppl 1:S91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/19\">",
"      Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/20\">",
"      Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/21\">",
"      Choo PW, Galil K, Donahue JG, et al. Risk factors for postherpetic neuralgia. Arch Intern Med 1997; 157:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/22\">",
"      Pavan-Langston D. Herpes zoster ophthalmicus. Neurology 1995; 45:S50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/23\">",
"      Liesegang TJ. Diagnosis and therapy of herpes zoster ophthalmicus. Ophthalmology 1991; 98:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/24\">",
"      Ragozzino MW, Melton LJ 3rd, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982; 61:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/25\">",
"      Tomkinson A, Roblin DG, Brown MJ. Hutchinson's sign and its importance in rhinology. Rhinology 1995; 33:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/26\">",
"      Zaal MJ, V&ouml;lker-Dieben HJ, D'Amaro J. Prognostic value of Hutchinson's sign in acute herpes zoster ophthalmicus. Graefes Arch Clin Exp Ophthalmol 2003; 241:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/27\">",
"      Severson EA, Baratz KH, Hodge DO, Burke JP. Herpes zoster ophthalmicus in olmsted county, Minnesota: have systemic antivirals made a difference? Arch Ophthalmol 2003; 121:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/28\">",
"      Herbort CP, Buechi ER, Piguet B, et al. High-dose oral acyclovir in acute herpes zoster ophthalmicus: the end of the corticosteroid era. Curr Eye Res 1991; 10 Suppl:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/29\">",
"      Lau CH, Missotten T, Salzmann J, Lightman SL. Acute retinal necrosis features, management, and outcomes. Ophthalmology 2007; 114:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/30\">",
"      Hellinger WC, Bolling JP, Smith TF, Campbell RJ. Varicella-zoster virus retinitis in a patient with AIDS-related complex: case report and brief review of the acute retinal necrosis syndrome. Clin Infect Dis 1993; 16:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/31\">",
"      Culbertson WW, Blumenkranz MS, Pepose JS, et al. Varicella zoster virus is a cause of the acute retinal necrosis syndrome. Ophthalmology 1986; 93:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/32\">",
"      Muthiah MN, Michaelides M, Child CS, Mitchell SM. Acute retinal necrosis: a national population-based study to assess the incidence, methods of diagnosis, treatment strategies and outcomes in the UK. Br J Ophthalmol 2007; 91:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/33\">",
"      Vandercam T, Hintzen RQ, de Boer JH, Van der Lelij A. Herpetic encephalitis is a risk factor for acute retinal necrosis. Neurology 2008; 71:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/34\">",
"      Garweg J, B&ouml;hnke M. Varicella-zoster virus is strongly associated with atypical necrotizing herpetic retinopathies. Clin Infect Dis 1997; 24:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/35\">",
"      Urayama A, Yamada N, Sasaki T, et al. Unilateral acute uveitis with periarteritis and detachment. Jpn J Clin Ophthalmol 1971; 25:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/36\">",
"      Kezuka T, Sakai J, Usui N, et al. Evidence for antigen-specific immune deviation in patients with acute retinal necrosis. Arch Ophthalmol 2001; 119:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/37\">",
"      Ormerod LD, Larkin JA, Margo CA, et al. Rapidly progressive herpetic retinal necrosis: a blinding disease characteristic of advanced AIDS. Clin Infect Dis 1998; 26:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/38\">",
"      Huynh TH, Johnson MW, Comer GM, Fish DN. Vitreous penetration of orally administered valacyclovir. Am J Ophthalmol 2008; 145:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/39\">",
"      Emerson GG, Smith JR, Wilson DJ, et al. Primary treatment of acute retinal necrosis with oral antiviral therapy. Ophthalmology 2006; 113:2259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/40\">",
"      Yin PD, Kurup SK, Fischer SH, et al. Progressive outer retinal necrosis in the era of highly active antiretroviral therapy: successful management with intravitreal injections and monitoring with quantitative PCR. J Clin Virol 2007; 38:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/41\">",
"      Adour KK. Otological complications of herpes zoster. Ann Neurol 1994; 35 Suppl:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/42\">",
"      Mishell JH, Applebaum EL. Ramsay-Hunt syndrome in a patient with HIV infection. Otolaryngol Head Neck Surg 1990; 102:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/43\">",
"      Diaz GA, Rakita RM, Koelle DM. A case of Ramsay Hunt-like syndrome caused by herpes simplex virus type 2. Clin Infect Dis 2005; 40:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/44\">",
"      Hunt JR. On herpetic inflammation of the geniculate ganglion: A new syndrome and its complications. J Nerv Ment Dis 1907; 34:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/45\">",
"      Furuta Y, Takasu T, Fukuda S, et al. Detection of varicella-zoster virus DNA in human geniculate ganglia by polymerase chain reaction. J Infect Dis 1992; 166:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/46\">",
"      Robillard RB, Hilsinger RL Jr, Adour KK. Ramsay Hunt facial paralysis: clinical analyses of 185 patients. Otolaryngol Head Neck Surg 1986; 95:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/47\">",
"      Lee DH, Chae SY, Park YS, Yeo SW. Prognostic value of electroneurography in Bell's palsy and Ramsay-Hunt's syndrome. Clin Otolaryngol 2006; 31:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/48\">",
"      Uscategui T, Dor&eacute;e C, Chamberlain IJ, Burton MJ. Antiviral therapy for Ramsay Hunt syndrome (herpes zoster oticus with facial palsy) in adults. Cochrane Database Syst Rev 2008; :CD006851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/49\">",
"      Elliott KJ. Other neurological complications of herpes zoster and their management. Ann Neurol 1994; 35 Suppl:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/50\">",
"      Gold E. Serologic and virus-isolation studies of patients with varicella or herpes-zoster infection. N Engl J Med 1966; 274:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/51\">",
"      Kupila L, Vuorinen T, Vainionp&auml;&auml; R, et al. Etiology of aseptic meningitis and encephalitis in an adult population. Neurology 2006; 66:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/52\">",
"      Echevarr&iacute;a JM, Mart&iacute;nez-Mart&iacute;n P, T&eacute;llez A, et al. Aseptic meningitis due to varicella-zoster virus: serum antibody levels and local synthesis of specific IgG, IgM, and IgA. J Infect Dis 1987; 155:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/53\">",
"      Ihekwaba UK, Kudesia G, McKendrick MW. Clinical features of viral meningitis in adults: significant differences in cerebrospinal fluid findings among herpes simplex virus, varicella zoster virus, and enterovirus infections. Clin Infect Dis 2008; 47:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/54\">",
"      Chang CM, Woo E, Yu YL, et al. Herpes zoster and its neurological complications. Postgrad Med J 1987; 63:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/55\">",
"      Dolin R, Reichman RC, Mazur MH, Whitley RJ. NIH conference. Herpes zoster-varicella infections in immunosuppressed patients. Ann Intern Med 1978; 89:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/56\">",
"      Steiner I, Kennedy PG, Pachner AR. The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol 2007; 6:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/57\">",
"      Manian FA, Kindred M, Fulling KH. Chronic varicella-zoster virus myelitis without cutaneous eruption in a patient with AIDS: report of a fatal case. Clin Infect Dis 1995; 21:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/58\">",
"      Chr&eacute;tien F, Gray F, Lescs MC, et al. Acute varicella-zoster virus ventriculitis and meningo-myelo-radiculitis in acquired immunodeficiency syndrome. Acta Neuropathol 1993; 86:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/59\">",
"      Jemsek J, Greenberg SB, Taber L, et al. Herpes zoster-associated encephalitis: clinicopathologic report of 12 cases and review of the literature. Medicine (Baltimore) 1983; 62:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/60\">",
"      Gilden DH, Murray RS, Wellish M, et al. Chronic progressive varicella-zoster virus encephalitis in an AIDS patient. Neurology 1988; 38:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/61\">",
"      Archuleta S. Neurologic complications of varicella-zoster virus reactivation in a person with HIV/AIDS. AIDS Read 2007; 17:58, 64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/62\">",
"      Morgello S, Block GA, Price RW, Petito CK. Varicella-zoster virus leukoencephalitis and cerebral vasculopathy. Arch Pathol Lab Med 1988; 112:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/63\">",
"      Breton G, Fillet AM, Katlama C, et al. Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy. Clin Infect Dis 1998; 27:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/64\">",
"      Jacobson MA, Berger TG, Fikrig S, et al. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 112:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/65\">",
"      Linnemann CC Jr, Biron KK, Hoppenjans WG, Solinger AM. Emergence of acyclovir-resistant varicella zoster virus in an AIDS patient on prolonged acyclovir therapy. AIDS 1990; 4:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/66\">",
"      Burke DG, Kalayjian RC, Vann VR, et al. Polymerase chain reaction detection and clinical significance of varicella-zoster virus in cerebrospinal fluid from human immunodeficiency virus-infected patients. J Infect Dis 1997; 176:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/67\">",
"      Cinque P, Bossolasco S, Vago L, et al. Varicella-zoster virus (VZV) DNA in cerebrospinal fluid of patients infected with human immunodeficiency virus: VZV disease of the central nervous system or subclinical reactivation of VZV infection? Clin Infect Dis 1997; 25:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/68\">",
"      Kang JH, Sheu JJ, Lin HC. Increased risk of Guillain-Barr&eacute; Syndrome following recent herpes zoster: a population-based study across Taiwan. Clin Infect Dis 2010; 51:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/69\">",
"      Nagel MA, Cohrs RJ, Mahalingam R, et al. The varicella zoster virus vasculopathies: clinical, CSF, imaging, and virologic features. Neurology 2008; 70:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/70\">",
"      Melanson M, Chalk C, Georgevich L, et al. Varicella-zoster virus DNA in CSF and arteries in delayed contralateral hemiplegia: evidence for viral invasion of cerebral arteries. Neurology 1996; 47:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/71\">",
"      Hilt DC, Buchholz D, Krumholz A, et al. Herpes zoster ophthalmicus and delayed contralateral hemiparesis caused by cerebral angiitis: diagnosis and management approaches. Ann Neurol 1983; 14:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/72\">",
"      Gilden DH, Lipton HL, Wolf JS, et al. Two patients with unusual forms of varicella-zoster virus vasculopathy. N Engl J Med 2002; 347:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/73\">",
"      Eidelberg D, Sotrel A, Horoupian DS, et al. Thrombotic cerebral vasculopathy associated with herpes zoster. Ann Neurol 1986; 19:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/74\">",
"      Woznowski M, Quack I, B&ouml;lke E, et al. Fulminant staphylococcus lugdunensis septicaemia following a pelvic varicella-zoster virus infection in an immune-deficient patient: a case report. Eur J Med Res 2010; 15:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/75\">",
"      Oyler A, Riveros-Angel M, Shaw K, Forrest GN. Community-acquired methicillin-resistant Staphylococcus aureus endomyocardial abscesses in a heart transplant recipient. Transpl Infect Dis 2009; 11:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/76\">",
"      Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis 1995; 21:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/77\">",
"      Rusthoven JJ, Ahlgren P, Elhakim T, et al. Varicella-zoster infection in adult cancer patients. A population study. Arch Intern Med 1988; 148:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/78\">",
"      Rogers SY, Irving W, Harris A, Russell NH. Visceral varicella zoster infection after bone marrow transplantation without skin involvement and the use of PCR for diagnosis. Bone Marrow Transplant 1995; 15:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/79\">",
"      Tojimbara T, So SK, Cox KL, et al. Fulminant hepatic failure following varicella-zoster infection in a child. A case report of successful treatment with liver transplantation and perioperative acyclovir. Transplantation 1995; 60:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/80\">",
"      Cvjetkovi�� D, Jovanovi�� J, Hrnjakovi��-Cvjetkovi�� I, et al. [Reactivation of herpes zoster infection by varicella-zoster virus]. Med Pregl 1999; 52:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/81\">",
"      Jantsch J, Schmidt B, Bardutzky J, et al. Lethal varicella-zoster virus reactivation without skin lesions following renal transplantation. Nephrol Dial Transplant 2011; 26:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/82\">",
"      Chilek K, Routhouska S, Tamburro J. Disseminated varicella zoster virus in an immunized child as the acquired immunodeficiency syndrome-defining illness. Pediatr Dermatol 2010; 27:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/83\">",
"      Verdonck LF, Cornelissen JJ, Dekker AW, Rozenberg-Arska M. Acute abdominal pain as a presenting symptom of varicella-zoster virus infection in recipients of bone marrow transplants. Clin Infect Dis 1993; 16:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/84\">",
"      Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985; 152:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/85\">",
"      Feldman S, Hughes WT, Kim HY. Herpes zoster in children with cancer. Am J Dis Child 1973; 126:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/86\">",
"      Miller GG, Dummer JS. Herpes simplex and varicella zoster viruses: forgotten but not gone. Am J Transplant 2007; 7:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/87\">",
"      Lauzurica R, Bay&eacute;s B, Fr&iacute;as C, et al. Disseminated varicella infection in adult renal allograft recipients: role of mycophenolate mofetil. Transplant Proc 2003; 35:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/88\">",
"      Fleisher G, Henry W, McSorley M, et al. Life-threatening complications of varicella. Am J Dis Child 1981; 135:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/89\">",
"      GOOD RA, ZAK SJ. Disturbances in gamma globulin synthesis as experiments of nature. Pediatrics 1956; 18:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/90\">",
"      Schiller GJ, Nimer SD, Gajewski JL, Golde DW. Abdominal presentation of varicella-zoster infection in recipients of allogeneic bone marrow transplantation. Bone Marrow Transplant 1991; 7:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/91\">",
"      Hung CC, Hsiao CF, Wang JL, et al. Herpes zoster in HIV-1-infected patients in the era of highly active antiretroviral therapy: a prospective observational study. Int J STD AIDS 2005; 16:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/92\">",
"      Puthanakit T, Oberdorfer P, Akarathum N, et al. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children. Pediatr Infect Dis J 2006; 25:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/93\">",
"      Feller L, Wood NH, Lemmer J. Herpes zoster infection as an immune reconstitution inflammatory syndrome in HIV-seropositive subjects: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/20/2378/abstract/94\">",
"      Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42:418.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8327 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-F1EFE81ED1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_20_2378=[""].join("\n");
var outline_f2_20_2378=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acute neuritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Atypical pain without rash",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RECURRENT ZOSTER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COMPLICATIONS IN IMMUNOCOMPETENT PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Incidence of complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Postherpetic neuralgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Herpes zoster ophthalmicus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acute retinal necrosis (ARN)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - ARN in the immunocompetent host",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - ARN in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Ramsay Hunt syndrome (Herpes zoster oticus)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other neurologic complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Aseptic meningitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Peripheral motor neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Myelitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Encephalitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4574869\">",
"      - Guillain-Barr&eacute; syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Stroke syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1051738\">",
"      Bacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      COMPLICATIONS IN IMMUNOCOMPROMISED HOSTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Bone marrow transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8327\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8327|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/63/18420\" title=\"figure 1\">",
"      Thoracic dermatomes 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/59/15282\" title=\"figure 2\">",
"      Cervical dermatomes 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8327|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/25/11669\" title=\"picture 1\">",
"      Herpes zoster vesicles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/49/12048\" title=\"picture 2\">",
"      Herpes zoster rash A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/42/9903\" title=\"picture 3\">",
"      Herpes zoster rash B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/50/28453\" title=\"picture 4\">",
"      Herpes zoster ophthalmicus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=related_link\">",
"      Clinical features of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/77?source=related_link\">",
"      Diagnosis of varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=related_link\">",
"      Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/12/13507?source=related_link\">",
"      Patient information: Shingles (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/0/14338?source=related_link\">",
"      Patient information: Shingles (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21608?source=related_link\">",
"      Postherpetic neuralgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33561?source=related_link\">",
"      Retinal vasculitis associated with systemic disorders and infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21288?source=related_link\">",
"      Stroke caused by varicella zoster virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33096?source=related_link\">",
"      Treatment of herpes zoster in the immunocompetent host",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23817?source=related_link\">",
"      Uveitis: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_20_2379="Symptoms serious disease";
var content_f2_20_2379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Symptoms suggesting serious disease in patients with neck pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       History of recent significant fall or major trauma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Unexplained weight loss",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fever or chills",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       History of cancer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Immunosuppression",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Intravenous drug use",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic steroid use",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neurological signs or symptoms (arm clumsiness, gait difficulty, bowel or bladder dysfunction, Babinski's sign)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_20_2379=[""].join("\n");
var outline_f2_20_2379=null;
var title_f2_20_2380="Arterial needle catheter size";
var content_f2_20_2380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Arterial needle and catheter sizes by site and body weight",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"7\" width=\"14%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Artery",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        &lt;10 kg",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        10-40 kg",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        &gt;40 kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Needle/catheter size*",
"       </td>",
"       <td class=\"subtitle2\">",
"        French size",
"       </td>",
"       <td class=\"subtitle2\">",
"        Needle/catheter size*",
"       </td>",
"       <td class=\"subtitle2\">",
"        French size",
"       </td>",
"       <td class=\"subtitle2\">",
"        Needle/catheter size*",
"       </td>",
"       <td class=\"subtitle2\">",
"        French size",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radial, posterior tibial, dorsalis pedis, or brachial",
"       </td>",
"       <td>",
"        25 or 23 / 24 or 22",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        23 / 22",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        23 or 21 / 22 or 20",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Femoral or axillary",
"       </td>",
"       <td>",
"        23 / 20 or 18",
"       </td>",
"       <td>",
"        3.0-4.0",
"       </td>",
"       <td>",
"        23 or 21 / 18 or 16",
"       </td>",
"       <td>",
"        4.0-5.0",
"       </td>",
"       <td>",
"        21 &nbsp;/ 18, 16, or 14",
"       </td>",
"       <td>",
"        5.0-6.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Umbilical",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        3.5-5.0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Needle and catheter sizes refer to gauge.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Torrey SB, Saladino RA. Arterial puncture and catheterization. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. p.715.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_20_2380=[""].join("\n");
var outline_f2_20_2380=null;
var title_f2_20_2381="Conditions needing ventilation";
var content_f2_20_2381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of conditions often requiring mechanical ventilation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Alveolar filling processes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pneumonitis - infectious, aspiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Noncardiogenic pulmonary edema/ARDS (eg, due to infection, inhalation injury, near drowning, transfusion, contusion, high altitude)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cardiogenic pulmonary edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulmonary hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tumor (eg, choriocarcinoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alveolar proteinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intravascular volume overload of any cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pulmonary vascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulmonary thromboembolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amniotic fluid embolism, tumor emboli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diseases causing airways obstruction: central",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Laryngeal angioedema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tracheal stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diseases causing airways obstruction: distal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute exacerbation of chronic obstructive pulmonary disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute, severe asthma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hypoventilation: decreased central drive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        General anesthesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug overdose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hypoventilation: peripheral nervous system/respiratory muscle dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amyotrophic lateral sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cervical quadriplegia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Guillain-Barr&eacute; syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myasthenia gravis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tetanus, tick bite, ciguatera poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Toxins (eg, strychnine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Muscular dystrophy, myotonic dystrophy, myositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hypoventilation: chest wall and pleural disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Kyphoscoliosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trauma (eg, flail chest)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Massive pleural effusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pneumothorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Increased ventilatory demand",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Severe sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Septic shock",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Severe metabolic acidosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ARDS: adult respiratory distress syndrome.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_20_2381=[""].join("\n");
var outline_f2_20_2381=null;
var title_f2_20_2382="Average labor curve by parity";
var content_f2_20_2382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Average labor curve by parity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 286px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Average labor curves by parity in singleton term pregnancies with spontaneous onset of labor, vaginal delivery, and normal neonatal outcomes.",
"    <div class=\"footnotes\">",
"     P0: nulliparous women; P1: women of parity 1; P2+: women of parity 2 or higher.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Zhang J, Landy H, Ware Branch D, et al. Contemporary patterns of spontaneous labor with normal neonatal outcomes. Obstet Gynecol 2010; 116:1281. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_20_2382=[""].join("\n");
var outline_f2_20_2382=null;
var title_f2_20_2383="Rounded atelectasis CT";
var content_f2_20_2383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan of rounded atelectasis in the right lower lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 290px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEiAUQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5p2ClCD0p1KBmgBNo9KNgz0rc0Twvq+tRNJp1qZI16sTtFbUXw18TSBcWcYzxzIKAOK2D0o2D0r0GH4TeKZXVVt4Mnj/WCtZPgT4zkAMUVo4PHEtAHlOwelLsHpXs0X7Ofjlwpb+zkzxzN0p6fs5eNWcq02mIBxkzHmgDxbYKNg9K9yH7NfjAgZv9IB9PMb/Cl/4Zs8Wd9S0jP++3+FAHhoQelOCD0r3D/hm/xSM51LS+OvzH/CoV/Z91/eobVdOyTjgk4oA8V8selHlj0r3uD9m3XJM7tc09fTAJp8v7NmsoRjXtPx3ypFAHgXlj0o8sele3T/s/6rASJNatC3QBUJz+NWB+z7ciLL+Irff/AHVhJoA8J8selGwele92/wCz95jES+JFXHpbE5qyP2d4sAv4mwvtbE0AfPewelJsHpX0RD+zvas4DeJ2wf8Ap2q6P2b9PyQfE83HX/R+lAHzUUHpSeWPSvpCP9nCzeRlXxO5A6f6PVtP2Z7Mj5vEs31EFAHzGUFJsHpX09J+zLZYXy/Ek55+bMPb2ok/Zs0pTx4hu8Y6eUOtAHzBsHpSbBX0qf2eNKQ7W1q9c+ojAFNH7PejlsHWL4D/AHBQB817R6Um0elfTn/DPegKCX1bUCPoKil+Afh1RldQ1I+nIoA+Z9o9KQoPSvo6L4EaAxAbU9R3d8ACmXfwF0iP5oNQvnUcnOKAPnTYPQUbBXuUvwe0uJj5l1eY7c4/Oo4PhPpGWMs90yjphgKAPENo9KNo9K7/AMceAzoqG400vNaj7245YVwRFADNo9KNoz0p1FADdo9KNo9KU0tADdo9KNq+lLRQAm0elFLRQBIK3fB2itrurpag7Yx87n0UVhV6L8EoBN4juAeghNAHruhadFaWsdvbRiOKMYAx1966axgJXaI8k+lLptiXYKorstG0yNFBYd+poAb4d0hdodlAyc59K62zihhURx9e5NY95fR2y+XEQqDvXI+I/H+meHoGkvrtUbHCA8n8KAPTp5Y42iDMByTj14qNr23U7mxivljxN8e55JWXRbQ+gllP9K861b4m+K9SLeZqksSN/DHwKAPuW51azUHNzCgHq4qmfEGnKx/0uAn/AHxXwHPreqTkmbULlz15kNRLqF4DkXU3/fZoA+9bnxJaKrETRfgwqrb6xa3CNtcbj/EuM18X6Hr99DcIGuJWUkcE5r6O8E7rzTopkV9rDJZl/lQB6KmsBdwQlgBwSMGqs2qyOwU55GQT0qmLZcjJOMdlqlMjtKqRrxnrigDSgkNwSSxIHXI6Va8kEeuPaqVrYsvBJVj12g1sQQyx24AjDHOAB/8AXoArJA3XAVfcVJsUJjePw5q9HYTSD5kPPYGrNvphU4a1YL04delAGMuwSjZHk4xuOalxKWyRgeua6eLT4lAwvH0qY2sIxlRk0AcrGkiybiKnW9kjyCOD61vtZRnoKryachPA9xQBj/2plsAg54GDTHvS/wB0CtVNLhQELGipzkAU5LCFkDRgYPfFAGB5sjBthB49O9R7ZGXjrXSrp0SfdAH0FVL3SvNi2RO0JyDuQc9aAMJkdSM80wTRp/rcA1uS2oxhh+IrmdfsnWJmjJHf2/GgCpc3do052SqrU+HUYd20sCPXNfPnxJvtT0m9doZXVSc8Eiq3hD4qy20kdvq8fmQHgvnkUAfQl7HDcRvtAJPoa59olQFT27Vf8PX9lqlpFcWEweN+cA5xVvU9OLAvGcH2oA4rUYEkVkkjBR+Cprw34heFZNIumu7ZCbOQ9v4TX0Pf2UygsQcDoa5fWbNb2ze2uIy0Ugx06e9AHzWaStzxVocuiak8LgmJjlGx1FYlACd6KKKADtSUtIaACilFFAElep/s+R+b4qukxnMBrywV7N+y7a/a/HF0pBwtsScduaAPpbSrFIY145PWrV1OluhIbHGOtab2oVTt4z+leJ/HXxt/wjtl9hs5P9OmGBg/dHrQBj/Fb4nppbSWOlyCW8PBIOQlfPmpajdandPcXs7yyMcksarzzSXEzyzOXkc5LE9aZQAtLikpaAFpyikFSIKANjw5Ym71GJApILDtX1/4WsY9P0K3iVADsGRtr5u+EmlG/wBfts427gcYr6vECRRoNvyqMCgCh5IIyRjPTirFhab2yq4Xu2DVuC2M7AtjHpWxaWoGAowBQBVt7E78gfL9K1re0Uc1PFEBgAcVOBxQA1UCjpT8UUybf5beVt3443dKAH0EA/hSLnaN2N2OcUtAB3pGHfFIzAOBS9fpQBGRxxTSaJQTIqbW2/eLf0p5Ucc5oAhbduXaBjvmgDJ5HFSY6j0oxQBWmj3EHnA6j1rMv7RZVb5elbLrk5zjHb1qtMvX0oA+cvjnoedLkmROUySa+ZXGGIr7k+Kmmi58NXxCk4jJwO9fEWoR+Vdyp6NQB0/w/wDGt34Y1KNt7PaE4dM9q+r/AAprll4i05LiylWRGHI7g+9fEFdn8N/HN54Q1SN0YvZsR5kftQB9dahZ/Jjbx9K4fVbRoJnwCVc9COB9K9C8M6xZeI9FgvbNg8Uozx2NZviPTQULIAwFAHjHjTQE1rSpIig+0IN0bAd68DuYJLa4khmUrIhwQa+pbuPEpUptbrjFeRfFXw4Ef+1bSPg8SgD9aAPMqQ0tBoAQ0lO7UlABRSYooAkr6B/ZESP/AISHXZW++lsoB9ia+f690/ZRkC+KNXQ/ea1GPzoA+oNb1W30vR7u/vGVIoIy7HPoOlfCHjrxHP4p8S3epTk7XciNT/CvaveP2m/Fv2XTLfw/aS4ln+ecA/w9hXzPQAtLSUtACinj2pgpwoAcKlXio1qVR0oA9i/Z+ty+u+Z1Cqe1fTaRidcdu5rwP9m7TZZpLmcJhEUDcRX0XaWxXkYFADrOA8AqFP1rUjj2jjimQxbQDVkDtQAfhS00gllIYgDqPWnEZFABQRSEhVySABS0AFFFFADcYkz2IxTqKB+tABSYFLQaAGkdabzjPWnGkHpQAxxg9aqyng8+9WnHeq8vQ0AYmvW63FhPG4yGQjFfBvjq1Fn4nv4VGAsh4r781AAwPk8Yr4V+KwX/AITbUin3fMNAHG0UrDFJQB6t8CPHz+Gdfj0++lP9mXTbDk8I3Y19YOsd2AvBVxlSO4PSvz5UlSCDgjvX1z8A/GI8SeFUtLuUHUtPwhyeXXsaANbxDpZildtvzCuM1HT0uopIZkDJICGBNeza9bLPZCUD5gOfevPNTtkUkggfQ0AfLfjHQpdC1aSBlPkscxt6isE19D+PvD8OtaQ6Af6VEN0Z/pXz7cwvBO8UoKuhwQaAIqSndqb0oAKKKKAH169+ztqlvomp6/qd2wVLaxLcnqc15DVyzvpba2uoInKpcKFfHcCgDR8W65P4h1+71K6YlpnJUE/dXsKx6TOKBQA4UtNFOoAcKcKYKeKAJVFWrGPzLmND3NVErW8OxmXVrdAMksKAPrH4Fac1n4cPybBIc9+a9Yto8Dk5Ncx4AtRb6DaooH3BmuvUbFLHgYoAkAOBjGKUHPrTY2yMNw2MkelOHSgBaKKKAAjI5pqqQ7kuSDjCnGF+lOoIyMGgApCMjBoVQoAXgDoKWgAooxiigApCQM0tIwyMYGPegBpPI5+tHajoPemjJUEjB9KAGv8AWq8uMc84ORU71WmGc7hx60AZOsyCOzlbphSa+GPiO4k8SXkn96Qn9a+2/Ejq1ncRlvmVOeOma+IviKI08R3CRfdDHt70AcqTSUppKACuz+EfiZ/C/jWyuy2LeRvKlBPG0964unKdrAg8g54oA/Q+3miubQNGQ0ciZUj0NcHr0CxM4AHU81lfBLxaus+EbaKSUtcWw8ts9SB0rp9VVbh5ABxQBwV1Gd+MD868f+Knhzypv7StU4J/eAD9a90vbRhubZjFYGqWKXdtJBMm5H4PFAHy+elNroPGOhyaFq0kDj92x3IfUVgGgBKKXNFADqUUlKKAFpR1puaWgB2adTBTyCDg0AOFPFRinigCVB3rc8Kll1e3MYO7cMGsFa3/AAncrb6tAWOMsOfxoA+7PBabdBtNwG7ywTz7V0QHHP61g+D5Fl0OzZTnMY5H0rfHSgBaKO/tTIpUlXdGcjJGaAH0UUUAJtG7d3xiloooAKKOaQjJGaAFzRRQfegCKd2jVTujXLAfOcZ+nvT8Zbqfpmh0VwA6hgDkAjPNDDgkcH1xQAHmmdvemSRK8sbyE7k+7zgZ+lSEUARSVCwHI61M5wOmarztt4BoA4D4r60ukeHbiTIDbSBkV8T6zdG91KadzncxNe7/ALS3ijzLyPSbZxhBulI9fSvnpjzQAxutNIqQ9aY/WgBtFFFAHpfwM11tL8UC3dyILgbSM96+l8Esx3kg9B2r408KXRtNfs5h/DIK+v8ARJxc2Uc7ZO5QeO/FAFq+C+SUKDkda5q8sigLfpXT3Mby4yoBx0rKvonVSMcH2oA8I+OEaqunuQN+SM+1eT17D8dk2wad0HzNXj1ACGilooAWlFJSigBaXNJSjFACindDTeKevzLjuKAJoUieKUvMElUZRCpw/rz2NMFMFOFAEq1Yt5DHIrqcEHNVlqRT0oA+3PgVrg1bwXaZfdJCNjAHJFenjpXyd+zJ4nNrrEmkTPhJvmQE96+r4zkc+lAD6KTIAzniloAKKKKADvRSA5GQQRSMwUjOeTgYFADqKBxRQAUdetFJk49aAFpCaPxpG5xQA1+R0BpDyevFAAUYAwB2poPOKAI5fl47e9c14v1iHRNHubuVyNqnaPU1vXs6xKWcgKO5r5++OXiETQiAPhc8D2oA8D8dai+pavPcSsWllcuSa5ZiMc1a1Ccz3LyHpniqRNAC55pCc0lFABRRRQBLbP5dxG/owNfXnwuuhf8Aha0kDZYLivj4V9Sfs5ytf+Hmiz/q2xQB6b5eFH8RPeq97BvixtGMelbDweU7KQNo6VFNEPLIPSgD5q/aCi2R6d/vNXixr3j9pOILbaXIvKs7cjpXg5oASiiigBRThTRTloAKWiigAFPXOaTae1HagCSlpi06gB609e1RrT1oA7H4X3sll430mWI4PnKD9M196WEolhVs9Rmvg/4ZR2ieIre5vpliihO7k45r7H8J+IrO8tovJuonBHZhQB2TKHUr2NKBjjtTI5UcAhhzUmaACkPC+tJkL3o3rnGeaABTn2/CnUCigBFUKMClpAMdKCcdaAFopMgkYNIWw4XB570AAUB2YAZPWmqGy24gjPGB2oEqmYxjO4DJ44pXJ7UAIwqCVgh5OKdLJheaw9Rvo1jMEb9ODk5NAHKeO/EIhLxxZIUc8da+UfiT4gfUtWkRG+UHBxXqHxp8VpZI9raOjTNkEr1FfPUsjSOzucsTkmgBh6VEakamAZNADacFPfir1vAkcRmk+YDtVKV97E+vagBvQ0hoFB60AFfSn7JtyjxapasRuXDCvmuvYf2ZdXGn+OTbOfkuoymPegD62vYxtyBWdcbUXLEBfU1sXI325rHlOFJPT86APn39p/jT9KUcDzGr55r6G/ajx9k0jacguxr55NACUUZooAcOasQRbreaTuhFVxWvplu0ui6nKBkRbM+2TQBl9KKDRigABI6GlBpMYPNKKAHAU4UuAE4602gBwNOHFNFOHSgCWN2HQn8DWvpOvalpkoeyu5Y2ByMNWMnJqUMcYIFAHtvg347atpxSLWF+1Q9N38VewaJ8afDd/Cubo28pH3XGMV8Zg04MexoA+77bxhYXyboL6FgeR8wrZs9QWQAnp2I5zXwJZapd2bBoJmXHvXpvgj4qX+nSxx3rmaIcHPXFAH2DFcocfMMdKtqwI615x4V8Xabr9oHt5PnxypGCK7G2uMhdpPpzQBr5prNhST2qCCYSM20ZwcE+9TAqTz196AIfNBUeYoDHrikMigYVmH45qZ41Iqjcps5U8UASmcgHJDc/ShrtAPmBFZN9qcFpGXuJFQL6mvO/GHxG06ztJfLuVMg4AUjrQB1fjfxhY6Lp0kkky78YUA8mvmvxV8Vb+R5lsJCu48t3rl/HXimfXp97ylvQZ6CuNEMp2rtPzGgC5f3Fzqkct3cOWfOST3rIwcE4reuPD2qQWqyG3k8huS2OKoX5hSJY4l+bHzHHegDNamZp7Ak1t+GPD1zq92AkTeWOScUAZ0zGO1VCcbuao1veKLCazvjC8bIqccisE0AFJSkjsMUnegBa6L4faodH8X6ZeA4CSjP0rnKfC5jlR16qc0Afova3C3VhHKv3ZEDD8RWTIu5ju6Dt61zHws8RDVPBtjIxy6xhG/AV0quXJYnjPAoA8F/alUfYNGb/AG3FfOxr6G/amL/ZtH+bMZZsLjofrXzxQAUUUUAOFek/DDSTqvhLxoqruaO1R19iDXm9e8/sv2wuoPFkLAFXt0U5+tAHhbDBIPUcU3vWz4r05tL8QX1owx5crAfTNZOKAGHrQKXHNFACjpS00VNaW8l1dQ28IDSyuI0BYKCxOByeB9TQAwVKjhQQVzT9RsbrTb6eyv4JLe7gcxyxSLtZGHUEVCAetADhTwSODTBx1Fa1hBHqUscC4ifu56UAZwNOBJrotA0O2u9ZW2vboRW4bDSVv/EfwXZeH7S2vdMvoriCbjYHBYUAcByAKfE+1gfSozSigDqNJ8WXmlyq1o5jI7ivUvh78Wry61e2sdVxIjuPLOMYb+teDVNaTvb3MU0Zw8bBgR7UAfoPaTmWNW5ywzVtS6k9CT1Nch8MtbXXvB+nXqnLmMK4HYiuzTBXIoAqSXRTIOQfbvVS6unMTFCGIGcdK0BZeYxL96jeyCxn+8c0AfJ/xX+JN1e6rcafaqY4oWKtg4JIryS6vZbtyZ5WyexNe4fGH4Ral/al5rGjr58chMjxjqPpXg88M0LlJkKsvBVh3oA2tI0JNRhnla8hj8pNwDMBn2rF+1vDKwB3Y4GahDgcZZAeMqc0wxk/cIce3X8qAO/0b4jSwaBLpd9brOuwrG5HIrz+V/Nld1GMnpTQdpPHPoaYCVYkUAKjYcEjNdpYa/qGn6Rusk8tB1YCuHJOc1dOp3H2L7MD+7oAm1XW7vUyTdPuJ71kmlPNJQAUYoozQAUd6KUUAfT/AMCLrd4QjUMSVYrXrloUFvxwBxXjf7OMTTeGZh2Ele0QQtGWUigDwT9qbAtNF/3nr54NfRP7VUZW20Rj/ecV87HrQAUUUUASCvoP9k3/AF/iMescf86+fBX0P+ySD9o8QsOfkj/nQBlftG+GBZ6nDq9un7uf5ZCP71eKYr7j+IXhmPxJ4au7N0y7KWjPo3avinU7GXT9QntJ1KywuUII9KAKOBSEVIwxTDQA0U/bxmkFKcmgDvdLvLXxvYwaRrlxHb6/Agi07U5ThZ1H3bedv0SQ9Oh4wV4zULK60u/nsr+CS3u7dzHJFIuGRh1BFVh+td5p17beNrGDSNcnjt9fgQRadqcpws6jhbedv0SQ9Oh4wVAOHVz3rR0mcLdxgrjc2M0240XUbW5vre4sLpJ7En7UhiOYMHGX/ujJAyfUVDaMI51kP8PNAHWeKNOTTWhkgukk3ruIXjFc9ulvZ1hMzNk4AZsioLy6e5k3Ox/Oo7WQxTpIOqnNAF7VtKk02REmYEsM1QxV7V71764EjsScY5qmmc0AC4zzSgZNOBHfrQBzQB9H/sta4Wt77SJG4Q+Yg/nX0VF84BFfIX7N+9fGbsDhREd1fXdq3yJtAI7+woAtDgU04PPWnZ4z2poGe4P0oAhmgSQfMAc18o/tF+DBpesLqVnEFt7r7ygYAavrJgSwwRt7jHWvNfjtp8d74Ju3ZQXhHmKfQigD4lmtWCFh1HUVT6H0q9cTMJX5PNU25NACPuJyxyfWmg889K9R+F3gq08V6Td75ALmM4VfWrUvwc1R76a3iX7oyrZ4NAHkeATTHGODXUeIfBureH7po7+Dbg8Ed6TSvDd1rsiw2cTefjp60ActRXZ6v8OPEOlWrXF1ZOsQ7jmuPlieNirqQR60AMo60YooAMUDrRS0AfUH7KzLLouoR5+64OK90vIgoVsV89/slSEvq0f8IVTivoy8ObfPpQB82/tXN/omiL/tPzXzka+kv2rlH9maKSOfMavmygAooooAlFfSP7H8QeXxGefuxjH4183gV9LfseABvER9o/50AfSEFsGDJjP1r5y/aQ+HUiXa6/pUG5GGLgIOh9a+mIuJfrVPxNYpqGi3VvIgYPGRgj2oA/OW4Qo5UjBqHFbfiu1+yeIL2DGPLlZcfjWRjrQA3FLtOOlPQZNa0EEb2TrKNr9VNAGOoyRTwMc8U/yiDj0qW3haRgqgmgD7U+GOp+CvE/gldB03Uo9QllshbXiXOEu5QE2ksDycDgEZAGADxXx94w8P3PhXxTqWi3pzNZzGPdjG9eqsPYqQfxqhJHNZXEckMjxzIQysjFWU+oNWdd1vU9fuobjWruS8uYolhWWUAuVBONzYyx5PJye2eKAKYt2aMyLyB3pPLOM44rs/AGjRa0Lm1Y4l27lHrWn4e+Ht3q19cWtrsdkJBBYZBoA87IyMmrWmvFHKTOm4Y6V3mvfCbxDpaljaPIg7pzXHzaLfWkmJ7WVP95cUAZ1yweVmjAVT2pi5qzcWzR8kYHpUMUbPIqAHJOBQB7j+zpp7Bry+IwBhQa+l9JuN8AGNzCvLvhF4am0nwlbr5f7yYeY2c969GtYpYHBXgelAG/1HB5o55yKitpA+ePmHU1N096AIJmZZYgqk7jgkdF471x3xKRL7wrqVumSTE3briutvZgEMYzk8VzurR/aIJo5FIDKUC46DFAHwJdrtuplPG1iKrBTmtnxVaGy8RajAy7SkzAA+maxjxQB3Xwiur+28UW/2F5FQthwucEe9fUupXc2maR/aqETLGpZwB1Hevm34ReJrLw1DfXFzaLPLt+U8cV0+tfGS91nQ7izt7NIlYFWPXigDlvi147j8R36yWQZYwMbT2Ncz4H8WT6Bq0dz99R1BPaue1AhpmwMAnOKpg4oA9o8V/GefUbE21pbhARgk815VqOqG7be0agk5PFZZ606Mbjt9aAJ2nideYgD6iq7Y7UhGCQaM0AJSjrQcUlAH0J+yZNjV9Uj9Ywf1r6Xuzi1fHODXy5+yrkeIb9s4HlCvp6/b/QWNAHz1+1OFfRNJkY/OJSAM9sV81mvor9qOVv7P0iLHBdjmvnU0AFFFFAE4r6T/AGQTt/4SI+0f86+bhX0d+yPIsa+Id3RvLH60AfT0LDg9asuNyEeorLt5hjg/hWjA4ZfegD4R+NelPpXxC1SJhgO5kX6GuCIr6T/aw8O/6RZa3BHnI8uUgflXzeRQBJZIrXMYY8E81sauFjnCgYjxxisVPlOe9Wp7hpokD8kUAQglnO0E5rf8Mw+VdJNPEWQNypHUVc+HOlLqerbWRXCqTtNXvE+LG5kjhXbsbBxQBVljtNX8YxwQosFs7AYP8NUfGOnQ6brslrCwZEOAR3qpp7Mdbhc9S46V2HxM0R7S8srwKfLnQcgd6AL3wxu7LS9WhuJ1YliFJHavoKz8GW02twa7os7W7sAXCn5XH0rgfg14KttQ0l7u4jyT93Ir3zQ7BbGxSIdAMCgCdLVJEQyqCyj8DVW68P6ZcgiWzgbPcoDWrjFFAHj/AMUPhJY6xp01xpFvHb3kall2DG/2xXi/wu+G+oax4rAvrWSKztHzKXXGSO1fZBAJ5FRJBFGT5caIWOTtGM0AVdLsxbW6x7VVFG1QB2q0IFzmpaAMDigBAoAwBihVC9KRk3FTuYYOeO9OoAjmhSVSHXORiqQsY4YRGAfLQYHOeK0aRiACWIA96APir9ovRF07xzLcwLthuVDfj3ryYjFfZX7SHg5NY8Iy6lax/wCk2fznHde9fG0gINAFi3laK1lAON3BqOzuGilA3YQnmm8i3PuahQZYCgD1nw/8NV8XaBNe2c6pPGpKr6n0rybUbOWwu5bacYkjYqw9xXX+HPGWp+F2/wCJfOQjrhl6g1zuvXTajey3jfelO5vrQBkmgcUGigCTAkXOfmqI8UoODmnPg8igBg4pRSUvegD3z9mKLy59QuWzjAWvofV7rZpq46ntXinwBsGtvC4lwMzyZr1nWXJjjT0oA8H/AGl5zLZ6QD2ZjXgVe5ftHAiLSs56tXhtABRRRQBZHvX0X+yagkXxCp9I/wCdfOor6N/ZIIz4gHfCH9aAPfVDRS8kirtpcsk2ScgfrUc8W/rwT096rqpQ4brQBU+JWhR+JvCt1ZunMiEpkchu1fC+r6fNpmo3FncoVlhYqQa/QGKUyQGNuSK8F+P/AMPPtkba7pMObhP9eij7w9aAPm0Dil609lKkqwII6g00D8qANjwxrU+hapFdW55U/MPUV7F4s8N2viLwh/bulHMrLvkUYznvXhAPzcV6V8MPG0mkXgsr07tPk4dG6CgDkfD0SjWrUXK/KsgDcds19Q6p4dstd0eJXhVljUGMkdOK878aeDLa4aLWfDaiS1YhnVDnHuK9y8HLBdaDZMUG7ygpJHOcUAVvhfbNa2DW/l7FRsAY7V6CBgYFc7oluLO4lB4Vm4GK6FSGGR0oAWij6UUAFNByxx2p1RpnOSACelAElGecUUUAB6Ug5A9/WlpFG0YzQAtIQCMEAg9jS0UAZXiqJZ/DuoxOu4PCwx+Ffnlq0Jg1C4iIwUkYY/Gv0X1RBJZSoRkEV8JfFrSG0nxnfR7Nscjl149aAOIJ+TFMU7TTmBBJz+FN75oACxOc0kbDayt3pD60xhxkUANbjg02nE5pvegBKWl4zz0pCBng0AJVrTrZ7u9ht4hlpGAAqtXpHwT8PNqniIXciE29v8xJHGaAPovwJpi6XoljbAYMcYLY9a3bna7MWPPalsoxFbEnAGOp4FMaNpLjA6UAeEftKIRZ6QxHBZq8FNfQv7UY22mioMY3NXz1QAlFLRQBZFfQf7J8qx3uuBsfMic/jXz4K9x/Zll8u81f3Rf50AfVUbKQOc02aLf8wxgdqyrK6yAHPHrWqj5HB57UAQIwRsdKfNbpKGDqGRhgg9DSTjJ3Y+YVPayByFbrQB4J8X/g8lxHPrPhuMLKPmlt1HDepFfOk0LwStHKpWRTgqRgiv0OeHapIUle4xXhvxt+FkWq2sut6DCI7xF3ywqMbx/jQB8wDrU8b7HVgcfSmSxPFIySKVdTgqeoNIORigD2v4PeOF0uePTtSIexlPDMfumvpzRobVrdZLRlMLjcNvSvgXT7t7ZwRyB2r3X4S/FL+zlWy1B2eDopJ5X2oA+mPs6ZBxyKXzBGPnIrF0bxNYapbiW3mUg+h6VqqkNw2/O6gCwjhxleR607vTUXbwAAPanUAFMlHFPJpk33aAFRsjnrTqjhPBBqSgAooooAKiV5PtDoYz5YAIfPU+mKkyKMjGe1ADZVDowPevmv9pjwwk1lBqtmu54mKSlR2r6PllAUqR1rl/FOmwarp81pcoGilUqRigD4BkHNRmuz+Ing698Ma7JbyRsYHbMTgcEVyNzBLbyGOdCjjsaAIPamZwfan45pjDPSgBD3pmKkIz9aaRxQA00UoqSCB5pVjiUs7HAAHWgCfStPuNTv4bS0jLzSttAHNfWnw88LJ4Z0G3tEiMk7YaZl65Nc38F/h2dHtY9SvYt2oTD5AR/qx/jXtSWi2sGX+93NAGfK4gTaF4FLbqcGQ9Wp0kfmyfMPlXoKe7JCmSMAdOKAPAv2pB+70bJ5y3FfPp617x+01cGZtKH+8RXg5oASiiigCyK9p/ZuuIU1PUoJJFSWRB5ak/exXiqmtLSNRuNLuobqzkMc0b7gQaAPt+1mZWIfaB2wa2LOcrg5yDXlXw08d23iywWOV1i1OEfOn9/3FehwTMMdR6igDpl2yLuziomjKP5iHgc1m293s5yB9a1LedZAASM0AadnKJUBOAw6ikntdwbGDn+HFVo/kYMp5rRikDr7+lAHgHxe+D6au0uq+H4xFe8tJABgP9Pevm7UtJvtMuHgvraWGRDghlIr9D5ohIOgz61ga14a0zVIympWME4PUsgz+dAHwKo5qe3keOQFGIr6+1L4MeEr1SYrNrdj3QmsB/2ftEL5S+uAv0FAHiHh/wAU6tp7YtLhx7A9a92+E/ibxPqcrRXNs8lv/wA9WGMVs+Fvg1oOi3qXTNLdMhyqygYH+Nemw20cKqsKBAv8KjANAEttv8sGUjeeuKlpuD9KQou4NzuAwOaAH1BcvxhetTcY4qKQYJwOKAEts7OnfvU9QLJhR2HvUwOQDQAtIRilpH3bTsxntmgCLG5sVIEAAHYUKpBJJp1AFaeFVLyM7YwPlPQVk3gJBwDkVvnGOazbi2O4lGHJoA4zxL4c03xLYta6nEGBGA2OVPqK+a/ib8LdX0WYT2qtd2SDCso5A96+t5rXPtioZYQyFJFVkxggjrQB+fE8EsMhWVGQjsRUPevtrX/hv4e1xDJPp6xSNzlRtNcJd/AXS3GYrl437gLkfhQB8v4pNpJ4HNfUFh8A7Hed1zIVI/uV0eifAfQLOVZLgPNg5w1AHy14c8J6vr9wkenWckgJwW28CvpH4XfBqHRBFe6oizXvUA8qleyaN4f07R4FhsraONF4G1QK0wm3PPf8hQBm2VpHDuVExt43ev0qG8YPuTpzVy6nVF2Iee5rIllWINuOT60AMfbEvPFYmozguxGc4x1qa+uvMIAbHpXG+MfFumeHLZpL2dWlxxGDliaAPK/2ist/ZbH/AGhXiddl8RPGcvi25iJjEcEJOxe9cZQAUUUUATL61Kp+WoRT1NAGjpOpXWlXsd3YTNFPGchlNfR/w4+LVhrUcVnrzraX4AUSnhX/APr18xg05WwQQefUUAfeIIKZGHjYcMDkGrVvMV6n5a+SfAPxT1jwxIkM7m90/oYpDkqPavo3wf4v0nxXZrPpdwomA+e3Y/MpoA7y3uxgDqDV+KXBDIQK5pH59DV+2uNvGRx60AdNFKr8dG9KkIBGDWRFcLJjJw3rVtLllKhhuHQkdqAJmgHO3vTPLYY+WrG7KkoQaFJ2jcAD3FAFbO0gA81Jlhjn3pZ0V025Ks3AZeopSoC4zQAwSHuaC2Tnr7Ug2KMKMU4Ece9ADVYk56D0pzqWHJ4petLx60AQ7O9PZgAv3uOw70/+E0xwD60AN89scAUsFyJG2sMN2qtKpAyM/wCFVS5SQE8Y70AbZOASaqPKzjIOB2qst2ZrcxyLtctjhs8fWpN6xgA9cflQAu915PIqdf3iZHQ1SknVF3MTgnbkDNTxyeWeBxQA25i2jNVCners8wkHsKrZPO7FAEark5NKw2gtgHvjFO4HQ0xm2qeRgetAE8UkYXjA9DUV46SIq+dLFhw+6NtpODnB9j3FZzzlTj+D1x0qGWRiobeOOx6UAbJvF5KiqlxekggkAVkvct3bj9BVO4n2qWdgFHVmPAoAs3V4ACFJrB1K/itojLeTpBEByXbFeffED4saboIkttMK3d90yD8qmvn3xN4u1jxFcNJqN27KTxGpwo/CgD2vxx8WdOsYpLfRHNxcEEeZ2WvA9a1a71e8e4vZWkdjnk9KoE0hoAQ9KTtSnpSUAFFFFAEgpymmUuaAJgaUGowacDQBIDWho+rXuj3qXWn3DwTIcgqcVmA07NAH0V4H+NlrcpHbeJk8mYDAuEHyn6ivWrLxFo93Es1vqlm6EZBMoBFfDgNKDjoWH0JoA+7v+Ej0yID/AImNmSeOJ14qzF4t0ZBh9WsAfeda+Cc/7TfmaPr/ADoA++x4w0ND/wAhrT1P/XwtPHjnw+jYk1/Sx3ybla+AcL3FG1P7q/iKAPvxviB4ZVdx8QaYF7j7QvNNm+IfhGPmTxDpo4zxMDXwNtTP3F/KlATH3F/KgD75b4j+D1Qs3iLTQBzxKM1W/wCFmeDbd5N/iWwIY7wN+ce1fB+Ez9xfyowg/hX8qAPumT4v+Bl6+I7X8A1Rn4yeAwPm8RW+cf3G/wAK+G8j0FGRnoKAPt9vjV4Bx/yMMXH/AEybn9Khf42eAOD/AG+v/fl/8K+Jd1IWoA+1bj45eAlHy60ZP92Fqyrj46+B3yBfXJ9D5Br4/wA00mgD7Ag+O3gSAEyXl5Iw/uQdaoz/ALQvg8ykqmplR0/cj/GvkzdTSaAPrD/hojwipyINWz6eSP8AGnv+0b4QUfLbauxx/wA8V/xr5LzSZoA+rT+0d4WJJ+x6t7fu1/xqOX9pDwwAfL03VXOOMqoz+tfKham5oA+oZP2k9FA/d6JqB9cuBVSb9pPTWYgeH7xkxxmYDNfNBNJQB9Gy/tH2ZY7PDlxtxjH2gf4VUl/aJhKkL4bl56ZuR/hXz7SUAe+v+0Nx+78NnP8AtXGf6VxHjH4t674jRoU/0G2PHlxN1+przmkoAfJI0jFnYsx6k03NJRQAUGikPWgANFGaKACiiigB9LRRQAtOWiigBy0veiigBe1LRRQAtFFFAAKUUUUAFL2oooAKO9FFABSUUUAFJRRQAGmmiigBDSGiigBO9NaiigBG60neiigBKDRRQAlFFFACUlFFAC0neiigBRSGiigA7UlFFABRRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan shows a subpleural mass in the right lower lobe with tentacle-like extensions towards the hilum (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_20_2383=[""].join("\n");
var outline_f2_20_2383=null;
